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Abstract 
Mapping the Alzheimer’s Disease Clinical Trial Space 
Timothy J. Schultz 
 
 
 
Over the past 20 years, the pharmaceutical industry has realized a disproportional 
trend in new drug approvals at the cost of increased spending.  While insights into 
underlying mechanisms of disease continues to grow, the accumulation and integration of 
this knowledge complicates its application to clinical practice in the form of clinical trial 
protocol design.  As knowledge is gained from the successes and failures of basic research 
and subsequent clinical trials, the landscape of the therapeutic space evolves: novel drug 
targets are assessed, new treatment approaches are developed, and patient populations are 
refined.  This has forced researchers to rethink strategies which facilitate the efficient 
development of next-generation clinical trials, by leveraging lessons-learned from outputs 
of past research.  Conventional protocol repositories such as ClinicalTrials.gov do not 
allow for this level of precise inquiry from its plain-text search and document retrieval 
functionality.  Instead, it is useful to devise analytical tools which quantify and visualize 
temporal shifts in treatment strategies for the purpose of better understanding the evolution 
of complex therapeutic spaces at various degrees of resolution, through the development 
of a novel protocol mining framework.  This framework is explored through its application 
to the complex Alzheimer’s Disease (AD) therapeutic space.  In light of recent high-profile 
AD clinical trial failures, the need for leveraging lessons-learned from trial results is 
apparent, since the century-old therapeutic space is dynamic and multi-faceted. 
ARRASTRA, a Python framework, has been developed for mining and analyzing large 
corpora of semantically annotated documents, specifically for this purpose, clinical trial 
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protocols.  Plain-text protocols are augmented with natural language processing (NLP) and 
semantic annotation routines.  By mining protocol collections and expressing them as 
temporally-directed similarity networks, graph theory can be employed to quantify the 
evolution of a therapeutic space at both the individual protocol level (nodes), and high-
level themes (clusters).  Firstly, the ability of a protocol to influence the genesis of new 
trials are quantified by their position in this network, and are analyzed over time by 
identifying significant “bursts” within those metrics.  Secondly, the evolution of a 
therapeutic space itself is visualized as temporal changes at the graph cluster level using a 
“MetroMap” visualization, which tracks sub-therapeutic themes as new ideas form and old 
ideas are abandoned.  Finally, these graph metrics when integrated with additional protocol 
metadata, are used to predict the viability of themes using survival models.  Overall, the 
ARRASTRA framework provides novel fine-grained insights into the changing nature of 
a therapeutic space by repurposing the content of clinical trial protocol repositories in ways 
not previously explored. 
 
  
Introduction 
 
Preface 
 
 
The phrase “standing on the shoulders of giants”, which is most frequently 
attributed to the 12th century French philosopher Bernardus Carnotensis, metaphorically 
reflects the notion that the development of technological knowledge is inherently derived 
from the toils of previously conducted research.  This systematic fusion of ideas is what 
nurtures innovation and ultimately evolves knowledge within scientific domains.  
However, with an ever-increasing and dynamically changing corpus of scholarly literature, 
it can be quite difficult to adequately identify the key successes and failures which drive 
the discovery of novel ideas.  In other words, the cost to climb on the shoulders of giants 
is rapidly increasing.  The framing of meaningful and valuable hypotheses requires an 
expansive knowledge of the relevant literature, especially where gaps in domain 
knowledge currently exist.  It also requires researchers to analyze and address the dogma 
which is pervasive throughout scientific research.  Thus, the ability to adequately harvest 
the relevant knowledge from a corpus of literature and understand how it influences the 
formulation of subsequent hypotheses is an immense challenge.  In order to understand 
how ideas permeate throughout research communities, novel informatics tools must be 
developed and employed, which can conceptualize the research space in ways which 
exploit its connective nature. 
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Executive Summary 
 
 
In recent years, a troubling trend has become apparent within the pharmaceutical 
industry: it has become apparent that the likelihood of a successful clinical trial leading to 
regulatory approval of New Molecular Entities (NMEs) intended to diagnose, cure, 
mitigate, or prevent disease and health disorders has been decreasing in light of rising costs 
required to execute such trials.  Increased complexity of the clinical trial protocol designed 
to guide the execution of an investigation is often associated with the rising cost and 
duration of a clinical trial.  The vast amounts of published biomedical literature amassed 
each year make this a daunting challenge to understand the genesis and influence of 
transformative ideas over time.  As such, it is critical to understand how past clinical trial 
successes and failures have shaped the current landscape of gold standards and best 
practices in key therapeutic areas.  Such information is helpful for supporting 
organizational strategies to judiciously enter or expeditiously exit a therapeutic space.  This 
is especially true for the Alzheimer’s Disease (AD) therapeutic space, which has strived 
for an approved disease-modifying therapy since its discovery in postmortem brain 
autopsies over a century ago.  As a result, the pharmaceutical industry has been forced to 
challenge conventional therapeutic strategies. However, the exact nature of how and when 
shifts in treatment strategies occur is obfuscated within the mounting volumes of text-based 
literature, specifically in clinical trial protocols. 
In the United States, ClinicalTrials.gov has served as the definitive data source for 
collecting protocol information regarding past, on-going, and planned clinical trials since 
its inception in 2000.  The importance of open clinical trial protocol repositories and their 
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continued development has become a focal point for collaborations between government 
health agencies, pharmaceutical companies, and points of care in recent years.  It is within 
such repositories that clinical research activities along the pharmaceutical development life 
cycle are captured.  In the interest of regulatory transparency, it is now mandatory that all 
research organizations file protocols of planned clinical trials in the United States to the 
ClinicalTrials.gov database.  Information related to study rationale, design, and subject 
eligibility criteria are disclosed.  Additionally, protocols indexed by ClinicalTrials.gov are 
semi-structured and segmented into high-level “zones”, and provide timestamps which 
indicate key events that occurred throughout the lifecycle of a trial.  However, 
ClinicalTrials.gov is severely under-utilized due to the fact that they mainly serve as 
document storage repositories where protocols can only be interrogated at the individual 
document level.  Recently, government-funded initiatives such as President Obama’s “Data 
to Knowledge to Action” has recruited pharmaceutical companies to collaborate with the 
goal of extending the functionality of ClinicalTrials.gov.  These solutions mainly focus on 
patient outreach and enhanced trial enrollment, having yielded solutions which allow users 
to easily locate and understand trials that may be of interest to them, given sets of basic 
medical criteria.  This fact suggests that a gap still exists with respect to the utility of 
ClinicalTrials.gov from the perspective of the researcher. 
From the ever-growing challenges impeding the successful execution and 
completion of clinical trials arise clear opportunities.  One such opportunity involves 
mapping and understanding the key evolution points of domain knowledge resulting from 
the clinical trial triumphs and failures of past decades.  Such knowledge facilitates the 
establishment of industry-accepted best practices as they appear in subsequent protocol 
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submissions.  Not only is it useful to understand where promising opportunities may lie in 
first-in-class therapies or the synergistic fusion of pre-existing ideas, but also which 
research strategies may ultimately prove fruitless.  In order to gain deeper insights into the 
evolution of therapeutic spaces within the pharmaceutical industry, information locked 
within large collections of clinical trial protocol documents must be extracted and distilled 
in meaningful ways which researchers can easily explore.  This challenge is framed within 
the context of information diffusion, through the quantification and visualization of both 
individual components within a research space (i.e. protocols) and high-level themes (i.e. 
research fronts).  Other efforts which embody the motivations of the proposed research 
exist, however the solutions have either focused on the published literature itself, or 
repurposes ClinicalTrials.gov in a way that identifying static clusters of clinical trials to 
support patient-searching activities. 
The goal of the proposed research is to establish a protocol mining, metric, and 
visualization framework from which to construct an application that uncovers the complex 
dynamics of latent therapeutic themes and trial design criteria as they exist locked within 
clinical trial protocols. It is hypothesized that this novel fusion of textual information with 
real-world clinical practice will ultimately shed insights into the overall resilience of sub-
therapeutic strategies within the AD clinical research space as a function of time.  This is 
achieved through the development of an integrated “Big Data” graph-based Python mining 
and visualization framework coined ARRASTRA.  ARRASTRA first extracts and 
ontologically annotates statements from biomedical literature, forming a massive 
distributed graph of heterogeneous biomedical concepts which connect protocol 
documents.  This interconnectivity of concepts can be queried using a functional path-
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based query language to provide a semantically-enriched feature space for latent theme 
detection within a collection of documents, produced by a variety of dimensionality 
reduction techniques supported in ARRASTRA.  These latent themes are then used to 
cluster and explicitly link protocols to construct a temporally-directed network based on 
when each protocol was first filed.  This static network is then segmented into time periods 
(i.e. years), clustered into communities, and node-based importance metrics are imputed to 
identify key areas of emerging research.  A novel interactive visualization method referred 
to as “MetroMaps” is then constructed based on the dynamic connectivity of network 
communities across time segments.  Using well-understood heuristics popularized by maps 
of subway lines, MetroMaps depict how communities within a graph of interconnected trial 
protocols merge and/or diverge over time to allow researchers to explore how new ideas 
form within a large collection of documents.  Finally, ARRASTRA provides time-based 
metric reporting, by searching for significant “bursts” in graph metrics over time, as well 
as integrates these metrics into novel survival models for comparing the vitality of 
competing high-level ideas.  These capabilities allow researchers to gain unprecedented 
insights into the contents of clinical trial protocols beyond the conventional capabilities of 
ClinicalTrials.gov. 
Overall, the ARRASTRA framework serves as an intermediary translator of 
information outputs from the natural sciences, explained through the diligent application 
of information science concepts.  It aims to analyze the relationships between research 
artifacts (i.e. clinical trial protocols) in order to summarize key shifts in gold standards of 
clinical trial design, with the intent of enabling researchers the capability to explore a 
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therapeutic space at different levels of resolution.  This concept is succinctly depicted in 
the in the graphic below. 
 
 
 
Use Cases 
 
 
 While the notion of an ever-expending body of scholarly literature made readily 
accessible to researchers around the world may imply the ease of acquiring new 
information, these repositories afford unforeseen challenges associated with not just 
understanding its content from a high level but also how that content is related in 
unforeseen contexts.  Conventional text-based search paradigms allow users to search for 
individual documents, which must be interrogated individually.  The most prevalent 
modern-day example is that of conventional search engines, where the World Wide Web 
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as a massive collection of interlinked documents, can be searched in its entirety using sets 
of textual keywords.  While this may be appropriate for most information retrieval needs, 
additional research questions based on understanding how a set of documents relate to each 
other as they are published over time.  Specifically, focus is given to the definitive public 
repository for conventional clinical trial protocols documents, ClinicalTrials.gov.  Since 
filing clinical trials with ClinicalTrials.gov is a mandatory requirement prior to publication 
of results, the repository provides comprehensive industry footprints about the therapeutic 
interventions pharmaceutical companies attempt to bring to market for ailments impacting 
the wellness of patients around the world.  ClinicalTrials.gov allows users to search and 
refine collections of protocols based on keywords, and supports these conventional search 
approaches. 
However, conventional approaches for seeking information across individual lists 
of documents does not always satisfy every type of information retrieval activity.  The 
term “information retrieval” is used generally to describe the actions a user takes, 
specifically by interacting with a user interface, to locate bits of relevant information for 
educated decision making.  This can be directed in nature, where a user has a distinct goal 
in mind, or foraging, where a user employs a more exploratory approach by meandering 
through search result prompts.  It is first appropriate to list some hypothetical information 
retrieval use cases through the lenses of specific research roles in order to identify 
information needs which transcend conventional document-retrieval systems, geared 
towards clinical research applications.  Where indicated, these use cases were inspired by 
in-person discussions that researchers have expressed specifically for their respective lines 
of work. 
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1. A compound development leader, tasked with devising strategies for a new 
therapeutic agent, has inquiries regarding competing therapies and similar 
interventions which did not bear fruit in the past. 
2. A clinician is interested in better understanding how new advances in a therapeutic 
space impact the availability of applicable clinical trials for patients in their care, 
in order to direct them to new potentially life-altering studies. 
3. A medical writer tasked with composing informative literature about the genesis of 
new clinical trials wishes to understand the current state of a specific therapeutic 
space and the key trials within it.1 
4. Members of government regulatory authorities wish to monitor the historical 
performance of a particular sub-therapy within a therapeutic space over the span of 
the last 10 years.2 
While this list of specific information inquiries is certainly not exhaustive, there is 
a clear overarching theme which encompasses them all: the need for extending search 
capabilities beyond itemized collections of documents, through novel data mining and 
information visualization capabilities.  Indeed, textual research artifacts such as clinical 
trial protocols contain latent themes which persist across periods of time and can be 
used to succinctly summarize research activities.  While it is possible for researchers 
to manually interrogate and parse the information by manually reviewing each relevant 
document, this task is certainly time-consuming.  As such, the underlying motivation 
for this dissertation is to develop a data mining and visualization toolset which can 
                                                 
 
1 8th Annual Healthcare Informatics Symposium, Philadelphia, October 2015 
2 iFellows Coherence at Scale Conference, Washington D.C., November 2015 
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automatically summarize the temporal relationships between research outputs and key 
changes across research domains, given a large set of documents.  Having briefly 
discussed some potential use cases for expanded solutions to ClinicalTrials.gov, it is 
now appropriate to discuss the intricacies of clinical research and trial design in order 
to lay the foundation for the proposed solution. 
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Chapter 1: An Introduction to the Current State of Clinical Research 
 
 
The domain of clinical research is advanced through the execution of meticulously 
planned clinical trials which typically aim to demonstrate both the safety and efficacy of a 
therapeutic solution addressing the symptoms and/or complications of a disease or 
disorder compared to a placebo.  This is accomplished in a “four phased” approach across 
the product lifecycle, typically beginning with First-in-Human Phase 1 clinical trials.  
Perhaps one of the most visible and press-worthy therapeutic areas of the past decade can 
be found in Alzheimer’s Disease.  Since its discovery in 1905, a disease-modifying solution 
for Alzheimer’s has not yet been brought to market, as the research area has recently been 
marred by the failure of promising therapeutic solutions.  These failures, as well as past 
triumphs found in symptom-masking drugs brought to market, have shaped researchers’ 
current understandings of the disease and the underlying pathology which to target. 
 
 
Clinical Trial Overview 
 
 
Fundamental Principles 
 
 
The domain of clinical research is largely advanced by the meticulous planning and 
execution of observational and interventional clinical trials typically conducted based on 
details described in a clinical trial protocol.  Through clinical trials, complex 
pathophysiological insights into a disease state are obtained by either observing it in its 
natural state, or attempting to alter its trajectory through novel therapeutic interventions.  
While both clinical trial formats share similar challenges such as patient recruitment and 
enrollment, interventional clinical trials in which therapeutic agents are administered to the 
patient, present a litany of additional daunting challenges. 
11 
 
Before a new therapeutic agent can become commercially available it must be 
systematically tested in a comprehensive series of clinical trials, segmented into phases, to 
assess safety, tolerability, and most importantly, efficacy.  Generally, these product 
attributes are evaluated in three distinct clinical trial phases following the submission of an 
Investigational New Drug (IND) application by a sponsor.  The sponsor of an IND 
intended to ultimately commercialize a pharmaceutical product is typically a research-
based pharmaceutical company.  Interventional clinical trials aim to demonstrate efficacy 
of a therapeutic solution by comparing its impact on a clinical endpoint when compared 
to a placebo.  A clinical endpoint measures the biomedical phenomena being probed, such 
as blood-glucose levels for a treatment of Type 2 Diabetes, or a memory test for treatment 
of symptoms of Alzheimer’s Disease.  A clinical trial may also include multiple endpoints, 
with a primary endpoint and additional secondary endpoints.  In addition, clinical trial 
populations can be segmented into different treatment arms, or subject groups.  Such 
segmentation may be achieved through criteria such as dosing regimens or phenotypical 
characteristics in order to stratify cohorts based on some relevant biomedical attribute.  The 
planning and execution of a clinical trial for a novel therapy, as well as its subsequent 
approval, is overseen by government agencies such as the Food and Drug Administration 
(FDA) in the United States. 
 
Four Phases of Clinical Trials 
 
 
Phase 1 clinical trials are primarily intended to study the safety of a new molecular 
entity (NME) in a small group, typically in a small population of healthy subjects who are 
not members of the target population for which the NME is intended to treat.  However, 
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there are exceptions to this general requirement.  Such an exception could be the exclusion 
of “healthy volunteers” in the evaluation of cytotoxic agents to treat various forms of 
cancer.  It is also in Phase 1 that the projected commercial dose is initially proposed based 
on observed tolerability during dose escalation studies.  Since the demonstration of safety 
is the primary goal of a Phase 1 clinical trial, the evaluation of clinical endpoints is typically 
omitted.  Once the safety and tolerability within a definitive dose range are established, 
Phase 2 clinical trials can be initiated.  The goal of Phase 2 clinical trials is to study the 
NME in a larger group, typically 100 to 500 subjects.  In addition to the number of subjects, 
the criterion that typically must be satisfied before a subject can be enrolled also differs 
between Phase 1 and Phase 2 trials.  Unlike Phase 1 trials, subjects in Phase 2 are diagnosed 
to exhibit the disease indication or condition in which the NME is intended to treat.  Phase 
2 trials are therefore primarily designed to provide a preliminary indication of the drug’s 
effectiveness within the target population based on predefined clinical endpoints.  The 
safety risks, associated side-effects, and anticipated doses initially evaluated in Phase 1 are 
again assessed in Phase 2.  However, the observations gained from Phase 2 trials are more 
indicative of what could be expected in a much broader target population.  The final phase 
of clinical drug development is Phase 3, and is typically conducted prior to the submission 
of a New Drug Application (NDA) or Biologics License Application (BLA).  Much like 
Phase 2, subjects enrolled in Phase 3 trials exhibit the disease or condition for which the 
NME is intended to be indicated.  However unlike Phase 2, Phase 3 trials routinely study 
the NME in a significantly larger group, typically 500 to 1,000 patients based on the target 
disease indication.  This large number of subjects is necessary to establish statistical 
significance demonstrating that the NME achieves an acceptable safety, tolerability, and 
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efficacy profile in real-world populations.  Phase 4 clinical trials may also be executed 
after a drug is approved in order to further monitor the drug’s efficacy in larger populations 
in what’s referred to as pharmacovigilance.  In extraordinary instances based on the 
consideration of factors such as patient risk versus ultimate reward in the form of extended 
survival and/or quality of life as well as the lack of alternative therapy, a sponsor of an IND 
may seek FDA approval for accelerated development and subsequent review.  Once 
granted, the potential to expedite approval of the NDA or BLA, often by the circumvention 
of Phase 3 clinical trials, is established.  Various mechanisms associated with the ability to 
accelerate commercial availability of a NME are described in the FDA guidance document 
entitled “Expedited Programs for Serious Conditions – Drugs and Biologics” [1].  A 
commitment on the part of the sponsor to conduct pharmacovigilance studies following 
expedited approval is anticipated. 
 
 
Trial Design Considerations, Success Factors, and External Validity 
 
 
The success of a clinical trial, regardless of the phase of development, is largely 
attributed to its diligent study design.  A clinical trial protocol captures these design 
considerations, along with the rationale and execution of the study.  The study rationale 
may contain information such as which disease targets are being engaged in the study, the 
drug’s proposed mechanism of action (MOA), and/or additional background about the 
disease as it pertains to the treatment.  The study execution details dosing considerations 
such as trial visit schedules and dosage arms (including placebo).  The study design section 
of a clinical trial protocol is arguably the most critical element associated with the success 
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or failure of a clinical trial.  This includes the selected clinical endpoints and patient 
eligibility consideration.  The eligibility of a patient to participate in a clinical trial is 
contingent on pre-assigned criteria.  These are known as inclusion and exclusion criteria 
and they are typically found in the Selection/Withdrawal element of the clinical trial 
protocol.  More specifically, inclusion/exclusion criteria are sets of demographic, 
genotypic, and phenotypic conditions a patient must satisfy in order to be considered for 
enrollment into the clinical trial.  Inclusion criteria are carefully selected to identify the 
patients who are most representative of the disease state or condition intended to be treated.  
Similarly, exclusion criteria often serve to prevent the enrollment of patients with 
comorbid health conditions.  A condition is said to be comorbid if it correlates with a 
primary clinical endpoint in patient populations.  It is in the best interest to control for 
comorbid conditions within subject populations when conducting a clinical trial, such that 
it does not confound treatment signals of the clinical endpoints.  For example, depression 
and/or apathy are comorbid conditions within some populations of Alzheimer’s Disease 
patients [2].  Since these conditions have been shown to impact memory assessment scores, 
whether as a consequence of cognitive dysfunction or as an indirect indicator of synaptic 
disruption, they would ideally be controlled for in such clinical studies.  As such, the 
diligent planning and controlling of confounding factors which may hamper clinical 
endpoints is a critical key to realizing a successful clinical trial.  This does, however, raise 
one key issue: the external validity of the clinical trial.  The external validity of a study 
defines how generalizable its results are outside of the study itself.  Controlling for 
confounding factors in a clinical trial may test therapeutic agents in populations that are 
not truly indicative of real-world populations for which the therapeutic intervention is 
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intended.  It has been proposed as one possible consideration responsible for limited 
efficacy of a therapeutic agent outside the scope of a controlled clinical trial [3,4].  As 
discussed previously, clinical depression, while often used to exclude subjects in 
Alzheimer’s Disease trials, may be a consequence of the patient’s recognition in the early 
stages of the disease in real-world populations.  The impact these comorbid conditions 
ultimately have on patient populations are not well-understood within the scope of a 
clinical trial.  As such, eligibility criteria considerations to this day remains an incredibly 
focal topic of clinical research, not just for the design of clinical trials, but also for 
understanding how those criteria impact patient populations as they exist in nature [5–7]. 
The monumental challenges of advancing novel therapeutic solutions through the 
three phases of clinical development prior to commercialization are best illustrated by the 
on-going research activities within the Alzheimer’s Disease space.  Indeed, Alzheimer’s 
Disease is a highly storied area of clinical research marked with many more failures than 
successes.  By analyzing the nature of how these failures have shaped the therapeutic space 
over decades of exhaustive research, researchers can better understand how best practices 
and standards of care have emerged.  However, before the highly complex clinical trial 
space of Alzheimer’s Disease is analyzed, it is essential to establish current understandings 
of its pathogenesis and progression.  In doing so, an appreciation for the disease’s multi-
faceted complexities and how they influence clinical trial design considerations can then 
be gained. 
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Pertinent Aspects of Alzheimer’s Disease 
 
 
Historical Overview 
 
 
 
In 1906, psychologist Alois Alzheimer identified the first known case of what was 
initially referred to as “presenile dementia” during a post-mortem brain examination.  Now 
referred to as Alzheimer’s Disease (AD), researchers have spent more than a century 
conducting exhaustive clinical research in the hopes of ultimately understanding and curing 
this devastating neurological disorder.  AD is a progressive neurological condition 
characterized by the accumulation of senile plaques, neurofibrillary tangles, and neuronal 
death, leading to cognitive dysfunction.  AD systematically dismantles synaptic 
connections between neurons, which are vital for normal cognitive function.  As a result, 
patterns of atrophy in key anatomical structures of the brain’s temporal lobe, specifically 
the hippocampus, are noted on magnetic resonance imaging (MRI) images.  Episodic 
memory is first impacted as a consequence.  As this insidious disease progresses, patients 
lose their ability to function efficiently in simple daily activities, until the point where 
institutionalization and full-time care is required.  In the absence of a major medical 
breakthrough, it is estimated that by the year 2050, over 106 million people across the globe 
will be afflicted with this disease, resulting in a projected burden of $500 billion dollars on 
healthcare systems worldwide [8,9].  Promising strides in understanding the underlying 
disease mechanisms and risk factors associated with AD continue to be made through the 
identification and refinement of biomarkers.  Unfortunately, however, a viable disease-
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modifying therapeutic solution for altering the course of cognitive decline due to AD still 
does not exist. 
 
 
Biomarker Cascade 
 
 
From a pathophysiological perspective, AD is dynamic in the manner in which it 
presents itself over the course of the disease in the form of biomarkers.  Biomarkers are 
measurable substances, both genotypic and phenotypic in nature, that serve as diagnostic 
indicators for the presence of disease [10].  For example, a positive confirmation of AD 
pathology can be established from the intensity of radioactive tracers bound to amyloid 
plaques in key anatomical regions of the brain, acquired through positron emission 
tomography (PET) imaging [11].  The deposition of amyloid plaques within specific 
subcortical brain regions, as measured by a standard uptake value ratio (SUVR), is one 
example of a diagnostic biomarker.  Not only are these biomarkers useful from a diagnostic 
perspective, but they can also serve as potential drug targets for directly engaging 
pathology which drive disease.  A biomarker cascade arranges the dynamics of these 
biomarkers on a temporal scale.  Specifically, for AD, the Jack Model proposes a 
theoretical timeline of changes in measurable biomarker quantities as the disease 
progresses, including: amyloid plaque deposition, neuronal death, changes in the 
cerebrospinal fluid (CSF), changes in brain morphology, cognitive dysfunction, and finally 
impaired daily living [12,13]. 
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Figure 1. The Jack Model depicts the theoretical trajectory of hallmark AD biomarkers 
 
 
Characterizing the dynamics of these biomarkers is vital to the understanding of the 
clinical research space of AD in its entirety.  A paramount benefit of such analysis is the 
pharmaceutical industry’s ability to begin to understand the evolution of how and when 
researchers have attempted to engage the disease at specific points along the disease 
cascade.  It is proposed that these shifts in knowledge lie buried within collections of 
clinical trial protocols.  While the exact pathogenesis of AD is still not entirely understood, 
the establishment of the Jack Model and subsequent research which empirically validate 
its theoretical underpinnings with real observational data, allows researchers to better 
understand how and when to directly engage the disease with therapeutic solutions.  
Numerous clinical strategies intended to slow or halt the insidious progression of AD have 
been proposed and evaluated in countless clinical trials.  Such trials have included patients 
whose disease state spans the entire disease cascade. 
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Types of AD Clinical Trials 
 
 
Overview 
 
 
The clinical research domain of Alzheimer’s Disease is complex and multifaceted.  
Consequently, it is imperative to first understand the domain at a high-level.  As previously 
mentioned, the domain of clinical research is largely advanced by the meticulous planning 
and execution of observational and interventional clinical trials. Clinical trials indexed in 
clinical trial protocol repositories represent both observational and interventional trials.  
Observational studies aim to better understand natural disease progression or validate 
new technologies which propose to probe disease pathology to yield further clarity about 
the pathogenesis or progression of a disease.  Examples include studies which attempt to 
understand disease progression through the dynamics of predictive biomarkers such as 
those in cerebrospinal fluid (CSF) [14], validating diagnosis cohort-sensitive cognition 
tests [15], or evaluating the utility of amyloid tracers used in Positron Emission 
Tomography (PET) imaging for quantifying the amount of amyloid burden in key 
anatomical brain structures [16].  The importance of observational trials can be linked to 
how they advance knowledge regarding underlying pathophysiological phenomena 
associated with AD.  Through these studies, the natural progression of the disease, 
uninterrupted by intervening medications, can be observed.  There is evidence that 
observational trials may eventually intersect with intervention trials as the observed 
approach matures.  For example, observational trials seeking to understand the properties 
of PET imaging tracers have matured to the point where they are implemented in amyloid-
clearance intervention trials as a means to quantify drug efficacy [17].  Additionally, the 
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identification of more diagnostically predictive biomarkers and cognitive tests in the form 
of best-practice guidelines can serve as better screening criteria for interventional clinical 
trials [18].   
Interventional studies can be further broken down into non-pharmacological and 
pharmacological therapeutic solutions.  Traditionally, pharmacological solutions are often 
further classified as either disease-masking or disease-modifying.  Recognizing the roles 
which these types of clinical trials have in the context of AD treatment strategies provides 
a foundational understanding of the research field itself. 
 
 
Non-pharmacological Studies 
 
 
Non-pharmacological interventional solutions for AD typically rely on methods 
of treating a disease without introducing a medicinal compound into the body.  These 
include exercise and dieting programs [19], cognitive group therapy and counseling [20], 
and cognitive training and memory-strengthening games [21].  Other types of non-
pharmacological trials can focus on alleviating the burden for caregivers of AD patients 
through support programs [22] to improve health outcomes.  Music programs, for example, 
provide enjoyment and stimulation to reduce apathy and depression [23].  In general, these 
types of clinical trials aim to improve quality of life for patients and their families, and 
correlate such improvements with better health outcomes. 
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Pharmacological Studies 
 
 
Pharmacological interventional based therapies are considered potentially more 
transformational in nature and are frequently further categorized as disease-masking or 
disease-modifying.  Disease-masking therapeutic solutions attempt to alleviate primary 
and secondary symptoms of the disease.  With regards to AD, such symptoms may include 
memory deficit, agitation, aggression, depression, sleep irregularities, decline in quality of 
life, and general health.  While these medicinal therapies may address symptoms, both 
primary and secondary, they are generally superficial in nature.  Pharmacologically, these 
symptom-treating drug classes include therapeutic solutions such as acetylcholinesterase 
inhibitors [24] and antipsychotics [25].  Since they do not alter the trajectory of the disease 
by directly engaging disease pathology, their efficacy may weaken as the disease 
progresses.  For example, therapies which stimulate the activity of certain classes of 
neurons (i.e. cholinergic, gamma-aminobutyric acid (GABAergic), dopaminergic 
receptors, etc.) to improve cognition tend to exhibit efficacy as long as those drug targets 
remain in abundance.  Since AD progressively destroys these potential receptors, 
eventually a point in time will be reached when the disease worsens to an extent whereby 
these therapies will have little therapeutic effect.  Additionally, disease-masking 
intervention trials have also studied the combined efficacy of multiple therapies when taken 
simultaneously in order to address comorbid symptoms [26].  Studies may also repurpose 
over the counter (OTC) products such as vitamins and herbal supplements [27] to address 
disease symptoms.  This is true for physician-prescribed medications as well.  A variety of 
examples can be found in the literature including the use of statins for controlling 
cholesterol [28] to insulin nasal sprays for maintaining brain-glucose levels [29].  Other 
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studies represent “gray areas” of research, such as deep-brain stimulation with magnetic 
waves [30]. 
The ultimate goal of AD research is to one day make available therapies meeting 
the criteria of disease-modifying solutions.  Disease-modifying therapies directly engage 
hallmark pathology which is believed to drive the disease at various points along the 
disease cascade.  For example, past therapies proposed the ability to clear amyloid deposits 
directly from structures contained within the neocortex through the parenteral 
administration of monoclonal antibodies [31].  After disappointing results suggested that 
clearing amyloid deposits by invoking immune responses did not improve the worsening 
of cognitive dysfunction, research efforts shifted to biomarker targets further upstream in 
the disease cascade.  As a result, next-generation therapies began focusing on inhibiting 
the formation of amyloid before they oligomerize and deposit in the brain [32].  Some 
therapies attempt to protect neurons from neurotoxic factors believed to induce neuronal 
death or bolster neuronal connections [33], while others propose to address the role that 
oxidative stress plays with neuro-inflammation and cognitive worsening [34].  Microglial 
activation is another therapeutic strategy which proposes to effectively clear the brain of 
cellular waste [35].  Per FDA regulations, disease-modifying solutions not only must be 
safe and exhibit an efficacious effect on halting or slowing decline in cognition over time 
by directly engaging primary disease pathology, but also demonstrate a correlation to 
improvement in function of daily living [36].  In other words, beyond being safe and 
efficacious, a true disease-modifying treatment for AD must additionally demonstrate 
patient stability in their capacity to live independently through carrying out basic daily 
tasks.  While this may seem overly intricate, it ensures that patients’ lives will not be 
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harshly extended without the added benefit of living an improved life, free of reliance on 
caregivers. 
 
 
Evolving Gold Standard Approaches for Disease Treatment 
 
 
Recent failures of promising disease-modifying therapies have caused the 
pharmaceutical industry to reevaluate conventional hypotheses into the pathogenesis of AD 
which will most certainly lead to further modifications of the Jack Model.  Inquiries such 
as how amyloid deposition ultimately leads to neuronal death and hallmark neurofibrillary 
tau tangles are being actively investigated.  This raises an even more important question 
regarding how early a drug intervention should begin, a term coined as disease 
interception [37,38].  It is becoming increasingly clear that once a decline in cognition 
becomes measurable on sensitive memory tests, the disease has already progressed to the 
point where irreparable damage has occurred to the brain’s neuronal connectivity.  This 
consequently makes the chances of improving cognition at late stages of the disease 
through disease-modifying therapies less likely.  As a result, the industry in the past decade 
has since shifted from treating subjects with mild to moderate AD, to those at earlier stages 
of the disease, such as prodromal AD.  Subjects suspected of prodromal AD are those not 
currently demonstrating cognitive symptoms but exhibiting amyloid pathology in the brain.  
In light of these challenges, revolutionary approaches to designing and implementing 
clinical trials must be devised.  Indeed, having to accurately screen for ideal subjects who 
have AD pathology accumulated in the brain but not yet exhibiting cognitive deficits will 
require strategies which balance both cost and accuracy.  Accurate biomarkers for 
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screening AD pathology in patients can be found in PET imaging (amyloid burden), but is 
a costly method.  Another screening option is measuring the ratio of amyloid beta and 
phosphorylated tau proteins in the CSF via spinal tap.  However, this process is highly 
invasive and the potential for complications does exist.  New screening biomarkers may be 
found in panels of analytes circulating throughout the blood which correlate with amyloid 
burden, and could theoretically be administered with a simple blood test [39,40]. 
The purpose of this high-level introduction highlighting historical areas of AD 
research and proposed future directions is not to simply provide foundational information 
about the disease within the context of this dissertation, but additionally to demonstrate the 
complexities of the domain which has been seeking viable disease-modifying solutions for 
over a century.  It is clear that a much deeper understanding of how these sub-therapies 
originated and progressed over time is appropriate.  However, the nature of how and when 
gold standards outmode and emerge becomes obfuscated within the growing amount of 
research studies conducted over time.  It is therefore proposed that the diligent historical 
analysis of clinical trial protocol collections be considered for gaining deeper insights into 
trends contained within those collections.    This first requires an understanding of how, 
from a process-oriented perspective, data is openly shared and integrated across functional 
research areas through the concept of translational research.  Having established the utility 
of open biomedical data, the official clinical trial protocol repository in the United States, 
ClinicalTrials.gov will then be introduced and discussed in this context.  Lastly, the 
challenges and limitations of ClinicalTrials.gov will then be introduced, as they ultimately 
influence how subsequent analyses in this dissertation are conducted. 
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Chapter 2: Open Biomedical Data: Reshaping Pharmaceutical Research 
 
 
The proliferation of open biomedical repositories has reshaped how researchers 
share and integrate data in order to derive new insights. The subsequent advent of 
“translational research” coupled with the expanding reliance on biomarkers associated 
with AD capitalizes on prior knowledge generated, making it a suitable clinical research 
domain to explore as captured within collections of clinical trial protocols.  
ClinicalTrials.gov, the de facto index for these protocols in the United States, serves as a 
basic document storage to fulfill the minimum requirements of regulatory transparency.  
While the use of ClinicalTrials.gov is mandatory for NDA filings and thus serves as a 
“pulse” of the current state of the industry, it still lacks levels of highly descriptive detail 
to make it a heavily utilized database for research purposes.  The fact that this mandate 
exists, however, suggests unique opportunities from which to build new healthcare 
applications by repurposing the data and integrating it with other preexisting data sources.  
As a result, initiatives to extend the utility of ClinicalTrials.gov have been conducted 
recently through both private and government funding.  These efforts, however, mainly 
focus on patient-facing solutions to streamline trial engagement and enrollment.  This 
positions the proposed dissertation research to fill unmet research-oriented applications. 
 
 
Translational Research 
 
 
The ability to one day “intercept” Alzheimer’s Disease in the prodromal phase, 
prior to irreversible neuronal damage, will require collaboration and information sharing 
across the entire medical community on a scale previously thought to be insurmountable.  
Enhancing the transparency of the on-going activities within key therapeutic spaces such 
as AD requires an ever strengthening partnership such as that currently being established 
between universities, research-based pharmaceutical companies, healthcare practitioners 
and global health authorities.  Despite unprecedented cooperation, significant challenges 
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continue to exist within and across the drug discovery, drug development, clinical testing 
and regulatory approval processes.  As previously mentioned, in recent years a troubling 
trend has become apparent.  The probability of successful clinical trials leading to 
regulatory approval of NMEs have been decreasing in light of rising costs required to 
execute such trials [41,42].  This unfortunate fact has forced researchers to rethink best 
practices regarding how disease targets are identified and engaged through the management 
of biomarkers and clinical endpoints.  In parallel, clinicians are reevaluating strategies to 
optimize the prospective patient recruitment process to maximize the probability that safety 
and efficacy can be successfully demonstrated.  The concept of translational research 
was formulated largely in response to these challenges [43].  Instead of relying upon a 
traditional linear drug development process model which follows an incremental stepwise 
workflow, researchers established an iterative approach in which drug discovery and 
clinical research establish common research threads through increased communication and 
data sharing.  As the name implies, translational research capitalizes on the knowledge 
gained by scientists in the laboratory and “translates” in a feed-forward manner those 
insights to physicians in the clinic.  The physicians then feed-back the knowledge they gain 
to the scientist in the laboratory.  Consequently, the term “bench to bedside” and “bedside 
to bench” is often used to describe this relatively new interdisciplinary approach of medical 
research [44].  This type of iterative knowledge sharing and translation requires novel 
information fusion capabilities to which the industry is currently ill-equipped to 
accommodate.  As a response to these challenges in recent years, industry leaders have 
turned to harnessing open data systems to further advance the integration of insights shared 
across functional research areas.  In some instances, such databases are specific to AD (e.g. 
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Alzheimer’s Disease Neuroimaging Initiative) and in other cases general to the field of 
clinical trial management (e.g. ClinicalTrials.gov). 
 
 
 
Figure 2. Translational Research flow of information 
 
 
Open Clinical Trial Data Initiatives Born from Translational Research 
 
 
While the establishment of innovative synergies through translational research has 
promised revolutions in the design of clinical trials and the quality of data collected, it has 
consequently created a tremendous challenge associated with the ability to effectively 
manage/translate the plethora of data generated.  In order to better understand the 
pathogenesis and progression of AD in large populations, massive multi-center initiatives 
have been launched in order to compile comprehensive real-world longitudinal biomedical 
databases specific to AD.  It was becoming woefully apparent that isolated efforts internal 
to research organizations could not effectively acquire the amount of longitudinal clinical 
and biomarker data required to shed new insights into this insidious disease.  Indeed, open 
and collaborative multi-site efforts were needed to provide the global research community 
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with comprehensive observational data, such that knowledge of the progression of AD 
could be advanced at a faster rate.  Most notable is the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) [45].  This consortium of clinics and laboratories across the United States 
compiles a comprehensive dataset made publicly available to researchers who register their 
research intentions for using the data.  Since its inception in 2005, the ADNI effort spans 
multiple memory centers throughout the United States and codifies their findings into a 
comprehensive anonymized longitudinal observation dataset.  It provides numerous 
demographic, genotypic and phenotypic endpoints (e.g. cerebrospinal fluid, PiB-PET 
imaging, MRI brain scans, etc.) as well as cognitive and functional assessments (e.g. Mini 
Mental State Examination, Neuropsychiatric Inventory, ADAS-Cog, Frequent Activities 
Questionnaire, etc.) for cognitively normal (CN), mildly cognitive impaired (MCI), and 
diagnosed AD subjects [46].  At this time, over 200 publications which are attributed to 
the use of the ADNI dataset have been published, making it an incredibly pivotal dataset 
for researchers to utilize in the fight against AD [47].  Another key effort is the Australian 
Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), which targets similar 
goals to ADNI [48].   
However, most research involving ADNI and AIBL focuses either on utilizing 
biomarker data to better understand the insidious pathophysiological timeline of the disease 
or attempts to provide predictive models for accurately diagnosing the disease using less 
expensive and invasive means.  As a future research opportunity that should be considered 
by research organizations, it is envisioned that the ability to translate these data into an 
understanding of how patient eligibility criteria has evolved over the lifetime of a 
therapeutic space in light of continued clinical trial failures is novel, and would provide an 
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invaluable tool in assisting the design and execution of future AD clinical trials.  The 
principles that these open data initiatives embody suggest a radical methodological shift in 
how clinical research is conducted.  By one day successfully integrating clinical, genotypic, 
phenotypic, and imaging modalities, and sharing these observations across the broader 
research community, the vision of translational research can be realized. 
As previously stated, the success of translational research in facilitating the 
discovery of next-generation therapeutic agents is directly linked to the ability of a research 
organization (e.g. a research-based pharmaceutical company, hospital, university, NIH, 
etc.) to capitalize on learning experiences gained from successfully executing clinical trial 
protocols (e.g. dosing design, patient outreach, screening and enrollment) based on 
predefined inclusion/exclusion criteria.  Furthermore, success is predicated on 
understanding an expanding body of interconnected research as well as how implications 
derived from associated trials translate across numerous specialized domains of biomedical 
research.  While each research sub-domain (e.g. genomics, proteomics, clinical research, 
etc.) views a research problem from different perspectives, these are merely pieces to a 
puzzle that together are intended to yield a much bigger solution.  The challenge is realized 
in understanding how findings translate across these different perspectives.  Enabling these 
capabilities allows researchers to make decisions in a timelier manner, specifically to 
address challenges associated with target identification (e.g. appropriate biomarkers) and 
patient enrollment. 
In 2014, the AllTrials initiative associated with the Open Knowledge Foundation 
[49] undertook a mission that is simply summarized as “All Trials Registered, All Trials 
Reported”.  As forerunner to the AllTrials initiative and similar in many respects to ADNI, 
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in 2006 a number of major pharmaceutical companies released clinical trial data of placebo 
arms of their most profitable acetylcholinesterase clinical trials through an initiative called 
Coalition Against Major Diseases (CAMD), conducted by the Critical Path Institute 
[50,51].  Surprisingly, the two leading global pharmaceutical trade association, 
Pharmaceutical Researchers and Manufacturers of America (PhRMA) and the European 
Federation of Pharmaceutical Industries and Associations (EFPIA), were not fully 
supportive of AllTrials as a voluntary initiative.  Fortunately, some major pharmaceutical 
companies such as Johnson & Johnson (J&J) and Glaxo SmithKline (GSK) have broken 
ranks with PhRMA and EFPIA to offer full cooperation in support of the AllTrials mission.  
Unlike their trade associations, J&J and GSK do not see a redundancy, but rather a synergy, 
between the AllTrials and clinical trial protocol databases.  In fact, the considerations taken 
into designing successful clinical trials have been made publicly available to clinicians, 
health practitioners, medical writers, and patients alike, in the name of regulatory 
transparency.  These come in the form of digital documents hosted on publicly-facing 
document storages, such as the definitive website maintained by the National Institute for 
Health (NIH): ClinicalTrials.gov. 
 
 
Overview of the ClinicalTrials.gov Clinical Trial Database 
 
 
Background 
 
 
In the United States, ClinicalTrials.gov has been the definitive data source for 
collecting and indexing such information about past, on-going, and planned clinical trials 
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since its inception in 2000.  The National Institute for Health (NIH) serves as the website 
host.  As of 2005, all research organizations conducting a trial are required to submit 
information regarding the description, efficacy endpoints, and inclusion/exclusion criteria 
for the trial before submitting the work for publication [52].  Public-facing clinical trial 
protocol documents exist primarily to inform regulatory agencies about which methods 
will be employed to measure both safety and efficacy of the proposed therapeutic solution 
for the given indication [53].  This transparency also benefits primary care physicians, 
specialists, and prospective patients alike by informing them of pertinent trials currently 
recruiting subjects.  In 2009, researchers were also encouraged to provide results of their 
trial in a semi-structured format, although adoption for this feature has been modest thus 
far [54,55].  ClinicalTrials.gov has also been utilized by researchers around the world to 
aid their efforts in developing strategies to optimize the processes associated with trial 
transparency, subject outreach, and enrollment [56].  Indeed, the importance of open trial 
repositories should not be understated, as they capture the required footprints of industry 
activity before publications of those trial results are released to the broader research 
community. 
The foundation of the ClinicalTrials.gov database is the clinical trial protocol.  As 
previously defined, a clinical trial protocol is a document which outlines the rationale, 
design, and execution of a clinical trial.  Before the advent of clinical trial document 
repositories, protocols were stored and maintained internally as lengthy text documents 
from which qualified researchers would have to manually interrogate.  Efforts to catalog 
these documents with standardized structures and fields have since been undertaken such 
that information can be more easily located.  This effectively segments text-based protocols 
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into finer-grained fields of information.  In theory, clinical trial protocols are assigned a 
title appropriately describing the nature of the research and a more detailed description 
field providing additional information about the study.  Furthermore, timestamps are 
supplied for marking key events in the trial lifecycle, such as when the protocol was first 
filed, when patient enrollment was opened, the official start date of the trial, and the 
termination or completion date of the trial.  An eligibility field may also be supplied, 
indicating the criteria from which a patient would be screened for enrollment into the trial.  
A trial arm field indicates how patients will be randomized into different treatment 
populations, including different dosing regimens and placebo groups.  An outcomes field 
lists the specific trial endpoints from which efficacy will be assessed.  A status field is also 
used to indicate overall status of trial with indicators such as “Planning”, “Recruiting”, 
“Ongoing”, “Terminated”, and “Completed”.  The “Terminated” indicator may include a 
brief description as to the reason for the trial to be terminated, including 
administrative/logistic issues, enrollment difficulties, and shifts in organization strategies 
(ex. a decision to stop pursuing the therapy due to past failures in efficacy).  Indexed 
clinical trial protocols are maintained by company employees overseeing the development 
of the proposed therapy, who in theory update these filings with the most recent 
information. Figure 3 depicts an excerpt of a clinical trial protocol, with high-level fields 
highlighted in orange, and key biomedical concept within those respective fields 
highlighted in green.  The relationship between protocol fields and the concepts which 
appear within them is an important concept which establishes the backbone of the 
underlying data structure for this solution, discussed in detail in Chapter 5. 
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Figure 3.  Clinical trial protocol example with annotated fields and highlighted concepts 
 
 
Importance 
 
 
In general, it is required that applicable clinical trial protocols, or interventional 
studies which span multiple U.S. sites, be filed with ClinicalTrials.gov prior to publication 
of clinical results.  As a result, ClinicalTrials.gov has the capability to serve as a “pulse” 
of the pharmaceutical industry as a whole.  Indeed, the efforts required for an organization 
to merely plan and file a new clinical trial study is significant.  It suggests that a 
groundswell of information is present and well-founded for research organizations to pool 
resources in the pursuit of clinical endeavors.  Unlike peer-reviewed published literature 
that can reflect biases for the most successful and popular areas of research, the documents 
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provided in clinical trial protocol represent a comprehensive set of all types of research 
activities.  However, clinical trials which are terminated due to poor patient recruitment 
shortly after they have been filed, changes in organizational strategies, as well as 
disappointing results in related or dependent trials may never reach a point where there is 
a record of its existence in published literature.  In addition, timestamps are generally 
associated with each of these trial milestones, making it possible to temporally arrange the 
on-going activities occurring within the pharmaceutical industry.  The semi-structured 
format of digital clinical trial protocols lends itself to provide additional context to the 
biomedical concepts they contain.  Overall, clinical trial protocols serve as documents 
which provide content that has historically been overlooked in favor of conventional 
published literature and provides previously unexplored text and metadata endpoints from 
which novel analyses can be conducted, due to government regulations dictating how 
protocols should be filed.  The potential utility of ClinicalTrials.gov has been noted by 
government and private research organizations alike.  While the content in its current form 
is generally not attractive to broader research communities, significant efforts originating 
from these groups have been made to further extend the functionality of ClinicalTrials.gov.  
This requires diligently curating and/or integrating clinical trial protocols with other 
biomedical data sources.  As will be discussed, since these efforts focus on patient-facing 
solutions, integrated data sources specifically focus on electronic health records for more 
efficiently matching patients with applicable trials that are currently recruiting. 
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Private and Government-Funded Initiatives 
 
 
Approaches to Extending ClinicalTrials.gov 
 
 
In order to properly convey the gaps in knowledge which exist within the space of 
clinical research informatics, it is first appropriate to provide a high-level survey of past 
works which most closely embody the proposed research.  The timeliness and utility of the 
research subsequently described in this dissertation are justified by exposing the major gaps 
in knowledge which currently exist within the associated space of clinical research 
informatics.  A high-level survey of both relevant unicentric research and polycentric 
collaborations which share similar themes in potentially extending the functionality of 
ClinicalTrials.gov will be presented.  This includes a broad range of efforts, from 
supporting the optimization of clinical trial design to the facilitation of patient recruitment 
and enrollment processes.  As will become evident, there is no single research effort which 
completely embodies the entire goals of this dissertation from which to directly draw 
comparisons.  Rather, the most relevant works which share similar themes in extending the 
functionality of ClinicalTrials.gov for a variety of reasons will be explored. 
 
Web-Based Clinical Trial Recruitment 
 
 
The NIH Big Data to Knowledge (BD2K) [57–59] initiative serves as an excellent 
example of the government’s commitment to address a major challenge in the 21st century, 
specifically, the medical community’s ability to effectively manage overwhelming 
volumes of data in an effort to enhance both the health and overall quality of life of all 
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citizens in the United States.  Similarly, acknowledging the expanding importance of open 
clinical data sharing in the interest of increased regulatory transparency but hindered by 
disparities in overall utility of available platforms, President Obama introduced a “Big 
Data” initiative in November 2013.  Formally known as Data to Knowledge to Action, this 
multifaceted effort continues to yield significant advancements.  One facet of this initiative 
attempts to extend both the functionality and usability of ClinicalTrials.gov.  In doing so, 
a targeted output was to develop the ability to ultimately link patients to ongoing or 
anticipated clinical trials captured in ClinicalTrials.gov through the use of individual 
patient electronic health profiles [60].  To achieve this goal, three research-based 
pharmaceutical companies, Pfizer, Novartis, and Eli Lilly, established a collaboration that 
led to the creation of the Patients to Trials consortium. Ultimately the consortium will 
revamp ClinicalTrials.gov in order to appeal to patients seeking to enroll in potentially life-
saving and/or life-enhancing clinical trials.  Indeed, with the advent of online health 
resources such as WebMD, the concept of patient empowerment has gained great 
popularity.  The ability to self-diagnosis and, in some cases, self-medicate has never been 
more common. Unfortunately, patient empowerment leading to self-treatment has 
unintended consequences.  There are, however, significant barriers for streamlining patient 
awareness to the existence of potentially life-saving/life-enhancing clinical trials that have 
been filed or are currently enrolling [61,62].  As a result, the Patient to Trials consortium 
recognized this unmet need as a useful way of extending the functionality and usability of 
ClinicalTrials.gov thereby linking patients to appropriate clinical trials.  One approach 
being explored is standardizing and structuring clinical trial protocols in such a way that 
can be easily understood by patients.  In cooperation with Patients to Trials, a third party 
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London-based start-up company named TrialReach has addressed the challenge [63].  
Currently, TrialReach has processed 781 diabetes clinical trials, and anticipates shifting 
focus to AD clinical trials in the near future.  The TrialReach Beta website 
(http://laennec.trialreach.com/) uses location information to pool on-going clinical trials 
within a specified radius identified by the user.  The user is then asked a series of simple 
health-related questions relevant to inclusion/exclusion criteria, and is presented a list of 
clinical trials of potential interest.  While there is little transparency into the exact ways 
TrialReach curates its clinical trial protocols, supposedly using Eli Lilly and Company’s 
clinical trial application interface (API), an important benefit of this concerted effort is the 
fact that it begins to bring actual structure to clinical trial protocols and integrates them 
with basic patient health data. 
OpenTrials is another web-based portal currently in a proof-of-concept phase [64].  
It is reportedly receiving early funding through the Laura and John Arnold Foundation.  Its 
goal is to serve as a portal which integrates multiple sources of heterogeneous information 
for different audiences involved in the clinical trial enrollment processes including 
subjects, researchers, and regulatory authorities.  This is proposed by harnessing open data 
and integrating it in such ways to provide new capabilities including a “transparency 
board”.  For example, this feature provides clinical trial monitors with the capability to 
report on aspects of a trial where data is missing or incomplete.  The curators of this portal 
suggest that these dashboarding tools will help adopt better transparency through enhanced 
and diligent data curation.  These recent and highly visible activities suggest that the efforts 
presented in this thesis are incredibly important as well as timely.  However, since these 
specific issues were given prioritized focus from top government agencies, this specific 
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approach to extending ClinicalTrials.gov may soon become over-saturated with a large 
amount of overlapping solutions. While these initiatives are undoubtedly useful for making 
trial protocol repositories more approachable to prospective patients, the research proposed 
in this dissertation targets more technical solutions geared towards facilitating informed 
clinical trial protocol design. 
However, Data to Knowledge to Action is not the first time researchers have 
established a multidisciplinary collaboration to more effectively curate and structure 
clinical trial protocols such that information can be more easily queried at finer levels of 
granularity.  In 2007, Duke University, in cooperation with a cadre of health-based 
companies forged an initiative which seeks to provide a curated database schema and dump 
of the ClinicalTrials.gov database on an annual basis to provide finer-grained access to the 
data it exposes [65].  Another initiative, LinkedCT.org, has explored structuring clinical 
trial protocol information in a linked data format (RDF) [66,67].  More recently, Eli Lilly 
and Company has developed a web-based application interface (API) to programmatically 
access curated data from ClinicalTrials.gov called the Lilly Clinical Open Innovation 
(LCOI) platform (https://lillypad.lilly.com/).  Rather than download clinical trial protocols 
in bulk XML files, LCOI provides programmers with HTTP endpoints from specific fields 
of specified protocols.  As mentioned previously, it is believed that services such as 
TrialReach also purposes the LCOI API as its core source of data retrieval. 
The various consortiums and polycentric collaborations cited, as well as the 
research described in this dissertation, has one common theme.  That is, regardless of the 
current limitations of the ClinicalTrials.gov database, the information captured within the 
voluminous amounts of clinical trial protocols can be repurposed in novel ways.  The 
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majority of cited initiatives intended to extend the use of ClinicalTrials.gov however has 
been largely focused on providing finer-grained curated data structures rather than semi-
structured blocks of plain-text currently in production.  While these initiatives are 
undoubtedly useful, they serve more as a means to extending the utility of systems which 
store clinical trial protocols – they are not necessarily a complete solution themselves.  In 
other words, they allow for data regarding clinical trials to be repurposed in novel ways 
with less effort, but ultimately still host the same data at different resolutions and in a 
variety of data formats.  Additional steps still must be taken to process and synthesize the 
actual content of the data such that they provide the end user with meaningful information.  
Additionally, the inspiration for these initiatives has mainly been driven by patient-facing 
needs in educating both patients and their physicians on new clinical trials and facilitating 
subject engagement and enrollment.  This leaves unmet opportunities which this 
dissertation looks to more fully address in extending functionality beyond patient 
recruitment for the purpose of supporting scientific research efforts, specifically, 
identifying optimizations in AD clinical trial protocols to advance the current “standard of 
care”. 
While clinical trials fail to progress due to inadequate patient recruitment, one 
inherently related reason for termination is due to increasingly complex clinical trial design 
[68].  The former challenge is being actively and adequately addressed by web-based 
recruitment portals such as TrialReach and OpenTrials, as briefly described.  However, the 
latter poses an additional set of challenges due not only to database formats previously 
mentioned (e.g. lack of granularity), but also the inherent complexities of the underlying 
disease state itself (e.g. consistent/meaningful assessment scales).  For research 
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applications, expanded data processing is required beyond those presented previously in 
order to parse biomedical text into more granular conceptual representations.  Next, it is 
appropriate to briefly describe additional data needs which exist with ClinicalTrials.gov 
which are currently unmet by these recent initiatives. 
 
 
Data Usability Challenges Associated with ClinicalTrials.gov 
 
 
While researchers have used the ClinicalTrials.gov database for diverse purposes 
mentioned previously, it is often maligned for its lack of usability and features.  
Consequently, it is relatively under-utilized for the data it currently contains.  The current 
capabilities of ClinicalTrials.gov reflect the fact that such document repositories were 
initially created merely as a way to meet government regulations of clinical transparency 
– not a platform from which mining activities can be performed to gain deep insights about 
a therapeutic space as a whole.  The website itself serves mostly as a simple document 
retrieval storage system, indexed directly from the protocol text using plain-text keyword 
identifiers derived from the Medical Subject Headings (MeSH) terminology.  As a result, 
users must manually seek relevant protocol documents from lengthy lists of results, and 
interrogate each one individually.  The website does conveniently provide bulk export of 
protocols from search results in a variety of data formats, however.  As will be developed 
as a fundamental premise of this dissertation, this in itself suggests a key unmet need that 
can be addressed by further extending the website from a semi-structured plain-text 
document storage to an informatics platform from which latent temporal trends can be 
extracted and visualized. 
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The plain-text indexing of MeSH keywords also presents inherent challenges.  
While MeSH is a hierarchically-structured terminology, the website uses plain-text 
representations of these terms as tags to simply index protocols much like a journal may 
require authors to provide keywords used to describe a publication.  While this is not 
particularly an issue in itself, the tags used are extremely generic in nature.  For example, 
the majority of clinical trials are tagged with “Alzheimer’s Disease”, “Neurological 
Disorders”, and “Dementia”; they do not adequately capture the specific nature of the trial 
itself.  However simply “tagging” a clinical trial with a small set of definitive keywords 
presents issues in itself due to the nature of clinical trials which are complex and multi-
faceted.  For example, an AD clinical trial may measure the impact that the long-term use 
of a drug has on halting or slowing the rate at which a brain atrophies.  Clearly, this 
pharmacological intervention which includes a key imaging component can be categorized 
in more than one way.  As such, relying on a small collection of “tags”, specifically to 
individually bucket similar clinical trials, is not a straight-forward approach.  Furthermore, 
ClinicalTrial.gov’s MeSH indexing system does not fully exploit the inherent hierarchical 
structure of the terminology.  Indeed, it would be particularly useful if tags could be 
inserted at varying degrees of granularity.  For instance, one clinical trial evaluating the 
effectiveness of “galantamine hydrobromide” and another “donepezil hydrochloride”, even 
if properly tagged as such, will fail to establish the fact that they are both 
acetylcholinesterase inhibitors (AChE) unless it is explicitly stated in each protocol.  As 
will be expanded upon, this is a key pitfall when analyzing data provided by the 
ClinicalTrials.gov database, especially when detailed information about individual clinical 
trial protocols is considerably sparse. 
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Another key limitation of the ClinicalTrials.gov database is the generally terse 
nature in which information about the clinical trial is presented in the text.  Since novel 
therapeutic solutions in their infancy are closely guarded company secrets, there is certainly 
little incentive for a research organization to provide detailed information about the 
rationale behind the study or the mechanism of action of the drug being tested.  This is 
especially true during the early phases of clinical development (ex. Phase I), and even more 
so for those potential therapeutic agents that are considered to be first-in-class.  The desire 
of organizations to protect such proprietary details associated with a potential billion-dollar 
investment is certainly understandable.  As a result, the clinical trial description may be 
presented in a vague manner while still meeting the regulatory requirement.  Additionally, 
generic names (e.g. donepezil hydrochloride) and associated commercial trade name 
(Aricept®) are not assigned and granted, respectively until later clinical trial phases.  
Instead, pharmaceutical companies such as Eisai Co. Ltd, the discoverer of donepezil 
hydrochloride which is marketed under the trade name Aricept®, tend to rely on internal 
compound naming conventions (i.e. E2020) during early phases of clinical development.  
Although varying from company to company, this naming convention typically takes the 
form of an abbreviation for the company’s name and a string of numbers, meaningful only 
to the company filing the trial (e.g. E2020).  Solutions which mine content from 
ClinicalTrials.gov must be able to resolve these discrepancies.  While ClinicalTrials.gov 
provides researchers with virtually every clinical effort conducted since its inception in a 
semi-structured way, there are concerns with the overall quality of the information 
provided by the sponsor of a clinical trial.  In the absence of standardized terminology, a 
variety of terms can be used in a protocol to denote the same concept. The sometimes 
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intentional lack of transparency due to proprietary concerns is an important concept and 
potential challenge to consider, especially when approaching the data with the intentions 
of extracting meaningful information from it. 
 
 
Extending ClinicalTrials.gov for Research Applications 
 
 
As discussed previously, diligent protocol design including selection of 
inclusion/exclusion criteria is vital to conducting a successful clinical trial.  For the variety 
of reasons stated above, the eligibility criteria selection process is incredibly complex.  The 
AD clinical space, spanning over 100 years, is a truly storied one with both successes and 
failures constantly reshaping the medical community’s understanding of the disease and 
how to best treat it.  The shifts in treatment strategies leading to new gold standards and 
changes in clinical trial design practices which have occurred over the decades did not 
happen in a vacuum; they are iterative and the products of conclusions derived from 
exhaustive research.  However, how and when these changes occur and the impacts they 
have on prospective patient populations cannot be easily obtained.  Since 
ClinicalTrials.gov proposes to be the de facto storage of historical activities being 
performed within the clinical research space, it is postulated that these changes can be 
extrapolated from the protocol text currently contained within it.  By doing so, the 
functionality and usability of the database can be extended. Indeed, visual dashboarding 
functionality, for example, used to summarize therapeutic areas beyond the document level 
would serve as a much-welcomed addition to the current capabilities of ClincialTrials.gov.  
This however requires a method of extracting key clinical trial design concepts, identifying 
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latent themes from these concepts, visualizing the temporal dynamics of the identified 
themes over time, and evaluating the impact these themes have on prospective patient 
populations.  Therefore, to address this complex challenge, a framework for extracting 
meaningful therapeutic strategies from a corpus of ClinicalTrials.gov was rationalized, 
developed, and empirically evaluated. 
With the foundation and underlying key principles established in Chapter 1, this 
thesis is sequentially structured to subsequently:  
1. Present a retrospective survey of key issues of data within ClinicalTrials.gov which 
historically influenced design decisions associated with AD clinical trials (Chapter 
3). 
2. Describe the most currently pertinent conventional standard of care solutions for 
tracking the evolution of knowledge within a therapeutic space (Chapter 3). 
3. Propose a novel mining framework designed to quantify and qualify the evolution 
of AD clinical trials (Chapter 4). 
4. Construct a clinical trial protocol annotation process capable of being expressed as 
a queryable graph of interconnected annotated biomedical concepts (Chapter 5). 
5. Devise a novel graph-based mining toolkit for exploring large collections of clinical 
trial protocol documents (Chapter 6). 
6. Demonstrate a process which summarizes and subsequently visualizes these 
clusters as dynamic groups which change over time (Chapter 6). 
7. Validate the novel mining process by comparing and contrasting the approach to 
text-mining gold standards (Chapter 7). 
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8. Translate these findings into how they reflect past and current states of AD research 
in terms of prospective patient populations (Chapter 8). 
Next, a comprehensive review of the current state-of-the-art regarding the challenges 
associated with mining biomedical text, including those contained within published 
literature and clinical trial protocols will be explored.  This will establish the current state 
of relevant research from which the proposed research can be compared and contrasted.  
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Chapter 3: Information Diffusion Extends ClinicalTrial.gov Utility: State of the Art 
 
 
The trials and tribulations of scientific research, conducted through diligent 
empirical experiments shape its current state of gold standards: humanity’s collective and 
most widely-accepted understandings of natural phenomenon.  The means by which 
domains evolve over time becomes obfuscated within mounting volumes of academic 
literature and ever-expanding entries in the ClinicalTrials.gov database.  Numerous 
solutions, reviewed in detail in this chapter as a baseline to establish the current “state-
of-the-art”, have been devised to facilitate the communication of these novel ideas to 
broader research communities.  They conventionally range from review articles to novel 
means employing descriptive and intuitive visualizations.  It is hypothesized that open 
clinical trial protocol repositories such as ClinicalTrials.gov contain implicit information, 
locked away within the plain-text content of its indexed protocols, which allude to the 
current state of the AD domain at a given point in time.  Therefore, it would benefit the 
therapeutic space greatly if this information could be distilled in useful ways and ultimately 
extend the functionality of ClinicalTrials.gov within the context of information diffusion.  
The theory of information diffusion suggests that a research domain can be conceptualized 
as networks of interconnected entities – literature citations, journals, authors, research 
organizations, etc. – which form the mathematical and algorithmic basis of graphs.  In 
order to bring tangibility to information diffusion, a framework, founded on the concept of 
evolving research fronts is established grounded in graph theory.  This framework sets the 
foundation for proposing a graph-based data mining framework which quantifies and 
qualifies key changes within a therapeutic space, given a corpus of clinical trial protocols 
found within ClinicalTrials.gov. 
 
 
The Diffusion of Information Expands Understanding of AD Domain 
 
 
 For therapeutic spaces which involve diseases with complex genotypic and 
phenotypic qualities, the nature of how and when pivotal information is discovered, 
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communicated, and implemented within the broader research community is often difficult 
to capture from high levels of granularity.  This information is locked within collections of 
biomedical literature produced over time, whose ideas are inherently interconnected in 
ways that are not always explicitly stated or understood.  Once analyzed, these documents 
have the ability to reveal defining characteristics about the information pertaining to 
specific therapeutic spaces over time.  While this dissertation focuses on clinical trial 
protocol text, the majority of research conducted by the scientific community to date 
utilizes text derived from scholarly published literature, such as publicly-available 
abstracts.  Recall that the nature of AD research is highly multi-faceted due to the fact that 
its insidious biomarker cascade provides numerous opportunities to engage and halt 
different mechanisms of the disease during its course.  Indeed, assessing the efficacy of an 
AD therapy is not entirely straightforward, as the clinical endpoint of “improved cognition” 
is more abstract when compared to other diseases such as diabetes, as measured by changes 
in blood glucose levels.  The concept of cognition extends well beyond the notion of 
“memory”.  It entails a comprehensive set of constructs established in psychology such as 
working memory, delayed recall, executive function, and ideation praxis.  Numerous 
cognitive scales have been developed to probe the condition of these distinct constructs, as 
they are implicated in the functioning of numerous brain sub-regions.  Since the trajectories 
in which AD pathology propagates through the brain and systematically dismantles 
neuronal connectivity within key sub-regions is still an active area of research [69], there 
is still active work being conducted to understand the sensitivity of these scales in patient 
sub-populations.  Assessment scale/scoring serves as one of many variables associated with 
the complexity often introduced when both recruiting for and reporting an AD trial in the 
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ClinicalTrial.gov database.  In order for a clinical trial to successfully demonstrate efficacy, 
the selected primary endpoint must be sensitive enough to accurately detect subtle 
cognitive changes for the target patient population.  For example, while the Alzheimer's 
Disease Assessment Scale- Cognitive (ADAS-Cog) subscale has been shown to be 
appropriate for mild-to-moderate AD populations, it is not sensitive for preclinical AD 
populations [70].  In 2007, experts in the field of AD revisited and updated a 
comprehensive set of diagnostic criteria ranging from presymptomatic, mild cognitively 
impaired, and AD diagnosed subjects using the National Institute of Neurological 
Disorders and Stroke–Alzheimer Disease and Related Disorders (NINCDS–ADRDA) 
criteria, referenced previously [18].  The intent was that validated pre-built patient profiles 
could be used as screening criteria for next generation clinical trials to consequently 
streamline patient recruitment and screening.  However, since efforts have recently shifted 
towards developing disease-intercepting strategies in preclinical populations, scales such 
as the Preclinical Alzheimer Cognitive Composite (PACC) have been developed for these 
next-generation AD clinical trials [71].  This conundrum is depicted in Figure 4, and 
demonstrates the challenges of attempting to phenotypically qualify recruitment subjects 
whose disease progressions lie on an insidious and continuous disease trajectory. 
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Figure 4.  The Challenges in conceptualizing the progression of AD 
 
 
The failure of highly visible and promising clinical trials have forced researchers 
to rethink not only the inconsistent scoring scales used to set inclusion/exclusion 
recruitment criteria but also how the disease progression is qualitatively/quantitatively 
reported in the ClinicalTrial.gov database.  Such complexity consequently influences 
conventional knowledge about how and when to best alter the disease’s trajectory.  When 
these shifts in knowledge occurred, and which research organizations first pioneered the 
implementation of such knowledge in the form of a formal clinical trial filing is a crucial 
insight that can be synthesized from the diligent analysis of protocol collections.  
Unfortunately, this level of distilled insights cannot be easily obtained simply from 
manually digesting a large collection of plain-text documents such as found in the 
ClinicalTrials.gov database.  Consequently, focus must shift to understanding exactly how 
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disease state “standard of care” have been conventionally communicated to the broader 
research community.  Most notably are scholarly works which are published in domain-
specific research journals.  However, a scholarly journal is merely a vector for transmitting 
this information through text, tables, and figures, and consequently requires manual 
intervention to understand.  The ability to fully conceptualize how this information is 
transmitted and used in new applications is an active area of research broadly defined as 
information diffusion.  Since AD is such a storied domain in which countless hypotheses 
have failed to bring a single disease-altering solution to market, it is a prime example where 
quantifying and qualifying the nature of information diffusion through the medical 
community for optimizing development of a clinical trial protocol intended to shape the 
current disease state “standard of care”.  Next, it is appropriate to clearly define information 
diffusion within the general context of biomedical research and the ways in which 
information is extracted and analyzed from the textual resources which it produces. 
 
 
Domain Evolution Through Dissemination of Literature-based Information 
 
 
Information Diffusion – General Principles 
 
 
Identifying the evolution of gold standards within scientific domains such as AD 
has been conventionally captured within collections of time-stamped pieces of literature 
(e.g. peer reviewed research journals).  To reach this understanding, it is first appropriate 
to survey sentinel approaches for which this has been conducted in the past.  Information 
is defined as “the opposite of uncertainty” [72], or “an objective entity … generated or 
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carried by messages or by other products of cognizers” [73].  This aforementioned 
“message” is the result when data is synthesized, becoming knowledge once 
contextualized, and ultimately wisdom once actively applied in practice [74].  Together, 
these concepts form a hierarchy illustrating the levels from which data is consumed and 
contextualized, depicted in Figure 5.  One would say that published literature 
communicates “information” rather than “data”, since “information” represents facts 
extrapolated from the interpretation of raw “data”.  In other words, scholarly literature does 
not just communicate raw numbers acquired through observations, but rather translates 
these observations into actual insights, thus becoming “information".  It is then up to the 
consumer of that information to apply it within the context of novel applications. 
 
 
Figure 5.  Levels of Conversion between Data and Wisdom 
 
One area of information science involves analyzing the spread of information 
across communities of interconnected entities.  This is known as the aforementioned 
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information diffusion.  Information diffusion is defined as “the process through which an 
innovation, defined as an idea perceived as new, spreads via certain communication 
channels over time among the members of a social system” [75].  A core tenet of 
information diffusion is that its flow is highly dictated upon the dynamics of research 
community structures.  This principle seeks to understand the dynamics between research 
communities and the knowledge they produce by conceptualizing how information is 
disseminated.  In other words, information diffusion analyzes the nature of information 
transmission between entities such as people and communities.  Information diffusion has 
more recently become popularized by the proliferation of social media networks [76].  
Researchers have examined how information diffuses through social networks in an 
attempt to observe interactions between conferences attendees [77], as well as those 
disseminating information about natural disasters [78], and communication between people 
during times of political unrest [79].  This is done by diligently analyzing how ties between 
actors or entities in a network ultimately determine the structure of a network.  The 
concepts of strong and weak ties have been suggested as phenomena that link network 
entities together [80–82].  Strong ties serve as direct links forming tight communities and 
promote information flow within those communities.  Weak ties form connections outside 
these communities and are vital in the transmission of information spanning different 
communities.  However, a conventional way of inspecting information diffusion dynamics, 
specifically before the advent of social media, is by first analyzing the nature of published 
literature.  Indeed, scientific research is inherently driven by social dynamics between 
individual researchers and organizations, which are reflected in the structure of the cited 
literature itself [83–85].  High-impact publications which garner much attention and 
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acceptance from the overall research community will undoubtedly be more influential in 
dictating the course of future research [86].  These important pieces of literature are said 
to be “influential” based on the number of times a work is cited over time by other 
publications.  A citation is issued by a published work, typically as a means to explicitly 
reference past works as direct evidence supporting a hypothesis.  As will be discussed, 
these references form networks of interconnected literature.  As such, information diffusion 
can equally be applied to a body of literature itself. 
The ultimate goal of this dissertation is to propose a novel strategy to quantify and 
qualify the information dynamics evident by the evolution of AD clinical trial protocols.  
As will be further discussed, information diffusion theory provides a theoretical foundation 
on which to construct such a novel solution.  In order to begin laying this foundation 
through the application of technological aspects of information diffusion and its 
relationship with AD clinical trials, a brief survey of the most conventional means for 
disseminating information will first be explored.  Once accomplished, approaches that 
apply technical solutions to literature-based information diffusion problems, specifically 
within the fields of bibliometrics and science mapping, will be discussed. 
 
 
Conventional Literature Review Articles – General Principles 
 
 
Peer-reviewed scholarly literature is the primary driver which ultimately influences 
disease management standards of care.  The success of published literature in this regard 
is largely based on how wide-spread the information they contain is disseminated to other 
works.  Papers published in highly regarded journals such as the New England Journal of 
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Medicine continually communicate new advances in scientific domains.  When a critical 
mass of interconnected insights form and gain wide acceptance by the research community 
as a whole, actionable steps can then be taken to further operationalize these insights into 
new ideas, and subsequently new studies.  It should be reiterated that these decisions to 
pursue the testing of new therapeutic agents are not trivial, as they are incredibly costly 
from both a financial and logistical perspective.  While many researchers spend 
considerable time reading the newest and most pertinent pieces of literature in order to stay 
informed on advancements in their respective domains, it can be a considerable effort to 
search and filter relevant content manually.  Consequently, domain-specific review articles 
are occasionally published to provide condensed updates on new advancements within a 
research space.  These review articles serve as major citation hubs which can direct 
researchers to more specific areas of research for more in-depth exploration.  For example, 
due to the slow and insidious nature of how AD progresses, one active area of research 
involves modernizing clinical trial design and structure beyond conventional double-blind 
randomized clinical trial approaches.  In “Advances in Designs for Alzheimer's Disease 
Clinical Trials”, Cummings provides a comprehensive overview of these different 
potential strategies [87].  Although review articles remain the de facto standard for 
codifying and communicating new findings, it still requires a great deal of manual effort to 
digest their content.  Furthermore, review articles do not readily identify where synergistic 
connections may exist with other preexisting areas of knowledge, unless explicitly 
provided in the author’s commentary.  The next logical step beyond the reliance on peer-
reviewed articles is to consider how AD-relevant literature can be manually curated such 
that information can be communicated through simple interactive lists and basic 
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visualizations.  As will be discussed, these types of visual representations of data are a core 
tenet of information diffusion.  They summarize underlying patterns and trends from which 
researchers can launch future exploration of research questions in new and previous 
unforeseen directions. 
 
  
Manually Curated Sources 
 
 
 AlzForum.org is a preeminent source for compiling information about the most 
recent updates in the AD research space.  It includes both published literature and ongoing 
clinical trials.  Rather than presenting information in the form of comprehensive literature 
review articles, the website manually curates key areas of AD research such that they can 
be queried in interactive ways.  Research papers are arranged into “Milestone”, “AlzForum 
Recommends”, and “Papers of the Week” sections by knowledgeable curators to facilitate 
the discovery of the newest and most promising advancements.  Indeed, this approach 
appears to be a logical next-step in surfacing the most relevant literature beyond the use of 
technical review articles.  However more important is the website’s “Database” section.  
This resource extends these concepts by indexing datasets from which key insights are 
gained.  These databases are categorized into nine high-level groups: AlzBiomarker, 
AlzPedia, AlzRisk, Antibodies, Brain Banks, Genetics, AlzGene, Research Models, and 
Therapeutics.  For example, the AlzBiomarker section provides a meta-analysis of 
biomarker levels across disease severity from a recent study as outlined in Olsson et al. 
[88].  However, most notably and relevant to the proposed dissertation research, is the 
“Therapeutics” sub-section of the website.  This section provides users with an interface to 
56 
 
search 181 curated and indexed neurodegenerative clinical trials, using a series of filters: 
“FDA Status”, “Target Type”, “Therapy Type”, and “Condition”.  As mentioned 
previously, although it is the largest and most widely used registry, in its current format 
ClinicalTrials.gov only allows users to search for protocols based on a combination of 
plain-text keywords using fuzzy string matches to MeSH terms.  As such, this filtering 
approach offered by AlzForum.org is certainly a much welcomed improvement for 
searching clinical trials. 
 The website also provides some basic interactive tables which serve as high-level 
views of the overall industry by classifying clinical trials based on target and therapy types.  
For each type within a classification method, a clinical trial calendar akin to a Gantt chart 
can be generated.  Each row represents a specific compound being tested, and each timeline 
indicates the start and current status of the trial.  This is particularly interesting because, at 
the very least, such visualizations can be explored in order to reveal some temporally-based 
trends regarding when clinical trials with similar drug targets were first started in relation 
to each other.  Unfortunately, users cannot sort rows by trial start date, only alphabetically.  
Nevertheless, the solution represents a significant improvement for summarizing plain-text 
document collections in meaningful ways.  An example of this functionality is depicted in 
Figure 6. 
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Figure 6.  A clinical trial calendar outlining amyloid-related therapies 
 
It is also essential to note that for each row representing a specific compound being 
tested, users can drill down into more detailed information about that compound.  
Information provided includes an overview of the therapeutic agent’s mechanism of action 
if known, the type of chemical compound, and any other aliases for the compound used 
secondary to that research organization’s internal compound identification numbering 
system.  As discussed previously, one challenge associated with filed protocols on 
ClinicalTrials.gov is the lack of information provided regarding the context of company-
specific compound identifiers.  This further complicates text mining processes and is a 
challenge addressed in this dissertation.  These specific sections of AlzForum.org may 
58 
 
provide additional sources of data from which can be integrated with ClinicalTrial.gov 
protocols, and will be discussed in more detail in following sections.  Overall, the services 
provided by AlzForum.org are important to note in the context of this research, as they 
provide basic tools for allowing users to explore highly summarized pieces of information 
arranged in such ways that expose temporal relations, albeit basic ones.  Since this service 
requires a great deal of manual curation with domain-specific knowledge, these are still 
unmet needs which propose more advanced and extensible capabilities for mining and 
arranging collections of documents in meaningful ways.  Meanwhile, a growing body of 
research known as bibliometrics employs a portfolio of automated mining methods for 
extrapolating quantitative and qualitative insights into the phenomena of published 
literature. 
  
 
Bibliometrics and Science Mapping – General Principles 
 
 
 The area of bibliometrics is a well-established domain of information and library 
sciences [89].  The application of bibliometrics and related principles is a cornerstone to 
the doctoral research to be described.  In the field of bibliometrics, researchers typically 
employ both manual and automated approaches to quantify the nature of a research space 
through statistical means by exploiting the metadata which describes scholarly literature, 
specifically citation counts.  First coined by Alan Pritchard in 1969, bibliometrics predates 
conventional text and data mining approaches [90], and was proposed as a solution of 
automating citation analyses as captured by the Science Citation Index through 
computational means.  Simply stated, bibliometrics focuses on analyzing metadata 
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components of literature within a research domain through statistical analysis in order to 
identify how published works influence new ideas.  These methods include how concepts 
such as author, research organization, and journal productivity are operationalized.  For 
example, journal impact factor was devised to quantify the importance and prestige of a 
scholarly journal as operationalized by the average citations each paper of that journal 
receives in a given year [91].  This metric, while still utilized by publishers, has since been 
disregarded as a flawed approach to quantifying journal importance [92,93].  The h-index, 
as proposed by Jorge E. Hirsch in 2005, was devised to quantify the relative productivity 
of an author’s career as a function of the author’s highest cited paper and is restricted to 
the minimum number of papers published as a primary author [94].  These basic metrics 
exist to compare various units of published literature, and can be used appropriately to 
trend over time through the use of simple plotting tools.  Yet these metrics do not provide 
insight as to exactly why or how these bibliographic trends occurred.  In order to achieve 
this level of detail, more comprehensive approaches to obtaining insights from the literature 
must be explored.  
 More complex activities such as constructing citation networks based on 
authorship of published literature follow in this same vein.  This concept, referred to as 
science mapping, is defined as an area of research for “displaying the structural and 
dynamic aspects of scientific research” [95,96].  This area of research aims to extract 
statistical metrics from collections of related documents, as well as automate the 
construction of useful visualizations for illustrating the connective nature of scholarly 
works within and across areas of scientific research.  Science mapping focuses on 
identifying emerging areas of research by analyzing the nature of those highly cited 
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scholarly works which form tightly clustered pockets of knowledge, known as research 
fronts.  Research fronts such as those which can be constructed for Alzheimer’s Disease, 
are defined as the “convergence of scientific findings and social interests” [97], and 
represents areas of scientific disciplines which gain strong interests from research 
communities.  Indeed, when the concept of citation networks was first proposed, the main 
goal was to identify the social dynamics that shaped the current structure of science and 
technology, and how they changed over time [91]. 
At its core, there are eight distinct steps which define the science mapping 
workflow, depicted in Figure 7.  These steps include data acquisition, preprocessing, 
processing, summarization, and visualization activities.  The workflow typically starts with 
a collection of flat or plain-text files, and produces a series of visualizations, whether static 
or interactive, from which interpretation of results can be conducted. 
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Figure 7.  The Science Mapping workflow 
 
 
One of the most established ways in which science mapping conceptualizes 
interconnected phenomena in published literature is that of a network.  A network can be 
operationalized as a mathematical representation known as a graph, which has well-
established foundations in discrete mathematics.  A graph G consists of a series of vertices 
V connected by either undirected or directed edges E.  More formally, a graph is defined 
as: 𝐺 = (𝑉, 𝐸).  A vertex (interchangeably referred to as a node) represents some object 
involved with the interconnected phenomenon being explored: a word, a person in a social 
network, a journal article, etc.  In undirected graphs, vertices are said to be unordered, in 
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that there exists no distinction between which vertex is the source and target.  The 
directionality of an edge establishes additional information about the nature of the 
connection.  For example, the basis for the directionality can be temporal, such as a source 
vertex occurring before a target vertex, or as a point of reference, such as a source vertex 
citing a target vertex.  A co-citation network, for example, captures the dynamics of how 
literature explicitly references evidence provided in past publications [98].  Two articles 
are said to be “co-cited” if they are cited together in a third article, suggesting that they 
share logical similarities in content.  As such, each vertex represents a single journal article, 
and each edge establishes a connection that they appear together cited as evidence.  
Likewise, for a co-author network, vertices represent an article’s contributing authors, 
and an edge represents whether the pair appear as authors in the same article.   
Science mapping approaches through the use of network analyses have 
undoubtedly shed light on modeling information diffusion across scientific domains [99].  
For example, Sun et al. use “cross-field” authors, or those that straddle multiple computer 
science sub-domains in order to identify emerging areas of research [100].  The rationale 
behind this is that those authors whose work spans multiple disciplines may provide some 
synergistic insights which link previously disconnected bodies of knowledge.  Yan and 
Ding propose a co-author network approach to quantify author impact in the domain of 
bibliometrics through use of both centrality measures [101] and weighted PageRank 
algorithms [102].  In order to capture a set of authors most representative of the area of 
bibliometrics, Yan and Ding extracted a corpus of relevant literature from “Web of 
Science” (WoS) using a previously established search query. A co-author network was 
constructed by imputing a symmetric adjacency matrix, where rows and columns represent 
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a specific author.  Row/column values represent the frequency of the co-authorship 
between pairs of authors, while the matrix diagonal is set to zero due to the fact that authors 
cannot co-author with themselves.  They found that the weighted PageRank metric 
outperforms conventional author impacts metrics such as h-index discussed previously.  
This was accomplished by comparing the ability of these metrics to identify recipients of 
the Price Award issued during the International Society for Scientometrics and 
Informetrics conference.  Another use of co-author networks, and more relevant to the areas 
of AD research, has been proposed by Lehner et al. for mapping the convergence of 
“competitive collaboration” in specialized areas of psychiatric genomics [103].  The 
authors use this approach to qualify the impacts that relatively new industry collaborative 
consortiums and open data initiatives have in bringing diverse groups of researchers 
together based on their co-authoring in the literature.  Using a growing sliding window to 
assess co-author networks from 2001-2005, 2001-2009, and 2001-2013, a noted increase 
in co-author networks over time suggested new partnerships forming as a result. 
Science mapping becomes increasingly more complex when transitioning between 
co-author networks where the entities being measured are “people” and the analysis of the 
literature itself.  The ability to establish networks capturing literature-based entities is a 
focus of this dissertation and described in the following example and subsequently 
expanded upon in greater detail.  In 2009 researchers at the Los Alamos Research 
Laboratories constructed a high-resolution map of the “Web of Science” by analyzing 
aggregated click-stream data logs from 6 top web portals over a period of 11 months, 
capturing the browsing behavior of users navigating across different publisher collections 
(ex. Thompson Reuters WoS, JSTOR, etc.) [104].  The Getty Research Institute's Art and 
64 
 
Architecture Thesaurus (AAT) was used to annotate the user’s explicit request for a journal 
entry, with the main scientific research field represented by that journal.  A user was 
identified by a unique session identifier and linked to a series of time-stamped article 
requests as they occurred across journals.  This was done to reconstruct temporal sequences 
of browsing events.  The map itself was constructed by analyzing pair-wise transition 
probabilities of users browsing articles between two different journals during the same 
session.  This resulted in an n x n journal adjacency matrix with 6,783,552 non-zero entries, 
where each cell represents the “strength” between two journals.  The top 50,000 journal 
pairs were selected for constructing the overall graph and further filtered by retaining the 
top 5 strongest outbound connections between each journal.  In doing so, the authors 
compiled a network of 97,000 journal websites representing 300 areas of scientific 
research, and demonstrated the highly inter-connected nature of science. 
As will be discussed, the use of graph analytics in the field of bibliometrics is a 
popular way of conceptualizing the interconnectivity nature of published works and 
operationalizing the influence they exhibit in the overall collection of documents.  The 
work produced by Los Alamos laboratories has produced some interesting insights into 
how various scientific disciplines are related at the highest resolutions.  Tightly connected 
online journals form clusters which represent sub-domains of research fields.  However, 
the most interesting insights significantly influencing this dissertation come from sparse 
connections which link these clusters together, suggesting varying degrees of 
“intercommunication” between these fields.  In other words, two clusters representative of 
distinct areas of scientific research may share information overlaps as dictated by a smaller 
number of connections between them.  Detecting these connections where ideas fuse 
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together may occur is particularly interesting, especially within the context of translational 
research, as discussed previously.  For example, the resulting map demonstrates how brain 
research unifies areas of genetics, biology, and social and personality psychology.  These 
approaches are useful, in that they distill relevant information from large collections of 
documents in order to present interesting patterns and trends which would not necessarily 
be apparent otherwise.  Indeed, as Bollen et al. notes, this approach offers “an immediate 
perspective on what is taking place in science and can thus aid the detection of emerging 
trends” [104].  It should be reiterated that detecting where synergistic merges of seemingly 
disparate bodies of research exist is a particularly useful capability for the vision of 
translational research. 
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Figure 8.  Mapping science by online journal cross-talk3 
 
 
In order to formally conceptualize these abstract concepts and the dynamics which 
encompass their temporal changes, a framework must be referenced to concretely identify 
these phenomena.  For example, Upham and Small have devised such a method for 
conceptualizing the patterns in which research fronts form [97].  Here, research fronts are 
identified as clusters of highly co-cited literature formed within co-citation networks.  
                                                 
 
3 http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004803 
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Taking the top 1% of the most highly cited research papers within 22 broad disciplines, 
approximately 30,000 documents, a co-citation network was constructed using a single-
link clustering method.  Co-citation frequencies were normalized to each document’s pair-
wise cosine similarity, or the square root of the dot product of the citations the two 
documents share.  The single-link clustering routine employed a normalized co-citation 
frequency threshold of 0.3, and a maximum cluster size of 50 documents.  Upham and 
Small then focused on how these research fronts change over time, stating that either new 
research fronts can suddenly appear in a given year, or modifications to new research fronts 
can merge, split or continue on from the previous time point.  High-level domain labels 
were applied to every paper in the research based on their publishing journal.  Each cluster 
was given a discipline weight based on the number of articles representing a single domain 
within each cluster and trended over time.  The authors noted that there were increasing 
publication trends in specific areas of biology, namely microbiology and molecular 
biology.  Based on these counts, Upham and Small suggested that research fronts can 
exhibit five behaviors/trends: growing, shrinking, stable, emerging, and exiting.  In other 
words, the overall “health” of a research front, in this specific case, is measured by the 
number of documents representing that discipline in a given year.  Additionally, there are 
types of key events which occur within clusters of dynamic graphs as new information is 
added to them over time and consequently influence their proliferation across time.  In 
other words, one can begin to formally conceptualize what is actually meant by “evolving 
research fronts” such as optimization of an AD clinical trial design described in the 
protocol (e.g. selection of most relevant biomarkers) by directly applying it to graph theory.  
Based on this method, key graph-based events include: 
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1. Create: A new and potentially isolated cluster forms in a certain time period, 
signifying the start of a new research front. 
2. Continue: A cluster continues on an uninterrupted trajectory across time periods, 
signifying the continued proliferation of a research front. 
3. Merge: Linkages between two or more distinct clusters form within a time period, 
suggesting a fusion of distinct research fronts to form a new and novel one. 
4. Split: A cluster is divided into two or more smaller clusters within a time period, 
suggesting a shift in application of that research front towards different ideas. 
This requires a graph to be considered not as a final and static network of 
interconnected documents, but rather an ordered set of incremental sub-graphs expanding 
across time periods.  These four types of research front events, conceptualized as the 
interactions between clusters of highly connected documents, are depicted in Figure 9.  
Interestingly through this approach, Upham and Small retrospectively identified the role of 
amyloid-precursor protein (APP) in the pathogenesis of AD as an emerging front starting 
in 2001, which has since been acknowledged as a prime drug target to halt the progression 
of the disease. 
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Figure 9.  Interaction of research fronts reveals the genesis of new ideas 
 
 
As another example illustrating these concepts, similar efforts have since been 
conducted by SciTech Strategies and was funded through the National Science Foundation 
(NSF) in order to predict emerging areas of scientific research [105,106].  However, unlike 
the work conducted at Los Alamos Laboratories, these networks map millions of co-cited 
papers rather than the journals they appear in.  Figure 10 demonstrates a co-citation graph 
highlighting distinct high-level areas of research: brain research (yellow) and infectious 
disease (red) superimposed on top of each other.  The overlap in yellow and red areas 
suggests, naturally, that a level of interaction exists between brain research and infectious 
disease. 
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Figure 10.  Visualizing overlaps in brain and infectious disease research 
 
 
Having established the basis for bibliometrics, science mapping, and a framework 
for identifying influential and interconnected scholarly concepts through representative 
examples, focus can now be turned to surveying additional science mapping approaches.  
While the approaches just reviewed require considerable technical knowledge and 
computational power to process massive amounts of bibliographic metadata, approaches 
have been devised which allow users to automate these processes using personal computing 
devices.  These automated science mapping tools can be useful in the scientific process for 
hypothesis testing and validating results [107].  
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Automated Bibliometric Approaches – General Principles 
 
 
 Significant effort has also been focused on analyzing collections of documents and 
the nature in which they explicitly cite each other through co-citation networks.  
Applications such as Carrot2 [108] and SciMAT [109] allow users to import collections of 
document metadata exported from web portals such as Thompson Reuter’s Web of Science 
(WoS) and explore them with the aid of novel visualizations.  For example, Carrot2 utilizes 
hierarchical tree visualizations appropriately named FoamTree, as a means of depicting 
sub-collections of similar document as a result of various clustering methods including k-
means clustering [110] and Lingo [111].  Group boundaries are highlighted by distinct 
cluster colors.  The size of each sub-collection represents the relative number of documents 
belonging to that section.  As depicted in Figure 11, the FoamTree visualization can be 
quickly generated to detect high-level categories of AD research based on PubMed 
abstracts.  Indeed, these high-level research areas capture key disease targets reviewed 
previously and include: “Cerebral Blood Flow”, “CSF AB Levels”, “Glucose 
Metabolism”, and “Hyperphosphorylated Tau”. 
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Figure 11.  FoamTree visualization summarizing key AD research areas 
 
 
 While Carrot2 can reveal the high-level overview of documents, it is best suited 
for systematically arranging documents into coherent groups as an augmented means of 
document retrieval.  Additionally, the layout of FoamTree is intended for exploratory 
purposes and does so by optimally arranging clusters for the current rendering space.  The 
spatial relationship between high-level themes therefore is not necessarily indicative of 
their relationships to each other from a thematic context.  Perhaps more important science 
mapping capabilities aim to capture and communicate temporal insights into the thematic 
changes within collections of documents.  One such example is SciMAT, a science mapping 
73 
 
tool which, similar to Carrot2, maps sub-collections of documents to document clusters.  
Using the concept of article co-citation, SciMAT connects similar clusters with edges based 
on the number of citations the documents within each cluster share.  Key terms are 
extracted from these document clusters and similarly form a network of interconnected 
concepts based on the connectivity between their respective document clusters, in order to 
visualize the “conceptual evolution” of a collection of documents. Various network layout 
algorithms are employed in order to arrange clusters based on the nature of their 
connectivity; clusters sharing high degrees of connectivity tend to be “drawn” closer to 
each other [112].  SciMAT also arranges each cluster along an X-axis where each tick 
represents a specific unit in time (i.e. year), for which that specific topic first emerged.  
While this layout is fairly basic in that it merely arranges nodes along two axes, there are 
visualization heuristics which affords some level of intuitive detail about the temporal 
nature of concepts.  For example, the density of edges connecting to a specific concept may 
signify some level of importance for that concept in a given year.  While the features of 
SciMAT are numerous, this specific example demonstrates how document collections can 
be analyzed, with individual keywords being the unit of analysis.  
The most comprehensive science mapping tool currently available, however, is 
CiteSpace [113].  Like SciMAT, CiteSpace allows users to process WoS extracts containing 
citation metadata, but automatically segments article entries into “time slices” based on the 
year they were first published.  The most significant advancement associated with 
CiteSpace is its primary focus on understanding where temporal shifts in thought occur 
over time as encoded within published literature, referred to as intellectual turning points 
[114,115].  As previously discussed, increasing the probability of a successful clinical trial 
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is associated with the sponsor’s ability to understand how gold standards have emerged 
within clinical research domains.  Once identified, the “standard of care” is consequently 
recognized as the best known approach to treating a particular disease.  CiteSpace envisions 
tightly clustered groups of co-cited literature representing regions from which these gold 
standards originate over time. From an information science perspective, these clusters 
formed by interconnected literature have been referred to as the previously mentioned, 
research fronts [116,117].  The capabilities of CiteSpace represent further improvements 
for science mapping tools by extending the conventional notion of co-citation networks to 
communicate when bodies of knowledge first emerge and consequently change over 
periods of time.  As such, CiteSpace envisions co-citation networks not just as a single 
static graph, but a series of heterogeneous graph subsets for each successive time slice.  
The concept of a graph vertex in CiteSpace is further extended to capture its pervasiveness 
over time, or across time slices.  As Chen noted, this is referred to as a panoramic approach 
to visualizing an evolving network, as information regarding temporal changes accompany 
and/or augment conventional graph components through numerous visual heuristics [118].  
The main conventional dynamics which CiteSpace reveals about published literature are 
based on the position of vertices within a co-citation network, as well as their relationship 
with surrounding vertices.  Those visually salient features are described as landmark and 
hub nodes.  A landmark node is one which is highly cited, but does not necessarily exhibit 
a large number of links to other co-cited works, thus suggesting it being a piece of literature 
highly specialized for a specific research area.  A hub node is labeled as such, due to its 
high degree of connections, one which is cited by a large variety of other articles.  The 
temporal property of each vertex as they are cited over time is novel to CiteSpace, and is 
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introduced as a pivot node.  A pivot node is one which unites vertices across different time 
slices.  A node flagged as “pivotal” can be interpreted as being important, in that it 
potentially links together disparate information from multiple sources or across different 
time periods.  As will be discussed in greater detail, while there are mathematical properties 
which underlie the nature of these node types, these properties which denote visual salience 
can be mapped to various visualization heuristics, making them more apparent to the user.  
These vertex properties are namely: size, color, transparency, and shape.  For example, a 
highly cited vertex can be depicted by a larger radius relative to other vertices.  CiteSpace 
extends the concept of coloring a vertex from a single color to a series of colored rings, 
representing the years in which it appeared co-cited with other articles.  To more fully 
clarify these concepts, as well as provide some concrete examples of the science mapping 
workflow, the application of CiteSpace against relevant AD literature and the mining 
process is worthwhile. 
In order to further elucidate the comprehensive functionality of CiteSpace, the 
application was used to mine pivotal AD literature over time.  The motivation of this 
exercise was two-fold.  Firstly, a real-world example such as AD can be employed to 
explain the core capabilities of CiteSpace in a concrete manner.  Secondly, this analysis 
provides journal-based insights into the evolution of AD knowledge which can be 
referenced when analyzing the emergence of key clinical trial protocol filings.  More 
specifically, it is contended that in order to qualitatively validate the framework proposed 
in the following sections, key insights gained from CiteSpace can be used as “lagging” 
indicators signaling the surfacing of important knowledge which should be considered 
when designing a new clinical trial protocol.  This knowledge gained initially relies on 
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obtaining insights from CiteSpace. And as such is accomplished by preparing the data and 
configuring the process through a series of six steps: time slicing, thresholding, modeling, 
pruning, merging, and mapping [114].  Each of these steps will be discussed briefly to 
further elucidate the overall process of extracting insights from AD literature using 
Citespace.  A total of 58,590 article abstracts and citation metadata were extracted from 
WoS on 23 May 2016 using the search term “Alzheimer’s Disease” in the topic heading, 
spanning from the years 2000 to 2016.  Manual curation was used to remove false positives 
from the results by filtering those which originated from journals whose domains were 
unrelated to AD research (ex: “Physics”, “Inorganic Chemistry”, “Zoology”, “Plant 
Biology”).   
The resulting file exports were loaded into CiteSpace for processing.  Time slicing 
is a relatively straight-forward process which simply specifies how the documents will be 
segmented by time periods (i.e. decade, yearly, bi-yearly, quarterly, etc.).  Since the 
document time period only spans 16 years and one year is an appropriate length of time to 
consolidate a body of new research findings in the AD space, the collection was segmented 
into 16 slices.  The second step, thresholding, is another important consideration since it 
specifies how documents in the collection will be filtered based on some level of 
importance.  For example, users may simply specify the top percentage of most cited papers 
to be included in each time slice.  However, this is not an entirely advanced approach, since 
there are distinct differences between citation and co-citation counts that may ultimately 
impact results.  Instead, CiteSpace allows users to specify sets of citation counts (c), co-
citation counts (cc), and co-citation coefficient (cv) thresholds for the beginning, middle, 
and end of the time slice collection.  In this example, the thresholds specified are 
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(20,10,30), (15,5,20), and (5,5,10) respectively.  The reason for the decreasing metrics is 
that literature published in recent years have naturally not been cited as frequently and it is 
critical that emerging pieces of literature are not filtered out improperly.  The modeling 
step of the process specifies which entities are to be analyzed, such as articles, journals, 
authors, organizations, keywords, or a combination of these entities.  For this example, 
both articles and keywords are analyzed.  Pruning then specifies how the resulting network 
is trimmed of excessive or redundant edges in the resulting network visualization.  Two 
options are available in CiteSpace: Pathfinder and Minimum Spanning Tree (MST).  
While pruning will be discussed in more technical detail in later chapters, Pathfinder was 
selected due to the fact that MST pruned networks essentially result in hierarchical trees 
which may disconnect or weaken potentially important clusters.  Merging subsequently 
specifies how the resulting time slices should be presented; either as a series of individual 
slices, or as a merged network.  Since the interest is in identifying pivotal literature and 
transformative biomedical concepts over time, a merged network was selected, as it 
aggregates time slice information into a single coherent visualization.  Finally, the mapping 
process involves assigning visual attributes discussed previously to graph vertices in order 
to represent important bibliometric variables, such as time slice membership and vertex 
importance. 
From this process, two networks are constructed highlighting distinct entities: one 
visualizing co-cited literature and the other visualizing co-occurring biomedical keywords 
used within the literature.  In an attempt to identify emerging areas of AD research which 
may be reflected in the newest wave of proposed clinical trials, the time period of literature 
published between 2010 and 2016 are highlighted in this example.  Again, it is suggested 
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that published literature from basic research are lagging indicators of where the clinical 
research is headed, and will be discussed in more detail in the results and discussion 
sections.  For the co-citation network, proper visual aesthetics denoting “pivot” literature 
make them visually salient.  Figure 12 depicts this example co-citation network.  
Interestingly in this example, the definitive manuscript which establishes the Jack Model 
appears as pivotal [12] starting in 2010 and is linked directly to the manuscript which 
establishes the dynamics of Ab-42/p-tau in CSF [119] from 2009.  Burst citations are also 
indicated by large red nodes.  These nodes indicate more recent articles which are highly 
cited in a relatively brief period of time.  These types of articles may provide information 
that is timely for the current state of the research domain, but its longer applicability to the 
overall field is yet to be completely observed.  One example that demonstrates this type of 
published work is the Phase 3 results of the solanezumab clinical trial conducted by Eli 
Lilly and Company for mild-to-moderate AD [120].  While this clinical trial did not achieve 
levels of clinical efficacy in clearing sub-cortical amyloid deposits, the results reflect some 
of the most recently significant developments in the clinical trial AD space. 
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Figure 12.  A Co-citation network identify key AD research articles, 2010-2016 
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Figure 13 depicts keyword associations which were extracted from the same corpus used 
to generate the co-citation network.  Concepts such as “transgenic mouse” and “psen2 
gene” are highlighted as pivotal in this network. 
 
 
 
 
Figure 13.  Term Co-occurrence network identifies key AD concepts, 2010-2016 
 
 
In summary, thus far the general principles of information diffusion have been 
introduced by reviewing how bibliometric and science mapping approaches propose to 
quantify and qualify the dynamics between researchers and the works they produce.  While 
these examples do not yet directly involve the analysis of clinical trial protocol documents, 
it is vital to establish these concepts through their most conventional applications.  The 
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basic concepts of networks were introduced, as well as how these constructs reveal the 
nature of research fronts, citing recent examples.  Additionally, a framework which 
conceptualizes the changes which research fronts experience over time was established.  
Bibliometric and science mapping efforts specifically targeting AD literature provides 
innovative approaches to clinical research informatics.  These approaches propose 
specialized ways to extract various patterns and trends which occur throughout the 
literature, employing the principles of information diffusion.  
 
 
Bibliometric Applications to Analyzing Alzheimer’s Disease Literature 
 
 
While bibliometrics-based software provides researchers with tools to automate 
mining processes, some researchers may opt for more customized or specialized 
approaches, depending on the questions being posed.  These approaches require the 
development of innovative mining and statistical methods for accurately extrapolating 
trends from both literature metadata and plain-text.  In doing so, various phenomenon 
regarding the productivity of researchers, identification of highly influential literature and 
journals, etc. can be modeled.  For example, Sorensen et al. employed bibliometric 
approaches to map the major researchers who have contributed knowledge to the AD space 
over the years [121].  The analysis was later extended to construct co-authorship networks 
in order to identify communities which represented the “bench” and “bedside” aspects of 
AD translational research [122].  Chen et al. use bibliometric approaches to map the 
evolution of research hypotheses on acetylcholinesterase inhibitors over the course of a 
decade [123].  Most recently, Lee et al. analyzed how indexers, authors, and citers exhibit 
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different perspectives of the key issues surrounding the disease [124] through a specialized 
area of bibliometrics called entitymetrics [125].  They accomplished this by constructing 
heterogeneous networks comprised of MeSH terminology, keyword, and citation 
information.  The importance of this work suggests that these disparate perspectives have 
translational applications in the event that these insights are integrated to identify where 
research synergies may exist. 
Most applicable to the ongoing research activity in the bibliometrics space however 
is the work conducted by Song et al. who use advanced bibliometric techniques to map the 
landscape of AD research to identify emerging areas of thought [126].  Using named entity 
recognition, an established natural language processing (NLP) method for extracting 
noun-phrase keywords from plain-text using parts of speech, keywords were mapped to the 
Unified Medical Language System (UMLS) terminology.  As will be discussed, the use 
of structured terminologies and more advanced ontologies play an important role in 
encoding the numerous relationships between hierarchies of related biomedical concepts.  
Song expresses each document as a graph of interconnected co-occurring concepts, which 
contributes to an overall graph reflecting the entire corpus.  Using parent-children 
relationships established in UMLS, additional high-level concepts are added to the graph.  
A resulting global network of 20,409 vertices (biomedical concepts) and 50,312 edges 
(relationships) was established from 96,081 abstracts relating to AD research from 1950 – 
2014.  The weight of each edge represents a count of the number of times the two concepts 
co-occur in the corpus, and were filtered if this weight was below 300.  After applying this 
edge filter and removing disconnected nodes, the global graph contained 3,634 nodes and 
5,538 edges.  A set of graph metrics are used to identify key themes in the global graph, 
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including co-occurrence frequency, weighted degree centrality, betweenness centrality, 
closeness centrality, and PageRank.  These ranking approaches are similar to that of 
CiteSpace, discussed previously.  The authors extend their approach and employ a 
Dirichlet Multinomial Regression (DRM) algorithm [127], a variation of Latent 
Dirichlet Allocation (LDA) [128], to identify themes as they trend over time.  This 
process, known as topic modeling, conceptualizes documents as a mixture of themes, 
which in turn are operationalized as probability distributions over keywords extracted from 
those documents.  Simply stated, the combination of words in each document forms a linear 
combination of probabilities that form a latent topic.  Each document in the corpus is 
assigned a latent topic through this process.   
Song and co-authors identify 16 high-level themes through this process: AD-
associated factor, Transgenic mouse, Dementia, APP, Beta-amyloid protein, Tau protein, 
Oxidative stress, ApoE, CSF levels, Brain-image, Brain plaques/tangles, Cholinergic 
system, Induced cell activity, Memory/cognitive impairment, Treatment, and Caregiving.  
These themes, while fairly generic, encompass a large body of the primary areas of AD 
research.  However, it is important to note that some topics such as “Beta-amyloid protein” 
and “Tau protein” have broad relationships to the more generic theme, “Brain 
plaques/tangles”.  Perhaps the liberal filtering based on edge weights excluded more niche 
and/or emerging areas of AD research from the global graph that would have otherwise 
surfaced in their results.  Song et al. do note a caveat that the results “do not show novel 
relationships, but rather affirm core entities and relationships among them frequently 
studied in the literature” [126].  Nevertheless, the topics produced do indeed cover key 
areas of AD research, with clear parallels to the areas discussed previously regarding AD 
84 
 
clinical trials.  In order to track how prevalent these latent themes are over time, a relative 
distribution ratio of each assigned latent theme were calculated on a yearly basis.  Song et 
al. demonstrate that a conventional line plot can reveal interesting information about the 
temporal dynamics of research focus over time.  For example, “Transgenic mouse” trends 
high in more recent years, starting in 2006.  This may suggest research efforts at that time 
began to shift in order to gain better understandings regarding the pathogenesis of the 
disease in animal models.  In 2007 the “Tau protein” theme begins to trend in popularity.  
Overall, this approach employs a specialized set of statistical and data mining tools for first 
extracting and linking biomedical concepts into a network, identifying underlying latent 
themes from these concepts, and plotting these trends over time with line charts. 
Perhaps the most intriguing aspect of Song’s work is a shift from conventional 
bibliometrics to more specialized toolsets of data mining routines used in conjunction with 
each other, such as NLP, semantic expansion of biomedical concepts, and LDA.  These 
efforts have been applied to specific domain applications.  Although there are overlaps, a 
distinction can be established between conventional bibliometrics/science mapping and the 
more specialized realm of “Big Data” data mining, which aims to address specific research 
questions.  As such, focus will now be directed to those informatics-based initiatives which 
attempt to innovate new technologies, driven by the development of efficient and/or 
accurate routines and algorithms.  A more comprehensive consideration of LDA and 
similar topic modeling approaches as they specifically pertain to this dissertation will be 
discussed in Chapter 6.   
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Text Mining Approaches 
 
 
Overview of Text Mining 
 
 
 The concepts of bibliometrics and science mapping have enabled researchers to 
analyze the trends which exist within various units of scholarly literature metadata.  It has 
since spawned new areas of extended research efforts which aim to address more 
specialized approaches to modeling bodies of related text.  Such sources of text outside the 
scope of conventional literature include consumer product reviews [129,130] and patient 
narratives and profiles on health-based social media sites [131].  While sharing clear 
similarities to science mapping and overlapping approaches, the term “text mining” is used 
to further differentiate these high-level areas of research.  The main distinction that is most 
relevant to aspects of information diffusion as has been discussed thus far is that text 
mining aims to extrapolate meaning from plain text strings, through various natural 
language processing routines.  As previously illustrated in the science mapping workflow 
diagram (Figure 7), conventional bibliometric approaches envision preprocessing and 
network extraction steps as consecutive process.  However, bibliometric metadata 
explicitly states how literature is related through the use of citations.   
Pivotal in establishing co-citation networks, citations serve as a means to explicitly 
denote past works which provide supporting logic to bolster the evidence of the journal 
article issuing those citations.  Unless an extension of a previous investigation, clinical trial 
protocols do not inherently provide any metadata to indicate that its rationale or design was 
influenced by past clinical trials.  The majority of relevant work conducted in this area 
specifically focuses on exclusively analyzing the inclusion/exclusion criteria data of a 
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clinical trial protocol with the intent of providing platforms to improve clinical trial 
recruitment through patient awareness.  Indeed, ClinicalTrials.gov in its current form does 
not capture protocol information in fully structured and atomic formats.  Instead, text 
mining routines must be employed in order to extract relevant concepts and impute their 
similarities based on these concepts. 
In order to gain understandings of how clinical trials are related to each other, 
specifically within the lens of information diffusion, different approaches must be 
employed to infer their similarity.  Various text and data mining routines have been devised 
to infer similarities between documents based on their explicit content.  The relative 
concept of “similarity” can take on different meanings, but is generally based on the 
number of features (terms and phrases) two documents share.  Document similarity (or its 
inverse document distance), as a metric, is a broad topic of assorted approaches.  While 
these advanced similarity metrics will be discussed in more detail in Chapter 6, it is a 
crucial concept to establish in the context of science mapping.  Much like both explicit 
citations and co-citations have the ability to form graphs of scholarly literature, so too can 
imputed similarities be applied in the same way.  Simply, if two documents are similar 
above some given threshold, an edge can be drawn between them.  A large collection of 
documents can form a symmetric adjacency matrix of similarity scores, which in turn can 
form graphs of inter-connected documents.  Ahlgren and Colliander extends this concept 
as first-order similarities, as document similarities are being imputed from explicit textual 
content [132].  Additionally, they also discuss the possibility of a second-order similarity 
metric.  Here, document similarities are first imputed by their first-order similarity.  These 
document similarity vectors can then serve as the basis for a second similarity comparison 
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in order to cluster documents based on their nearest neighbors.  This suggests that text 
mining solutions are not just approaches in their own right, but rather an additional 
extension to science mapping capabilities.  These concepts play a key role in extending 
science mapping capabilities beyond data contained explicitly in citations.  As mentioned 
previously, this is an ideal approach to adopt for constructing networks of clinical trial 
protocols, where citation data is not applicable to that type of document.  Next, two research 
efforts conducted by Dr. Chunhua Weng’s group at Columbia University’s Data Science 
Institute will be discussed.  It is proposed that these works serve as an appropriate 
benchmark for applying text mining routines to clinical trial protocols. 
 
 
Columbia University Data Science Institute – Benchmark 
 
 
 Perhaps the most relevant area of research focused on applying data mining 
techniques to clinical trial protocols is that of the work conducted by Dr. Chunhua Weng 
and her group at Columbia University.  However, unlike the intended application of this 
dissertation to a variety of diverse clinical trial development variables, their primary focus 
is applying data mining and informatics solutions to address issues associated with clinical 
trial enrollment and therefore closely aligned with previous described efforts (e.g. 
AllTrials, OpenTrials, etc.).  For example, Boland et al. first explored the feasibility of 
mining clinical trial protocols through a semi-supervised approach [133].  Eighty Phase III 
breast cancer trials included in the ClinicalTrials.gov database were randomly selected to 
serve as a proof-of-concept corpus from which biomedical information was to be extracted.  
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It is worthwhile to note the eligibility section of a clinical trial protocol typically appears 
as an unordered list of biomedical requirements that a potential trial subject must satisfy.  
However, there is still a need for text mining support in order to filter those prerequisite 
concepts into the most atomic units possible.  Line items consisting of compound 
statements joined by conjunctions (“AND”) and disjunctions (“OR”) present issues that 
require additional textual parsing.  For example, “synchronous bilateral invasive or non-
invasive breast cancer” must be deconstructed into four atomic components: “synchronous 
bilateral breast cancer”, “invasive breast cancer”, “non-invasive breast cancer”, and “breast 
cancer”.  The competency decomposition method was used to extract these components 
from a set of sentence fragments and yield a list of biomedical concepts of increasing 
granularity [134].  Boland et al. also excluded those concepts which represented continuous 
variables such as laboratory results, but retained both age and life expectancy endpoints.  
The concepts were stratified into two high-level categories: disease-characteristic and 
patient-characteristic, and then mapped to the UMLS thesaurus resulting in over 1,400 
eligibility features.  These features construct a binary eligibility vector for each clinical 
trial protocol, where each cell of that document vector represents a specific biomedical 
concept extracted from the corpus.  Each cell is populated with either a one, indicating that 
the concept is present in that document’s eligibility section or zero elsewise.  Ward’s 
hierarchical clustering method was used incrementally by Boland, et al. to merge the 
corpus documents together into groups which minimize the variability of their Euclidean 
distances within those groups [135].  This process was executed three separate times to 
produce lists of grouped clinical trials using different combinations of the two eligibility 
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criteria classifications: disease-characteristics (D), patient-characteristics (P), and 
combined (C).   
Clustering approach D yielded five distinct clusters, clustering approach P yielded 
six clusters, and clustering approach C yielded only two clusters.  The fact that cluster 
arrangements varied between the combinations of high-level eligibility facets is quite 
telling and suggests that similarities are multi-dimensional in nature and exceed that of 2-
dimensional projections.  Two clusters of approach D shared 24 common tumor-related 
features across all trials, while only one group from that cluster shared 6 infection-related 
features with a third cluster.  The authors note that cluster approach P identified clinical 
trials with similar patient-eligibility requirements, but significantly different types of 
interventions.  Noting that there is currently no commonly accepted standard for 
establishing similarities between clinical trials from which to objectively compare, cluster 
membership was assessed manually.  The authors suggest that for the sake of a proof-of-
concept geared at providing ways of grouping clinical trials to make exploration easier for 
breast cancer patients, user interface functionality can address these disparities.  In other 
words, providing users with tools to explore clinical trials across these multiple facets by 
filtering on various properties is one way to address this issue.  However, the complexity 
surrounding the projection of high dimensional data is currently an important and heavily 
explored area of research which will be specifically addressed in following sections.   
 While Boland’s efforts established an approach for processing the eligibility criteria 
text of a small corpus of breast cancer clinical trials, further work was required to ensure 
the approach was both extensible and scalable.  Hao et al. applied similar approaches to a 
corpus of over 145,000 trial protocols, which represented the ClinicalTrials.gov database 
90 
 
in its entirety at the time of publication [136].  Parts-of-speech (POS) tagging was used to 
identify sentence and list item boundaries from which eligibility criteria was extracted.  
Similar to Boland et al., the resulting set of extracted biomedical concepts comprised the 
binary feature space of each document, with a one denoting that feature is present in the 
list of eligibility features.  It should be noted that, as will be discussed, more effective 
means of weighting terms for indicating relative importance within a document can be used 
as an alternative to binary vectors.  Hao et al. utilized Jaccard similarity to compute pair-
wise similarities between trial protocol eligibility lists, by dividing the total count of similar 
features shared between two documents by the total number of concepts in their union.  
Since the corpus is massive, calculating all pair-wise similarities is computationally 
intensive.  As such, documents were compared only if their similarities exceeded a certain 
threshold.  After pair-wise similarities were calculated, a nearest neighbor search (NNS) 
was conducted for each protocol, which constructs clusters by first testing each document 
as the center of its own cluster and identifying neighboring documents closest to its center, 
given a similarity threshold (in this case 0.9).  These individual center-based clusters were 
then merged using Density Based Spatial Clustering of Applications with Noise 
(DBSCAN) [137].  Hao et al. also envision the capability of expressing clinical trials as a 
network, linked together through the mutual sharing of similar biomedical concepts from 
the UMLS mapping.  Heterogeneous graphs, where nodes represent different types of 
entities, are difficult to apply conventional graph algorithms to and subsequently interpret, 
however.  The authors note that this approach is useful for visual inspection of clinical 
trials and the concepts they share, as higher number of common paths between them afford 
for easily identifying the most salient similarities.  This process of converting 
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heterogeneous labeled graphs to a homogeneous one in which nodes can be compared 
equally will be discussed further in Chapter 6, as the process is similar to the one outlined 
in Hao et al.   
 Throughout the course of this chapter, the concept and importance of information 
diffusion was discussed.  The nature in which information diffuses is largely conducted 
through the areas of bibliometrics.  Bibliometrics attempt to firstly quantify important or 
influential units of scholarly literature that are vital in transmitting novel information.  
Science mapping then develops this concept further to gain deeper understandings of how 
research fronts form over time.  This is achieved through the diligent analysis of 
bibliographic metadata, typically conceptualized as networks of interconnected units of 
entities (i.e. journal, author, paper, etc.).  Data mining approaches, specifically text mining, 
introduce additional capabilities to extracting and identifying latent underlying patterns in 
text.  Over the past two decades, numerous techniques were constructed to help understand 
the evolution of knowledge regarding the etiology and progression of AD captured in 
published literature has been explored through science mapping methods.  Recently, a 
research group at Columbia University has begun to apply similar data mining approaches 
to identify clusters of clinical trials which exhibit latent patient eligibility themes.  Various 
aspects of these efforts all share commonalities in that they attempt to model the 
information space of AD in order to gain better understandings of its body of research in 
different ways.  While this research undoubtedly advances the state-of-the-art with respect 
to facilitation of patient enrollment, there is currently no solution which completely unifies 
these concepts into a coherent framework.  In addressing that opportunity, the research 
presented in this dissertation establishes a framework to conceptualize how AD clinical 
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trials have evolved over time with respect to advancements made through knowledge 
gained historically.  Consequently, and for example, the tool developed has the potential 
ability to convey understandings into how to best engage drug targets with the ultimate 
goal of discovering a disease modifying solution. 
Ten significant knowledge gaps and considerations associated with various 
“science mapping” strategies have been identified and serve as a substrate for advancing 
the state-of-the-art in mapping the AD clinical trial design space.  These gaps can be 
condensed into higher level categories which span both aspects of clinical research and 
information science.  Individually and collectively they present a complexly unique 
challenge.  Capitalizing on the need to bridge these knowledge gaps, the framework for a 
novel mapping model will be established in this dissertation, and can be summarized into 
10 high-level statements. 
 
 
Knowledge Gaps to Be Bridged 
 
 
Currently, a detailed historical overview of research efforts which most closely relate 
to the ultimate goal of this dissertation has been reviewed.  Such efforts are representative 
of the current state-of-the-art associated with capturing various aspects of science mapping 
as it pertains to the clinical trial development space.  While there is currently no single 
standard which can be directly compared and contrasted to the innovative research 
described in this dissertation, the survey of bibliometric research efforts described 
represents a collection of ideas that encompass key research themes.  In order to 
subsequently demonstrate the novelty of the approaches developed to significantly advance 
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the state-of-the-art as it pertains to the AD clinical trial design space, the goals, scope, and 
extensibility of past research efforts will be considered collectively.  Inherent gaps in 
knowledge associated with these efforts provide intriguing opportunities for the proposed 
research.  Therefore, the knowledge gaps and associated challenges to be subsequently 
addressed by this doctoral research are related to three high-level topics, which can be 
broken down further into ten key considerations:  
Clinical Research Considerations: 
1. The pathogenesis of AD is not entirely understood.  Consequently, AD is a 
complex and multi-faceted area of research with a plethora of cognitive and 
functional scales aimed at operationalizing various stages of severity of 
dysfunction in cognition due to neuronal death. 
2. Published literature in the field of AD may over-represent the most successful 
and popular areas of research within a domain.  This consequently leads to 
publication bias and the potential to overlook smaller niche and/or emerging 
areas. 
ClinicalTrial.gov Data Considerations: 
3. Over the past few years, a great deal of highly visible government and industry 
efforts have been conducted on identifying ways which clinical trial protocol 
repositories could be extended in functionality and utility.  However, the 
primary focus has been on expediting patient recruitment and subsequent 
enrollment process, and not on enhancing the design rational of the clinical trial 
itself based on historical information. 
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4. Although ClinicalTrial.gov is the most comprehensive repository for accessible 
records of research intent, it is largely maligned for a variety of previously 
described shortcomings.  This is most notably due to its lack of highly 
descriptive information relating to disease targets.  Consequently, this 
repository presents unique challenges and not particularly attractive in its 
current form for text mining purposes. 
5. Past approaches to extending the ClinicalTrials.gov database have focused 
primarily on curating and making the data included readily accessible in a wide 
variety of formats for the intended purpose of fostering the creation of patient-
facing applications to enhance trial enrollment capabilities. 
Information Science Considerations: 
6. Clinical trial protocols are multi-faceted in nature and projecting the latent 
themes included in such protocols simply to a single 2-dimensional projection 
does not fully capture all of the relevant dimensions from which document 
similarities can be derived. 
7. Current novel bibliometric and informatics approaches such at the ones 
provided by Weng et al. do not allow for detecting high-level themes in clinical 
trial protocols nor capture their temporal changes over time. 
8. Rather than statically clustering clinical trial protocols based on eligibility 
criteria, an emphasis is placed on identifying similarities based on underlying 
biomedical themes, which are implicit indicators of the current state of domain 
knowledge. 
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9. Visualizing dynamic temporal changes of a network over time is currently an 
active area of information visualization research due to high data 
dimensionality constrains; by devising informative and aesthetically-pleasing 
visualizations which succinctly summarize key high-level changes across a 
collection of static graphs subset by time, these dimensionality challenges can 
be addressed. 
10.   Conventional document search and subsequent retrieval using paginated lists, 
currently implemented by ClinicalTrials.gov, can be restructured in more 
intuitive ways by presenting the collection at different levels of granularity and 
directing user attention to the most relevant concepts (themes) and individual 
components (documents) through novel analyses and visualizations. 
 
These knowledge gaps and associated challenges/considerations have been codified to 
facilitate the construction of a cohesive framework for mining and subsequently visualizing 
changes in themes within collections of documents, specifically AD clinical trial protocols, 
to further extend the ClinicalTrials.gov database within the scope of science mapping.  
Combined, they form the theoretical underpinnings upon which to set the stage for the 
rationale behind pursuing this doctoral research.  Overall, it is envisioned that this work 
serves as a translational layer between the science of the natural (clinical research) and the 
artificial (information science).  Using information diffusion through evolving research 
fronts as the foundation for this work, the intent is to translate the outputs of AD research 
into quantitative and qualitative insights through novel mining routines.  This overarching 
theme throughout this research is succinctly illustrated below in Figure 14.  Having 
established requisite foundational background information, rationale for the proposed 
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research, and pivotal works in the space, it is now appropriate to delve into the 
ARRASTRA framework.  Ten significant knowledge gaps have been identified, and will 
be addressed in the following chapters: firstly, introducing the overall novel framework, 
then establishing the technological aspects behind its core components, and finally 
evaluating and discussing the utility of the framework.  
 
 
Figure 14.  High-level overview of the proposed framework for translating research 
outputs  
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Chapter 4: The ARRASTRA Framework 
 
 
A comprehensive overview of clinical trial research within the context of AD has 
been presented, as well as recent efforts which aim to optimize, improve, and/or streamline 
underlying research activities.  Industry and government-funded efforts have primarily 
focused on improving patient-facing features of ClinicalTrials.gov to support trial 
enrollment through patient engagement.  Academic research efforts have primarily focused 
on mining published scholarly literature.  A solution must be devised which concretizes 
information diffusion into a coherent framework, by analyzing clinical trial protocols in 
previously unexplored ways.  In order to make use of the data clinical trial protocols 
contain, an appropriate data processing pipeline must first be devised.  Since the ultimate 
goal of identifying research fronts relies on graph-structured data, plain-text clinical trial 
protocols must be mined and expressed accordingly.  The following chapters will first 
introduce the rationale behind the framework, and then present the two high-level modules 
developed to implement the solutions. 
 
 
Rationale 
 
 
 As discussed in Chapter 3, bibliometric and text mining approaches have been 
employed to extract meaningful metrics that quantify the interconnected nature of 
biomedical literature.  While the majority of research has focused on published literature 
as the main source for analysis, recent efforts have since analyzed clinical trial protocol 
documents.  Information contained within plain-text government clinical trial protocol 
repositories, when diligently analyzed, can be repurposed to analyze historical trends 
across a therapeutic space.  In order to accomplish this, three high-level goals must be 
achieved.  Firstly, a framework must be devised, which can express collections of raw text 
through quantifiable data structures – in this case, a network of related and interconnected 
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entities (i.e. clinical trials).  Second, latent themes which best describe subsets of these 
entities can be determined by identifying communities of closely-related entities and their 
most salient features (i.e. research fronts).  Lastly, the fact that an emphasis has been placed 
on historical trends suggests the need for accommodating the added dimension of 
temporality when quantifying these metrics and themes.  Indeed, analyzing a graph at a 
single time point only provides a snapshot of its state and not its evolution.  A framework 
which satisfies these goals effectively implements the principles of information diffusion 
into concrete software components using graph-based logic. 
 Much like bibliometrics have quantified the importance of entities through 
constructs such as co-author and co-citation networks, these metrics too can be imputed for 
clinical trial protocols.  A therapeutic space can be conceptualized as a temporally-directed 
network of clinical trial protocols.  However unlike bibliometrics which rely on 
connections explicitly stated in literature citations, the relationships between protocols are 
implicit, and similarity measures must be employed to infer latent affinities between them.  
Additionally, the directionality of network edges retains a special characteristic, where the 
source node of this relationship represents a trial which predates the target trial.  This 
dictates the specific graph metrics which are relevant to the analysis – namely betweenness 
centrality and out-degree strength.  While technical details will be provided in subsequent 
chapters, these concepts are captured below in Figure 15.  Note the graph which results 
from these imputed protocol relationships is similar to a citation network, but with the 
noted differences just mentioned.  Graph clusters, or communities of tightly interconnected 
trials can then be detected to identify research fronts.  Betweenness centrality and out-
degree strength metrics can be used in this context as well to impute the amount of 
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information flow which is directed through that cluster.  This allows for the analysis of a 
therapeutic space at both the individual protocol level (nodes), as well as high-level themes 
(clusters).  However, the notion of “diffusion” suggests that these metrics must be imputed 
over time.  
 
 
 
Figure 15.  A collection of clinical trial protocols expressed as a graph of directed nodes 
 
 
The evolution of a therapeutic space can be described as interactions between both 
individual graph nodes as well as clusters across a collection of graphs subset by time.  For 
individual trials, Kleinberg burst profiles of node metrics measure protocol influence by 
identifying significant spikes in these metrics over time.  Themes derived from clusters can 
be visualized using novel visualizations which depicts the connectivity between those 
clusters and the amount of information which flows through them.  Node metrics can then 
be assessed to predict the “health” of temporally-salient research fronts (clusters) over time, 
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integrated with protocol metadata, using survival analyses.  Finally, the novel integration 
of real-world endpoints with imputed metrics reveals factors contributing to the success of 
trial sub-therapies based on disparate metrics indicating research productivity.  For 
example, imputed graph importance metrics can be correlated with citation counts of 
published literature resulting from those clinical trials.  From a high-level framework 
perspective, the dissertation work can be summarized by Figure 16.  Next, the 
ARRASTRA framework will be introduced in technological detail, which is responsible 
for extracting clinical trial protocol information and mining its content using graph-based 
representations of a therapeutic space. 
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Figure 16.  A Conceptual Overview of the Proposed Dissertation Research Framework 
 
 
Framework Overview 
 
 
 A variety of past research initiatives with the potential to extend the functionality 
of the ClinicalTrials.gov database has been discussed.  These range from rendering 
protocol data more fine-grained and accessible in a variety of data formats (e.g. SQL, REST 
web services, etc.), to applying informatics-based mining approaches against eligibility 
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criteria (e.g. Weng, et al).  A comprehensive review of the most notable areas of work has 
been presented, which identified gaps in knowledge addressed and which remain open. It 
is apparent that there exists a definitive need for a cohesive framework which annotates, 
persists, and mines information contained within collections of clinical trial protocols.  
Development of this framework is grounded in information theory, in that comprehending 
the dynamics of information diffusion within different contexts and granularities can be 
achieved through the exploitation of heterogeneous networks.  This is the basis for the 
ARRASTRA framework.  Coined after the ancient mining tool used to pulverize ore in 
order to extract precious gold and silver, ARRASTRA is a full graph-based software stack 
upon which sits a comprehensive Python API.  It is used to mine the evolution of latent 
time-based themes as they exist locked within corpora of clinical trial protocols.  As 
previously mentioned, the notion of research front “evolution” is conceptualized through 
the identification of novel events which occur within a graph of inter-connected objects, 
based on the nature of their connectivity and relationship to each other.  The following 
sections of this dissertation systematically review key software components of the 
ARRASTRA framework in the order in which data flows (Figure 17).  Applicable areas 
of past research which serve as state-of-the-art technical solutions and approaches will be 
compared and contrasted with this framework.  The framework itself is comprised of two 
core modules: ARRASTRA Miner and ARRASTRA Toolkit.  The former involves the back-
end data mining, text processing, ontology mapping, and storing of relevant clinical trial 
protocol metadata.  The latter is a user-facing API required for querying, manipulating, and 
visualizing clinical trial data in useful ways.  The API can be used to develop front-end 
web applications on frameworks such as Django or Flask, providing user interfaces to 
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interact with the underlying software stack.  The goal of this section is to first establish the 
framework at the level of its core software components.  Then, more technical algorithmic 
principles which establish the data processing routines and subsequent visualization will 
be discussed in Chapter 6. 
 
 
 
Figure 17.  The ARRASTRA Framework software stack 
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Chapter 5: The ARRASTRA Miner Module 
 
 
 The first step of the data mining process involves extracting relevant information 
from individual clinical trial protocols and expressing it in such a way which can be 
queried and directly manipulated.  In the ARRASTRA mining framework, two main 
approaches are used to first extract meaning from clinical trial protocol texts: natural 
language processing and parts-of-speech extraction, and semantic annotation.  The former 
deconstructs sentences into their appropriate parts in order to extract named-entities, as 
well as textual qualifiers of those entities.  The latter maps those identified named-entities 
to authoritative representations contained within structured term hierarchies, called 
ontologies.  These ontologies provide the foundational axioms of a domain, or statements 
about the relationships between the biomedical concepts used in the annotation process.  
Since clinical trial protocols are semi-structured, the fields in which these mappings occur 
provide a contextual label establishing a relationship between the trial and the annotated 
concepts.  This constructs a massive collection of triple statements describing multiple 
facets of clinical trial protocols.  The Titan graph database is used to capture this data due 
to both its scalability to run on a distributed cloud computing platform, and extensibility 
due to the numerous supported backend NoSQL data storages.  Its functional query 
language, Gremlin, provides path-based querying capabilities which enables concept 
inferencing at the time query. 
 
 
Graph Database Solutions – Encoding Information 
 
 
Past initiatives described that were intended to repackage information contained 
within clinical trial protocols using a variety of data models and access methods are 
undoubtedly useful.  They provide developers with a means to build innovative 
applications with less overhead required for querying and parsing the data.  While useful 
in providing developers the flexibility to choose how the data can be best accessed, these 
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existing data formats do not easily provide a means for understanding the interconnectivity 
among its components, a concept vital to understanding the nature of information diffusion 
within and across research fronts.  In other words, in the interest of information diffusion 
theory, it is ideal for data to be expressed as a heterogeneous set of objects which 
researchers can directly query using path-based logic. 
Information itself can be best conceptualized as the interconnectivity between 
various entities, such as people, journals, and cited literature.  The next logical step in 
understanding such interconnectivity is to recognize the exact manner in which information 
systems encode and retrieve these types of information using graph databases.  Consider 
information as it is encoded in the following statement which declares that a specific paper 
cites another: “[Paper DOI:10.1186/s12916-015-0297-4] [cites] [Paper DOI:10.3233/JAD-
2012-120286I]”.  This simple statement can be decomposed into three atomic parts: a 
subject, a predicate, and an object.  The subject and object are respectively the source and 
target vertices of a graph, indicated by a global Digital Object Identifier (DOI) string.  The 
predicate refers to the edge which connects the two nodes, with a labeled property “cites”.  
This predicate is directed in nature, as there is a clear delineation between a source and 
target vertex.  Likewise, “Fred knows Tracy” is another simple example of a triple 
statement, where “Fred” and “Tracy” are subject and object vertices respectively, and the 
property which connects them represents “knows”.  At its core, these sets of triple 
statement form the basis of a network.  Additionally, there may be some metadata both 
about “Fred” and “Tracy”, such as their ages or current hometown.  The property “knows” 
may also be associated with metadata as well, such as the date when the two first met.  
Therefore, a set of property/value pairs are also associated with these sets of triple 
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statements in order to provide additional context about the entities and their relationships.  
For another example, “APP interacts with MAPK1” encodes some information about two 
genes and their affinity to interact with each other within the context of some biological 
process.  The predicate “interacts with” may have additional metadata associated with it, 
such as a level of statistical power or certainty which quantifies the nature of the 
relationship.  However, additional metadata referred to as data provenance provide insights 
into the sources from which this statement is derived.  For example, a “study” property 
may indicate specifically which study this statement originated from, or a “last updated” 
timestamp property to indicate the last time the statement was modified or reassessed.  
Information systems which capture and persist the union of entities, their relationships, and 
their associated metadata in a linked data format are referred to as graph databases.  In 
order to convey the manner in which the ARRASTRA tool accurately encodes the 
prerequisite knowledge, a review of graph-based data storage technologies and their 
applications are initially reviewed to convey how current implementations pose to address 
storing and querying large networks.  Once clearly established, the technological 
framework for this aspect of the dissertation work will be introduced. 
 One may say, and rightfully so, that the World Wide Web (WWW) itself is the first 
well-known example of a decentralized graph database.  Growing exponentially in content 
and linked together through the use of explicit hyperlinks, the WWW essentially serves as 
a global database in which the total sum of digitized human knowledge is stored in the 
form of web pages, social media profiles, and various types of multimedia content.  These 
hyperlinks serve as explicit pointers to additional content, ultimately forming a massive 
graph of nearly immeasurable scope and size.  As such, the WWW itself can be viewed as 
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a directed graph, where content is represented as nodes, and hyperlinks represent unlabeled 
edges.  The term “unlabeled” is used here to indicate that there is no context as to the 
relationship which the link establishes, unless explicitly stated using additional metadata.  
The concept of contextual links which contain explicit properties will play a key role in 
future sections of this dissertation.  In the past, algorithms such as Hyperlink-Induced 
Topic Search (HITS) and PageRank have been devised in order to quantify the relative 
importance of a particular resource on the WWW.  For example, HITS calculates two 
metrics for each object based on its connectivity: a hub and authority score.  As discussed 
in Chapter 3, a “hub” node is one which links outward to many other nodes.  An “authority” 
node is one which has many links directed towards it.  Similar to this concept is the 
PageRank metric which calculates a probability distribution that is indicative of the chance 
a user randomly selecting a link will arrive at a given page.  These metrics are useful when 
sorting a large set of results by establishing a metric from which “importance” can be 
operationalized.  However, other than conventional search engines which accept keywords 
and phrases to compare against the content of billions of web pages, there are relatively 
few additional ways of querying the Web.  This is especially true from a path-based 
perspective.  One would need to create a custom web crawler which parsed web pages and 
iteratively trawled through their hyperlinks to new resources.  This can be a lengthy and 
computer-intensive process. 
More recently, web resource sites such as Wikipedia envision each page 
representing a clearly-defined topic, where labeled links point to related pages.  For 
example, one page may represent a specific author, with a labeled link “influence by” 
referring to a page of another author.  These properties are derived from sets of 
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terminologies or ontologies, which are embedded directly into the document using certain 
metadata fields.  While to the user of Wikipedia this appears as a series of conventional 
web pages, the underlying metadata embedded within its pages can also be indexed in ways 
such that it can be queried directly.  For example, DBPedia provides an endpoint in which 
SPARQL Protocol and RDF Query Language (SPARQL) queries can be issued against the 
totality of links captured by Wikipedia.  While concepts such as RDF and SPARQL will 
be discussed shortly, the previous example highlights the ability to query known link types 
which are represented by properties as indicated within the DBPedia namespace.  Briefly 
stated, SPARQL is a query language which can be used to match patterns as they exist in 
triple statements.  As previously mentioned, a triple statement takes the form: subject, 
predicate, object.  It is a basic way to encode and persist facts.  It should be clear that this 
triple format is the most atomic unit for establishing a single connection in a graph of 
statements, where the subject and object of a statement represent source and target vertices 
respectively.  For example, one can issue a query inquiring which painters were influenced 
by the French Baroque painter Claude Lorraine by issuing the following triple pattern in 
the form of a SPARQL query, where http://dbpedia.org/resource/Claude_Lorraine is the 
definitive DBPedia uniform resource locator (URI) representing “Claude Lorraine” 
(subject), http://dbpedia.org/property/influenced (predicate) the property indicating a 
specific type of link representing “influenced”, and ?artist indicates a variable which 
satisfies that pattern (object). 
\ 
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SELECT * WHERE {  
<http://dbpedia.org/resource/Claude_Lorrain> 
<http://dbpedia.org/property/influenced> ?artist. 
}  
 
The result of this query is two DBPedia URIs bound to the artists variable 
dbpedia:J._M._W._Turner and dbpedia:John_Constable, pointing to the painters J.M.W. 
Turner and John Constable respectively.  Simply, the DBPedia endpoint allows users to 
issue one-hop path queries in the form of triple patterns, where Claude Lorraine is a source 
node joined by directed edges to target nodes J.M.W. Turner and John Constable in the 
context of “influenced”.  Importantly, this allows users to pose questions about the 
information contained within links captured by Wikipedia such that they can be repurposed 
in novel ways.  Also, LinkedCT.org, discussed previously as one way of extending 
ClinicalTrials.gov, follows this similar format by exposing a SPARQL endpoint in order 
to query ClinicalTrial.gov data.  However, the data source does not necessarily expose 
novel statements about clinical trials.  It merely recasts pre-existing data in 
ClinicalTrials.gov in the XML-based Resource Description Framework (RDF) format.  
Each vertex then represents a specific clinical trial or a metadata entry for a given property.  
For example, a clinical trial may be connected to a “North Carolina” vertex for the given 
predicate “has sites”, indicating that North Carolina is one general location from which that 
clinical trial is being conducted.  This is the same for properties which point not to other 
class-based vertices, but also literal ones, such as an integer value indicating total number 
of trial enrollees, or a string value indicating the trial completion date.  In RDF, perhaps 
somewhat unintuitively, these vertices representing literal property values are considered 
a special type of vertex, and are not properties of the class-based vertex itself.  A further 
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look at RDF and how the framework is typically used to encode domain-level information 
in ontologies will be given in the following section. 
One should note a trend of decreasing granularity that is being represented as the 
nodes of these networks from: generic webpages, to structured Wiki pages representing a 
concept, to digital representations of actual entities, such as a gene or a clinical trial.  As 
the resolution of these objects becomes clearer and more defined, more specific questions 
can be asked of the underlying data.  It is worthwhile to note that the mechanics of 
performing a graph-based query is significantly different from that of a plain-text search 
using sets of keywords and phrases.  For example, the query “Show me the top potential 
recruiting center locations for a preclinical dementia trial” has network-based implications, 
as the co-occurrence of recruiting centers for trials with similar eligibility criteria can reveal 
a connected network of such sites.  For gene-gene interaction networks, a graph-based 
query may include “What other genes and biological processes link amyloid precursor 
protein (APP) to mitogen-activated protein kinase 1 (MAPK1)?”  Indeed, it may be 
interesting to understand the relationships two or more genes share within the context of 
some disease to infer biological pathways [138,139].  However, perhaps the most popular 
and consumer-facing example is that of Facebook’s Open Graph search, first introduced in 
2013 [140].  This searching allows users to issue queries such as “Show pictures of me 
with mutual friends of Brian”.  This type of query requires a new paradigm of information 
retrieval which exploits the edge-based connectivity of friends within a social graph based 
on their relationships.   
 Other researchers have enabled graph-based querying systems for specialized 
applications.  One example is the work conducted by Zhu, Yan, and Song, in which a 
111 
 
citation database, referred to as a graph-based interactive bibliographic information 
retrieval system (GIBIR) was developed to provide a graph querying system for citations 
[141].  The authors pose the following query “papers on information retrieval, which were 
cited by John’s papers that had been presented in SIGIR” as a prime example of a graph-
based query because it contains not only a metadata element (author name and conference), 
but a path-based inquiry as well.  The mechanisms behind this type of query are 
considerably different from a conventional text-based query using target keywords.  The 
example requires simply a single “hop” between nodes: a direct citation link, or path, from 
one conference paper to another.  More complex queries will require iterative attempts at 
traversing paths across multiple nodes.  Their experiments contrasting comparable queries 
on both the graph system to a relational database schema revealed significantly better 
performance: 72% improvement for a 3-node query, 89% improvement for a 4-node query, 
and 99% improvement for 5-node query.  Indeed, the development of graph-based queries 
addresses issues of computational perplexity that even specialized graph-oriented schemas 
in relational databases cannot adequately perform.  Other popular applications for graph-
based querying systems are for gene interaction networks.  Understanding the interactions 
between genes is a vital part of understanding the underlying basis of diseases and their 
pathogenesis.  Qnet for example proposes a custom querying method for interrogating 
gene-gene interactions using bounded treewidth graphs [138].  Other solutions repurpose 
graph database systems such as neo4j to provide querying interfaces to gene-gene 
interaction networks [142].  Another popular area of biomedical interest relates to the 
potential for two or more drugs to interact if taken concomitantly.  Genetic predisposition 
for such interactions and their potential impact on the safety or efficacy of a drug are often 
112 
 
confirmed or disproven through pharmacovigilance studies.  Associated networks 
identifying potential drug-drug interactions have also been developed to identify these 
relationships [143].  Systems such as NeXO use neo4j to explore the relationships between 
biomedical concepts in large ontologies such as the GeneOntology (GO) [144].  This 
sampling of examples clearly illustrates the fact that graph storage and processing has 
become a topic of extreme interest in information sciences within the past decade and 
accommodates a diverse set of applications.  The rationale behind graph storage 
technologies is a crucial component to the development of the ARRASTRA framework.  It 
is important to survey the current state of graph-based storage solutions in order to identify 
research efforts which best demonstrate those capabilities.  As will be discussed, 
ARRASTRA enables ClinicalTrials.gov to be queried not as plain-text documents, but as 
actual graphs of interconnected biomedical concepts. 
 At the heart of information diffusion is the desire to understand the dynamics 
between entities which constitute interconnected concepts.  As such, new data storage 
technologies which leverage graph-based logic are quickly becoming more widespread to 
address novel connectivity and path-based inquiries.  These technologies rethink how 
underlying data structures can be constructed to more efficiently persist the vertices and 
edges which comprise these massive graphs such that they can adequately handle iterative 
path-traversal queries.  More importantly, it allows for statements which communicate 
facts in the format of subject/predicate/object triples to be stored and subsequently queried.  
After establishing past efforts which either develop or repurpose graph storage and 
querying technologies, it is now appropriate to further explore how ClinicalTrials.gov data 
can be processed, such that it can be queried in similar ways.  
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A Graph-based Approach to ClinicalTrials.gov 
 
 
The advent of the “Big Data” movement has spawned new technologies which 
distribute the storage, querying, and processing of massive datasets which cannot 
adequately fit in storage or working memory (RAM) across virtual computational clusters.  
These solutions typically run on distributed computational resources through hosting 
services such as Amazon’s Elastic Cloud Computing (EC2) platform.  This type of scalable 
solution is required for supporting rapidly-expanding data sets, such as graphs which 
contain millions of vertices and edges.  At the heart of these technologies are relatively 
new types of data storage technologies broadly referred to as NoSQL databases [145], or 
ones which do not follow the relational database paradigm popularized by Structured 
Query Language (SQL) databases.  These specific data storage technologies support 
highly efficient BigTable data models, publicly introduced by Google in 2008 [146].  The 
general BigTable data model separates itself from conventional relational table models in 
that its conceptualization of a “table” is a persistent, semi-structured, sparse, scalable, and 
multi-dimensional key-value map.  A map is an associative array which can be accessed 
given a corresponding unique key.  In this format, a table contains a collection of such data 
structures, where rows, also referred to as “wide rows”, are identified and ordered by a row 
key, and contain an arbitrarily large set of columns.  Columns can be further organized into 
logical groupings called column families.  Perhaps the most popular examples of such 
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software which supports BigTable implementations are HBase4 and Cassandra5, both 
originating from the Apache Foundation.  On the backend, graph databases store node and 
edge data in two separate tables.  However, as discussed previously, dynamic metadata of 
varying data types must also be captured about these entities and their relationships.  Since 
these data types can represent fields which require additional levels of parsing, such as full-
text indexing for keyword search, geographic coordinates for places and locations, and 
numerical values for specifying value ranges, additional storage capabilities must be 
enabled.  One example data storage technology for such applications is ElasticSearch6, a 
“distributed, open source search and analytics engine, designed for horizontal scalability, 
reliability, and easy management”.  Since these backend databases merely capture and 
index the data in general ways, middleware is required to properly create the appropriate 
data schemas and serve as a conduit for querying and formatting the graph data.  This 
middleware technology is powered by Aurelius Titan7, a scalable and extensible 
framework that can purpose a wide array of NoSQL databases as backend data storages.  
Not only does Titan provide a Java-based API for programmatically accessing its 
underlying graph data, the graph data can also be accessed via RESTful means over HTTP 
with Rexster8, allowing for interoperability with other programming languages such as 
Titan.  This technology stack was chosen due to its scalable and extensible nature, as well 
as its ability to efficiently query massive amounts of graph data [147].  Additionally, Titan 
                                                 
 
4 http://hbase.apache.org/ 
5 http://cassandra.apache.org/ 
6 https://www.elastic.co/ 
7 http://titan.thinkaurelius.com/ 
8 https://github.com/tinkerpop/rexster 
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provides native hooks into both Apache Hadoop9 and Apache Spark10 from which 
distributed graph computations can be executed. 
Much like LinkedCT.org has exposed basic ClinicalTrials.gov metadata through 
linked data representations, this dissertation envisions the capability to extend the concept 
to even more fine-grained detail.  In other words, and as previously discussed, 
LinkedCT.org does not provide any extra insights into the meaning of the textual data itself.  
The question then is to understand how the data contained within clinical trial protocols 
can be augmented by expressing it in a graph format.  Reflecting on the “anatomy” of the 
clinical trial protocol as it is stored in the ClinicalTrials.gov repository, the semi-structured 
document is divided into clear document zones.  A zone represents a specific sub-section 
of a document from which additional context can be derived.  For example, the “Exclusion 
Criteria” section includes biomedical concepts which are obviously implicated in the 
eligibility section of the protocol.  Indeed, “Chronic mental illness” appearing in the 
exclusion criteria section of a protocol has a considerably different context than if it 
appeared in the title of the protocol.  As such, these zones provide clear opportunities to 
establish contextual relationships between the protocol and the biomedical concepts it 
contains.  Without the explicit establishment of zones, one could simply state a protocol 
was about some particular concept, or attempt to infer document zones automatically 
through zone identification [148,149].  As such, one could extract the following statement 
“This clinical trial excludes patients with chronic mental illness”, or more simply in the 
                                                 
 
9 http://hadoop.apache.org/ 
10 http://spark.apache.org/ 
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form of a triple statement “Trial excludes chronic mental illness”.  As such, the system can 
begin to convert blocks of text into sets of explicit statements. 
 One of the major challenges associated with extending the functionality of the 
ClinicalTrials.gov database is related to the fact that it is organized in a coarse-grained and 
semi-structured way, with the most atomic unit being a block of text of varying size.  From 
a technological standpoint, when a system interprets a block of text merely as a string of 
characters there is no understanding of word meanings, word boundaries, sentences, etc.  
In order to establish the meaning behind these chunks of characters, text mining routines 
must be applied to these blocks of text.  When the word “meaning” is used within the 
context of text mining, it indicates that two distinct types of metadata are present to 
accompany the text: parts-of-speech (POS) tags and semantic annotations.  The former 
involves extracting POS features from text such as verbs, adjectives, nouns, numerical 
value ranges, and acronyms.  Broadly, this involves the process of named-entity 
recognition, where key biomedical concepts are extracted from the text based on POS 
[150].  The latter involves mapping those keywords and phrases to authoritative thesaurus 
and ontology entities. There is a close relationship between named-entity recognition and 
semantic annotation, as the POS first identifies the location of key biomedical entities 
within the text, and semantic annotation resolves those entities to controlled terminologies.  
Additionally, POS tagging also provides additional quantifiers and qualifiers to the 
extracted entities.  For example, consider the clinical trial NCT01529619.  In its 
“Eligibility” section, it specifies “An MMSE score of > or = 10 and < or = 23”.  Naturally, 
the intent is to extract the following statement: “NCT01529619 has eligibility MMSE”.  
However, the MMSE concept is quantified by an inclusive range of scores between 10 and 
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23.  In other words, the given statement can also retain additional metadata about the nature 
of the connection: a minimum of 10, and a maximum of 23.  Extracting this value range 
requires POS and numeric parsing of this eligibility item which will be discussed shortly.  
As it should become increasingly apparent, the foundation for extending ClinicalTrials.gov 
is accomplished by extracting protocol information found in blocks of text, such that it can 
be stored in a fine-grained manner.  These statements and their accompanying metadata, 
such as the one provided in the MMSE example, form the basis for a massive graph of 
interconnected statements that make it possible to directly query the information contained 
within clinical trial protocols.  Having provided the technological basis for this, a closer 
look at how the ARRASTRA Miner module processes clinical trial protocol text follows.  
Then, the resulting graph generated from a collection of AD clinical trial documents will 
be introduced by demonstrating the capabilities of its underlying functional query 
language, Gremlin11. 
 
 
The ARRASTRA Miner Process 
 
 
Natural Language Processing 
 
 
 The following section outlines the mining process of the ARRASTRA Miner 
module.  The two-part process first parses clinical trial protocol text using POS tagging in 
order to extract named-entities and concept metadata.  It then maps those named-entities 
                                                 
 
11 https://github.com/tinkerpop/gremlin/wiki 
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to biomedical ontologies.  The entire data loading pipeline which will be discussed is 
illustrated in Figure 18.  Overall, the process extracts meaningful biomedical concepts and 
any specified quantities from collections of ClinicalTrial.gov protocols, and constructs an 
interconnected graph of clinical trial concepts. 
 
 
 
Figure 18.  The ARRASTRA Mining pipeline 
 
 
Firstly, one must gain understanding from plain-text documents, by systematically 
extracting and storing relevant pieces of information.  In order to achieve this, XML dumps 
from ClinicalTrials.gov are downloaded on a weekly basis, given a textual keyword search 
which represents the therapeutic space of interest (e.g. “Alzheimer’s Disease”).  This 
results in a large collection of protocols representing all different phases of clinical 
development (e.g. Phase 1 trials through pharmacovigilance studies).  Both interventional 
and observational trials are included.  Each XML document represents a single clinical 
trial, and encodes information for each zone of the protocol using closed tags (ex. 
brief_summary, eligibility, trial_arm, etc.).  It should be noted that other data sources 
discussed previously such as Duke’s CTTI SQL database dump was not leveraged for this 
process.  While it would have been much easier to process data that has already been 
curated into a relational database schema, these data sources are released on an annual basis 
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and do not necessarily reflect the most recent advances in clinical trial research.  In order 
to capture the most recent clinical trial filings, the decision was made to draw the protocols 
from its direct source.  Each document is routed through a processing pipeline, where each 
field of the individual protocol (e.g. title, descriptive summary, eligibility, outcomes 
measures, trial arms, etc.) is first annotated using Python’s Natural Language Toolkit12 
(NLTK) [151].  Parts of speech (POS) are initially determined for each sentence within the 
document using a Perceptron tagger.  Based on the Averaged Perceptron [152], this tagger 
utilizes a multi-layered neural network to probabilistically determine POS after being 
trained on the University of Pennsylvania’s Treebank13.  Studies have demonstrated the 
increased accuracy of this POS tagger in relation to other standard taggers [153].  Penn’s 
Treebank is a well-established source of linguistic trees which annotate the POS structure 
of sentences once parsed.  Linguistic trees envision sentence structures as trees of parts-of-
speech through the use of tagsets.  Tagsets are fields which denote the part-of-speech of a 
word within a sentence.  Starting with the root sentence tag, a linguistic tree represents an 
embedded structure of tree leafs represented by other linguistic tags which form annotated 
phrases.  Additional tags identifying various parts of speech include “noun, plural” (NNS), 
“proper noun, singular” (NNP), “verb, past tense” (VBD), “adjective” (JJ) and “cardinal 
number” (CD), although this list is not exhaustive.  Figure 19 depicts a parsed linguistic 
tree using NLTK representing the following sentence: “The study is to evaluate the safety, 
tolerability and whether there is an immune system response to multiple doses of ACC-
001”.   
                                                 
 
12 http://www.nltk.org/ 
13 http://www.cis.upenn.edu/~treebank/home.html 
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Figure 19.  An example of a parsed linguistic tree using NLTK 
 
 
For each document, blocks of text are tokenized into sentences and each sentence 
is parsed for named-entities and quantifying metadata if present.  Then, using a series of 
complex linguistic POS pattern rulesets, key nouns and phrases qualifying them within 
context of the protocol are extracted.  For example, the phrase “approximately 5-7 points” 
results in a tuple of (“approximately”, [5,7], “points”).  Acronyms, units of measurement, 
and special symbols (e.g. “%”) are also extracted from the text.  These custom rulesets are 
similar to regular expression statements, but match patterns of tagsets rather than series of 
characters.  Table 1 captures an example of rulesets for extracting quantifying metadata 
using the NLTK. 
 
"{<RB>?<JJ.*|NN.*><IN>}", 
"{<RB>?<IN><JJ.*>}", 
"{<RB>?<JJ.*|NN.*>?<IN>?<JJ.*>?<CD>+?<NN.*|CC>}",   
"{<RB>?<JJ.*|NN.*>?<IN>?<JJ.*>?<CD>+?<NN.*|CC><IN>+?<NN.*>+?}", 
"{<RB>?<IN>?<JJ.*>?<CD>+?<JJ>+?<NN.*|CC>}", 
"{<RB>?<IN>?<JJ.*>?<CD>+?<JJ>+?<NN.*|CC>}<IN>+?<NN.*>+?", 
"{<RB>?<JJ.*|NN.*>?<IN>?<JJ.*>?<CD>+?<JJ>+?<NN.*|CC>}<IN>+?<NN.*>+?” 
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Table 1.  Named-entity and Quantified Metadata Ruleset Examples 
 
All entries from which tagset patterns were detected based on the POS tags are 
temporarily stored in a MongoDB14 storage, indexed in the JavaScript Object Notation 
(JSON) format.  A JSON object is a dictionary-typed structure of key/value combinations, 
where possible values can represent other embedded dictionaries, arrays, strings, integers, 
and other basic literal types.  Figure 20 depicts an example entry captured in the temporary 
MongoDB index, specifically those with type BOUNDED_VALUE_ENTITY.  The 
structure contains the following fields: index – which captures the relative character index 
of the beginning and end of the phrase, name – which captures the exact text matching the 
POS pattern, level – an internal flag indicating the exact POS tagset pattern that matched 
the phrase, parts – an array which decomposes the phrase into its most atomic POS entries, 
and values – an array indicating the range of numerical values extracted from the pattern.  
The values field array can either represent a single value such as in this case 160 (mmHg), 
or two values which represent a minimum/maximum of a range of values with the first 
value representing the domain and the second value representing the range.  The next 
section of this chapter will deal with fields representing the ontological mappings of the 
named-entities, which are denoted in Figure 20 as type ONTOLOGY_MAPPING. 
 
                                                 
 
14 https://www.mongodb.com/ 
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Figure 20.  Results of POS tagset pattern matching in a MongoDB storage 
 
 
Having outlined the process for extracting the most important pieces of information 
from each clinical trial protocol and giving it meaningful structure based on the text’s POS 
patterns, the basis for the graph metadata is now established.  Using the extracted named-
entities from the text, one can then augment these extracted concepts with semantic data 
which authoritatively establish nodes of the clinical trial protocol graph. 
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Introduction to Ontologies 
 
 
 At this point of the text mining process, a series of structured data objects 
representing key entities and the values which quantify them within the context of semi-
structured clinical trials have been generated.  As such, a graph is not yet constructed until 
these data are expressed in a way that Titan recognizes.  In the previous section, the 
BOUNDED_VALUE_ENTITY construct was discussed, and the ONTOLOGY_MAPPING 
construct briefly introduced.  The ontology mapping step in now discussed as it requires 
an added step after the named-entity recognition process which definitively binds the 
extracted word or phrase to an authoritative representation of that concept in a controlled 
ontology.  To begin, a brief introduction to the foundations of structured ontologies is given 
in order to understand their implication in constructing graph representations of how these 
concepts are related.  Establishing these concepts are crucial for understanding how 
resources are expressed and identified across a collection of biomedical ontologies, and 
thus how they augment extracted text through semantic annotation. 
An ontology is a structured document, typically expressed in XML and modeled in 
the RDF format, which formalizes the relationship between concepts within a given 
domain.  RDF is a specification set by the World Wide Web Consortium (W3C) and 
backbone of the Semantic Web.  The framework provides the general syntactical 
foundation from which relationships between concepts are established in an effort to model 
information.  In other words, much like a relational schema defines the structure of SQL 
databases, RDF and its extension RDFS (Schema) provide the blueprints from which 
domain knowledge can be asserted.  The term class is used in conjunction with concept in 
this case to differentiate the mere idea of an entity from an actual instance of that entity.  
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In the context of the relational database example shared previously, a “class” would be 
comparable to a “patient” table, while an “instance” is a populated row in that table.  In the 
RDF framework, classes are authoritatively identified by unique resource identifiers 
(URI) which serve as global primary keys across the Semantic Web.  A URI may take the 
form of its more specific sibling uniform resource locator (URL), or an address which 
points to a specific location on the web.  However, unlike a URL, a URI does not have to 
explicitly resolve to an actual document; it is merely a naming convention to definitively 
identify a concept, no matter how abstract it may be, within an RDF document.  Like a 
URL, a URI can be decomposed into a namespace and a resource identifier.  The 
namespace specifies the global context from which a resource is being described.  For 
example, the namespace for RDF is http://www.w3.org/1999/02/22-rdf-syntax-ns#.  For 
brevity, a namespace is generally shortened by an appropriate namespace qualifier (i.e. 
“rdf”).  The pound (#) symbol indicates the end of the namespace, and anything which 
follows identifies either a resource or a property within the namespace’s context.  One such 
property is “http://www.w3.org/1999/02/22-rdf-syntax-ns#type” (or rdf:type) which 
specifies an “instance of” relationship between two resources, as in “Alzheimer’s Disease 
rdf:type Neurological Disease”. 
Higher-level ontologies exist which extend RDF by establishing increasingly 
specific axioms, such as the Web Ontology Language (OWL).  As discussed previously, 
the relationship between two entities, commonly referred to as an axiom, establishes a set 
of assertions in the form of a subject/predicate/object triple.  Axioms are properties which 
enforce class-based constraints on subjects and objects of such statements.  The concept of 
a constraint is where axioms differ from that of a generic property, as a constraint specifies 
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the specific classes which can represent subjects and objects.  For example, the hypothetical 
axiom for “isAdministered” may limit the subject to a class “Patient” and an object “Drug”.  
Therefore, this axiom would be violated if, for example, the statement “Patient 
isAdministered Car” was asserted.  Other ontologies referred to as upper ontologies such 
as the Suggested Upper Merged Ontology (SUMO) and the Basic Formal Ontology 
(BFO) serve as top-level models which provide the foundation for hierarchically 
classifying concepts, and promote aligned and interoperable semantic structures.  Focus 
will be given to BFO since it serves as the foundation for the Ontology for Biomedical 
Investigations (OBI), which in turn is adopted by the majority of specialized biomedical 
ontologies.  Figure 21 depicts the specific roles these different types of ontologies play in 
providing structure to the classes and axioms which formalize domain knowledge. 
 
 
 
Figure 21.  The backbone of ontologies which formalize assertions about concepts 
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 While upper-level ontologies such as the BFO play important roles in bringing 
structure to hierarchies of class-based concepts, their applications are more relevant to 
skilled ontologists who diligently construct the ontologies and not necessarily the 
consumers of the information they provide.  Indeed, ontologies most relevant to the 
research described in this dissertation involve the low-level biomedical ontologies which 
implement the BFO and OBI – the axioms which encode facts about the relationships 
between actual biomedical concepts.  Next, a review of key low-level ontologies and the 
efforts taken to both construct, curate, and apply them to biomedical applications will be 
given.  Then, the roles which ontologies serve in the ARRASTRA framework will be 
discussed. 
 Having established the basic concepts behind ontologies and specifically the ones 
which comprise their high-level foundations, it is appropriate to also address how lower-
level ontologies are being applied to biomedical research applications.  Broadly, these 
efforts can be categorized into two main groups: “developing” ontologies, and “applying” 
them within information systems.  To reiterate a very important concept, an ontology 
represents a formalization of domain-level facts, in the form of axioms expressed between 
class concepts.  This modeling may require the manual or semi-automated efforts of 
ontologists knowledgeable with the domain in question being modeled.  For example, the 
Translational Medicine Ontology and Knowledge Base was developed as a set of 
terminologies which introduce new concepts and relationships required to integrate 
information expressed across genomic, proteomic, chemogenomic, and clinical research 
domains [154].  This was accomplished through a lexical analysis of a diverse sample of 
research questions which spanned 14 different pharmaceutical research sub-disciplines.  
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However, the majority of research currently resides in fully automating the relationship 
extraction and formalization process.  As discussed previously, efforts such as 
AlzFoum.org proposed to summarize key information provided within recent AD 
manuscripts through manual curation and indexing on some basic levels of research facets.  
This process, in the most basic sense, separates the manuscript as a vector of information 
from the actual facts they intend to communicate, as sets of declarative statements.  As was 
discussed in the previous section, NLP data mining processes seek to extract these 
relationships between concepts in plain text such that they can be stored in structured ways.  
An ontology is one way in which these fact-based relationships, expressed as axioms, are 
captured through automated NLP means [155].  Most relevant to this dissertation is the 
ability to formally establish concepts relating to eligibility criteria, both generally and for 
disease-specific clinical trials.  For example, Miotto and Weng suggest unsupervised 
approaches to extracting tags of eligibility criteria from ClinicalTrials.gov protocols [156].  
This is an initial first step in the process of developing structured ontologies by first 
extracting the major concepts which comprise a domain.  Additionally, Bucur reported on 
constructing a standardized library of historical inclusion/exclusion criteria such that 
design concepts can be shared between researchers in a collaborative manner [157].  Milian 
et al. similarly constructed ontologies of eligibility criteria to enable patterns of their reuse, 
such that they assist in reducing overhead for designing future clinical trials [158].  The 
ELiXR ontology is another example of an eligibility criteria ontology [159], with an 
extension ELiXR-TIME, which formally conceptualizes time-based measurements in 
clinical trials [160].  Notable aspects of ontologies also include their domain scope and 
structure.  Well-known examples such as the UMLS, discussed previously, and the 
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Systematized Nomenclature of Medicine - Clinical Terms (SNOMEDCT), attempt to 
capture health and disease-related concepts in their entirety using deeply-embedded 
hierarchical structures.  The GeneOntology (GO), while slightly more specialized, 
captures the relationship between genes, pathways, and biological processes [161] and has 
been used extensively to annotate evidence-based results of gene interaction studies [162].  
More domain-specific ontologies have been developed as well.  For example, the 
Neuroscience Information Framework (NIF) was developed by ontologists at the 
University of California, San Diego in order to capture the relationships between concepts 
within the domain of neuroscience itself [163].  What makes the NIF particularly 
interesting is its alignment with the BFO, and its compartmentalized structure.  The NIF 
provides an ontological “glue” which allows for the modular addition and semantic 
alignment of various neuroscience sub-domains.  Figure 22 depicts the organizational 
structure of the NIF from a high-level conceptual view. 
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Figure 22.  An overview of the compartmentalized NIF ontology15 
 
 
These modular ontologies include, but are not limited to: Subcellular Anatomy 
Ontology (SAO) – an ontology which describes the anatomical components of cells such 
as neurons, Phenotype and Trait Ontology (PATO) – an ontology which describes the 
physical trails (phenotypes) of phenomenon such as neurological dysfunction, and 
Sequence Ontology (SO) – an ontology which describes biological sequences such as single 
nucleotide polymorphisms.  Typically, the information contained within ontologies can be 
interactively explored through web-based tools, such as the Sequence Ontology concept 
ribozymic (SO:0001186) depicted below in Figure 23.  The left panel allows users to 
explore concepts in a basic tree view, while the right panel displays parent-children 
                                                 
 
15 Image courtesy of Maryann Martone, Ph.D. 
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relationships to other concepts.  The image in the lower right visualizes these axioms as a 
network structure as has been discussed previously. 
 
 
 
Figure 23.  A web-based concept browser visualizing the sequence ontology hierarchy 
 
 
Conventionally, ontologies have been utilized to annotate biomedical literature 
[164], scientific study results [165], and other digital media such as images and video [166].  
Again, the term annotate is used to denote that some digital artifact has been indexed with 
additional structured metadata which maps the content to an authoritative representation of 
the concept expressed in its raw representation, such as plain-text.  Plain-text 
representations of the two terms Apolipoprotein E and ApoE do not adequately 
communicate that they are expressing the same concept.  However, annotating these two 
concepts each with an ontological representation from the Ontology of Genes and Genomes 
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(OGG:OGG_3000000348) can achieve this.  Similarly, apolipoprotein E recycling can be 
annotated with its ontological representation in the GeneOntology (GO:GO_0071828) to 
distinguish it as a biological process involving the protein and not the protein itself.  The 
axioms which form logical path-based relationships between concepts can also be exploited 
to infer new and implicit facts, leading to the creation of semantically-driven applications.  
This fact represents the ultimate goal of the semantic annotation step of the ARRASTRA 
mining process: to augment clinical trial protocols by encapsulating its plain-text 
representations with ontological mappings.  Once accomplished, the semantic annotations 
can be integrated with each protocol’s identified zones in order to produce sets of 
statements about each document.  These statements ultimately form a massive graph 
comprised of clinical trial identifiers and their mapped concepts, connected by zone 
properties. 
 
 
Semantic Annotation with BioPortal 
 
 
As discussed previously, named-entity relationships are extracted from each 
sentence of contained within labeled zones of a clinical trial protocol document.  Numerous 
applications exist which can be used to map these extracted named-entities to authoritative 
ontological concepts.  As previously mentioned, Bolen and colleagues from the Columbia 
University Digital Science Institute capitalized on the use of the UML Metathesaurus to 
establish these mappings.  However, for this dissertation, it was decided to leverage the 
more modular set of ontologies such as the NIF, as it is specialized for neuroscience 
applications.  Additionally, for this solution to be extensible to other therapeutic areas, 
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flexibility dictates that other ontologies should be easily referenced such that the process 
is not limited to a single ontological source.  Domain-specific applications, specifically 
those which may express topics such as relatively new compounds, advanced or specialized 
anatomical regions, or relatively obscure assessment scales may not be entirely covered by 
more monolithic ontologies which are generalized in nature.  Instead, the proposed solution 
opted for a more flexible approach where ontologies can be dynamically selected at the 
beginning of the annotation process.  The premier service for providing open interface and 
programmatic access to over 500 biomedical ontologies is the National Center for 
Biomedical Ontology (NCBO) BioPortal (http://bioportal.bioontology.org/) [167,168].  
Funded by the NIH, NCBO’s fundamental mission statement is to “support biomedical 
researchers in their knowledge-intensive work, by providing online tools and a Web portal 
enabling them to access, review, and integrate disparate ontological resources in all 
aspects of biomedical investigation and clinical practice”16.  Some of the functionality that 
BioPortal provides a web-based tool includes: 1.) search and locate ontologies of interest, 
2.) search for ontological concepts across all ontologies, 3.) browse and visualize specific 
ontologies, and 4.) annotate large chunks of plain-text with specific ontological 
information.  In short, BioPortal is a widely-accepted and comprehensive source of 
biomedical ontologies and mapping tools.  Specifically, focus was assigned to BioPortal’s 
Open Annotator service, as it provides the functionality from which large blocks of text 
can be annotated [169].  BioPortal provides RESTful access via HTTP to its annotation 
backend through a batch-processing API. 
                                                 
 
16 https://www.bioontology.org/about-ncbo 
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The annotator’s use has been documented extensively in the past for various 
applications.  For example, Morrell et al. integrate BioPortal’s annotation service with a 
patient-facing tool intended to assist in the management of health-related topics, called a 
“Personal Health Explorer” [170].  This integration allows the annotator to provide 
descriptive metadata to the user as an effort to assist them in understanding medical terms 
and concepts.  Similarly, Song et al. employed the annotator service to augment written 
clinical narratives which result during interactions between physicians and patients, 
through a tool called Semantator [164].  The annotation process provides enhanced 
indexing functionality to promote the proliferation of accurate and detailed electronic 
health records (EHR).  Hong et al. applied this annotation approach to provide structure to 
radiology imaging results such as chest x-rays and computed tomography (CT) brain scans 
[171].  Burcur et al. purposed the annotator service as a first step of extracting relevant 
eligibility concepts from clinical trial protocols [157], similar to the efforts of Weng et al. 
described previously in this section.  From an API standpoint, Maguire et al. implemented 
BioPortal’s annotator functionality as a Google Spreadsheets plugin called OntoMaton, in 
order to augment documents with semantic biomedical annotations [172].  Indeed, the 
RESTful architecture of the annotator allows seamless integration with numerous 
programming languages and frameworks.  Next, the mechanics of the annotation process 
using BioPortal’s Open Annotator service is discussed, as well as efforts to address a 
particularly problematic aspect of clinical trial protocols found in lack of ontological 
coverage of internal compound identifiers. 
As discussed, BioPortal’s Open Annotator exposes API endpoints through a 
RESTful HTTP endpoint as documented at http://data.bioontology.org/documentation/.  
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Briefly, this approach allows custom client software to communicate with a server using 
specially-crafted HTTP requests in order to send it bodies of clinical trial protocol plain-
text, directly as a parameter of the request URL.  The BioPortal Open Annotator in return 
responds with a JSON payload containing the annotated text results.  A high-level process 
summary is depicted below in Figure 24 of the annotation result “Melanoma is a malignant 
tumor of melanocytes which are found predominantly in skin”.  The key fields required to 
complete the minimum annotation process within the example JSON structure are noted: 
annotatedClass,@id references the actual ontological concept of the mapping, and the 
annotations structure contains an array of a single embedded dictionary with fields to, from, 
matchtype and text, which provide relative index offsets as to where the target annotated 
concept exists within the provided plain text.  These offsets are used to match the extracted 
named-entity from the previous NLP process to the resulting semantic annotation results 
provided by BioPortal.  This integration of these two processes further confirms the 
appropriate identification of a clear mapping.   
 
135 
 
 
 
Figure 24.  BioPortal JSON structure capturing annotated clinical trial protocol text 
 
 
Revisiting the temporary ontology mapping structure in MongoDB, illustrated in 
Figure 20, is appropriate.  Again, the concept of systolic blood pressure is highlighted.  The 
JSON structure captures the following information about the mapping through the 
following fields, in the order which they appear: preferredTerm – an array which contains 
one or more string labels of the annotated text, index – a data structure indicating the 
relative to and from offsets of where the term appears in the full text, score – a string-
matching score indicating the overlap between the identified concept and its preferred label 
(0 indicating no overlap, 1 indicating perfect match), xref – an array of cross-references 
(synonyms) to other appropriate mappings, subUri – an array of children concepts 
(deprecated), type – a flag which indicates the data structure is an ontology mapping, uri – 
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a shorthand notation of the mapped concept’s URI identifier, and fullUrl – the concept’s 
entire URI with full namespace qualifier.  Ultimately, this data will serve as the target node 
(object) of a statement about clinical trials, which will be discussed in more depth in the 
following section. 
There are three further challenges to this process that requires additional 
consideration.  They include: 1.) handling the annotation of complex compound concepts, 
2.) accounting for synonyms, and 3.) handling conceptual areas of biomedical concepts 
which lack coverage in current ontologies.  Firstly, one must consider the fact that words 
and phrases mapped to ontological concepts are not always atomic in nature.  Consider the 
following phrase “mild-to-moderate Alzheimer’s Disease”.  As was discussed previously 
in Chapter 3, the competency decomposition method was used to atomize the phrase into 
three different concepts of increasingly generality: mild-to-moderate Alzheimer’s Disease, 
Alzheimer’s Disease, and Disease.  A key consideration in the annotation process is how 
to best handle a single mapping which may encompass different levels of conceptual 
granularity.  Unlike Boland et al., the solution proposed in this dissertation has opted to 
only capture the single mapping in its purest form as represented in the plain text.  As will 
become evident in the following section, instead of explicitly stating every level of 
granularity that a concept may take, path-based logic against the underlying ontologies will 
be used to infer these relationships at the time of query.  Indeed, the qualifier “mild-to-
moderate” within the context of a clinical trial may have contextual significance, 
specifically with eligibility criteria, compared to trials which generally specify 
“Alzheimer’s Disease”. 
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Second, since multiple ontologies are being referenced in the annotation process, 
one must also account for incidents of mapping clashes, where synonymous concepts 
between two disparate ontologies satisfy the mapping of one concept.  Indeed, two different 
documents expressing the concept Alzheimer’s Disease derived from separate ontologies 
will not be adequately aligned unless the relationship is explicitly stated.  To address this 
during the overall mining process, three considerations are taken.  Firstly, since the NIF 
family of ontologies covers the majority of concepts across the domain of neuroscience 
and is semantically aligned with upper-level ontologies BFO and OBI, any mapping which 
originates from those namespaces is ultimately given priority.  Secondly, a running total of 
the number of annotations each additional namespace contributes to the overall annotation 
is tallied.  Those namespaces which are most representative of a concept are selected as an 
alternative.  However, this still does not entirely identify all cross-references.  Finally, after 
the entire mining is complete, a pair-wise comparison against all extracted preferred terms 
is conducted, using fuzzy string matching.  Filtering all matches which exceed or equal to 
a threshold (in this case, 0.85) and individually assessed for accuracy, a resulting list of 
110 previously unidentified cross-references were identified.  Again, this process would 
not be required with a single set of aligned ontologies which cover every aspect of 
neuroscience research.  This is, however, currently unfeasible, and thus in order to provide 
as much comprehensive ontological coverage as possible, this solution opted to include 
additional third-party ontologies into the annotation process. 
Lastly, the final issue experienced with accurately accommodating ontological 
coverage in the annotation process involves identifying organization-specific compound 
identifiers.  As discussed previously, while clinical trial repositories reflect the current state 
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of the pharmaceutical industry as a whole, they are deficient due to the lack of detailed 
information about the rationale and execution of those trials.  One clear issue is that 
therapies currently being tested in Phase 1 and early Phase 2 clinical trials are first listed 
using a company-specific compound identifier prior to the assignment of a generic name.  
For example, consider the following excerpt of the study description for NCT00244322: 
“The purposes of this study are to determine: The safety of LY450139 dihydrate and any 
side effects that might be associated with it”.  The compound identifier “LY450139” was 
used in early clinical trials conducted by Eli Lilly and Company prior to the assignment of 
the generic name, “semagacestat”.  These identifiers are internal to the research 
organization, and provide no context as to the nature of the therapeutic solution.  Again, 
the use of a company-assigned compound identifier during early phase clinical trials 
provides a degree of confidentiality.  This was the case for approximately 100 clinical trials 
in the corpus.  Fortunately, once these compounds progress to later stage trials, they are 
typically referenced by their generic name and information about the therapy, such as its 
mechanism of action, can be found elsewhere on the Internet.  As discussed previously in 
detail in Chapter 3, AlzForum.org serves as a separate website with manually-curated 
information about past, on-going, and planned clinical trials.  Ideally, this information 
would be made available in a structured way through an official ontology, although one 
does not currently exist.  As such, one had to be constructed.  Using a semi-supervised 
named-entity recognition mining process, key information regarding these internal 
compound identifiers were extracted, and converted into an ontology.  Figure 25 below 
depicts the ontology construction process in Protégé17, an open source ontology 
                                                 
17 http://protege.stanford.edu/ 
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construction application.  For illustration purposes, the mining process identifies the 
previously mentioned Eli Lilly and Company investigational compound, LY450139 now 
more commonly referred to by its generic name, “semagacestat”.  The ontology 
construction process maps to two biomedical concepts: it is a type of “gamma secretase 
inhibitor”, and its drug target is “amyloid beta - protein precursor”.  Ten clinical trial 
protocol filings cite the internal compound identifier LY450139, while five protocols 
reference the generic name “semagacestat”.  Without this step in the annotation process, a 
crucial disconnect would exist in this dataset.  The importance of linking concepts to their 
authoritative identifiers and thus augmenting the contents of clinical trial protocols will be 
further illustrated in the next chapter. 
 
 
Figure 25.  Compiling an ontology of Internal Compound Identifiers for AD trials 
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Currently. in the ARRASTRA mining process, clinical trial protocols are being stored as 
temporary JSON structures in MongoDB.  Next, the data import process into Titan will be 
discussed, and the underlying graph data formats reviewed. 
 
 
The ARRASTRA Data Format 
 
 
 The processed clinical trial protocol texts which pass through a pipeline which 
includes XML parsing and rudimentary zone identification, natural language processing, 
and semantic annotation, are still not yet expressed in a graph-based format.  However, 
before the actual protocol annotations can be loaded into the Titan graph database, the 
ontologies from which the annotations are derived must be loaded first.  This processing 
step ensures that the protocol annotations will naturally integrate with their underlying 
ontological representations, as well as their accompanying metadata (ex. textual labels, 
descriptions, etc.) and relationships (axioms).  In other words, the first step of the loading 
procedure involves the on-boarding of the ontological blueprints which comprise the 
graph’s nodes and node metadata, and the edges which explicitly link them together.  Then, 
the protocol annotations are loaded into Titan, as they only specify the concept URIs which 
serve as pointers to their full representations in their representative ontologies.  This step 
of the data loading process first provides the conceptual class and axiom backbones for 
which annotated statements of clinical trial protocols are derived.   
In order to provide this ontological foundation for protocol annotations, a custom 
data-loading module was developed as part of the ARRASTRA Miner framework.  First, 
all relevant ontologies are downloaded from BioPortal in either an OWL or Open 
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Biological Ontology (OBO) format.  OBO files are converted to OWL files using obo2owl.  
Files are processed by a batch script in order of decreasing generality, in order to ensure 
that concepts are loaded from their authoritative ontology of origin, and not from others 
which simply refer to them.  Each OWL file is parsed with the Redland librdf Python 
language bindings18, with all explicit axioms denoting hierarchical relationships, as well as 
literal properties loaded into memory.  For each ontology, class-based nodes are stored by 
first indexing all subject and object resource URIs.  For each of these nodes, their literal 
properties are extracted.  For example, labels and text-based descriptions are similarly 
indicated by properties across numerous ontologies.  These properties, taken from RDF, 
RDFS, OWL, Dublin Core, OBI, etc. were mapped to common graph properties.  For 
example, skos:prefLabel and rdfs:label mapped to a single node-based property “label”.  
Properties skos:definition, rdfs:isDefinedBy, and IAO:IAO_0000115 mapped to a node-
based “description” property.  For edge-based properties which encode the relationships 
between node entities, all explicit hierarchical properties were selected.  The data loading 
software utilizes the PyBulbs Python library19, which employs a RESTful API to load graph 
data into Titan by providing it JSON data structures, encapsulating properties of the 
extracted nodes and edges. 
 Another topic which should be discussed briefly is justifying Titan’s graph data 
format over other native RDF triple stores such as Virtuoso or OpenSesame.  There are two 
key areas to discuss: the ways in which the different data formats formulate graphs and the 
underlying querying mechanisms to pose against these data structures.  Previously, the data 
                                                 
 
18 http://librdf.org/ 
19 https://pypi.python.org/pypi/pybulb 
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structures of RDF documents in native RDF storages had been briefly discussed as an 
introduction to understanding the basic concepts of how RDF statements naturally form 
graphs of concepts.  A comparison of this means of data representation can be compared 
to that in Titan.  Previously, it had been alluded to that even literal properties (i.e. string, 
numbers, etc.) are expressed as a special type of node which differentiates them from 
conceptual class-based nodes.  In other words, this approach views a literal property of a 
node as a node itself, and not a property bounded to the node in which it quantifies or 
qualifies.  This approach is not entirely intuitive or practical in the sense that conventional 
graphs, while able to handle heterogeneous node types, use nodes to indicate actual 
concepts rather than atomic properties of them.  In other words, nodes represent things, not 
properties of things.  Additionally, there is currently no direct or intuitive way to quantify 
and qualify edge properties that exist between concepts.  In order to accommodate this, an 
additional node type, called a blank node was introduced.  Briefly, a blank node is one 
which has no inherent meaning, other than to serve as a “hub” from which a subject can be 
connected to an object by multiple predicates.  Like the literal node, this type of node serves 
only as a mechanism to chain multiple predicates together in order to describe multiple 
facets of a relationship, and does not easily translate to conventional graph logic.  Instead, 
it would be more intuitive if edge properties were bound to the edges themselves rather 
than additional nodes linked through a blank node.  Indeed, the goal of this research is to 
understand the diffusion of ideas and concepts using conventional graph logic, and as such, 
requires data representations which appropriately conform to those standard conventions.  
Next, this data structure is compared to that of the Titan solution. 
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Titan’s graph data format defines nodes, node properties, edges, and edge 
properties.  Therefore, the formal definition of a “graph” presented previously must be 
updated to adequately reflect an important delineation between a simple graph, and one 
that is multi-relational and attributed.  As such, a graph in Titan is defined as 𝐺 =  (𝑉, 𝐸, 𝑃) 
where P is a partial function 𝑃: ((𝑉 ∪ 𝐸) × ∑∗)  →  (𝑈 ∕ (𝑉 ∪ 𝐸)), which binds key-
value pairs to nodes and edges in the universal set U, enabling a flexible graph schema of 
constrained literals.  The possible keys which constitute this schema and the data types 
these properties are constrained to are provided to Titan prior to loading graph data.  These 
schemas are intended to be simplistic and flexible, as they only require the specification of 
a key property, whether the property is node or edge-based, and its literal data type.  Based 
on the provided information, Titan can appropriately assign properties to their underlying 
data storages: Cassandra for node-edge links and ElasticSearch for indexing property 
literals.  The schema itself is provided to Titan using the Gremlin functional language.  
The full script is provided in Appendix A: Full Titan Graph Schema Script, which 
documents the initial schema used for this research.  However, a high-level overview will 
be discussed to highlight key concepts about the underlying graph schema, as provided in 
Table 2.  Key components of these statements are discussed.  The mgmt object is the 
gateway to Titan’s configuration backend, instantiated by providing a configuration file 
specifying with the proper Cassandra and ElasticSearch settings.  It exposes a buildIndex 
method which establishes a graph property, bound to either a Vertex or Edge class.  Then, 
a text string is provided, which maps the property to a key and an appropriate data type by 
chaining the addKey method.  Statement 1 establishes a unique key “nctid” to a node which 
indicates the unique clinical trial ID as provided by ClinicalTrials.gov.  The 
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buildCompositeIndex method instructs Titan to use its native indexing system for this 
property, as it does not require any advanced full-text indexing, which is deferred to 
ElasticSearch.  Statements 2 – 4 utilize ElasticSearch for enhanced indexing capabilities 
by specifying specialized class types such as Mapping.TEXT and Geoshape.  By specifying 
the buildMixedIndex method and providing the name of the secondary indexing backend 
name specified in the Titan settings (in this case ‘search’), indexing will be appropriately 
deferred to ElasticSearch.  Here, text is tokenized and indexed, while latitude/longitude 
coordinates are indexed for global information system (GIS) style querying.  Statement 4 
specifies a property “value_restriction_min” for edges, allowing for ranges of edge values 
to be queried.  This is particularly useful for querying eligibility criteria of continuous 
quantities, described in the previous section.  Having now introduced the graph schema as 
sets of constrained properties, it is now appropriate to review how Titan stores node edge 
connectivity in a distributed manner in order to enable graphs of massive proportions. 
 
1. mgmt.buildIndex('nctid_idx',com.tinkerpop.blueprints.Vertex.class). 
addKey(mgmt.makePropertyKey('nctid').dataType(String.class).make()). 
unique().buildCompositeIndex(); 
 
2. mgmt.buildIndex('description_idx',com.tinkerpop.blueprints.Vertex. 
class).addKey(mgmt.makePropertyKey('description').dataType(String.class).make(),com.t
hinkaurelius.titan.core.schema.Mapping.TEXT.getParameter()). 
buildMixedIndex('search'); 
 
3. mgmt.buildIndex('geo_loc_idx',com.tinkerpop.blueprints.Vertex.class). 
addKey(mgmt.makePropertyKey('geo_loc'). 
dataType(com.thinkaurelius.titan.core.attribute.Geoshape.class).make()). 
buildMixedIndex('search'); 
 
4. mgmt.buildIndex('restriction_min_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgm
t.makePropertyKey('value_restriction_min'). 
dataType(Double.class).make()).buildMixedIndex('search'); 
 
 
Table 2.  Sample of Titan Schema Field Declaration Statements in Gremlin 
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 Titan stores graph information in an adjacency list format using NoSQL data 
storage technologies that supports BigTable data models, as discussed previously in this 
chapter.  In this model, each row represents a single node, with columns storing edge-based 
connectivity information about the nodes adjacent to it.  There are three main 
considerations which ensure Titan’s computational efficiency and scalability than 
compared to, for example, a graph storage schema in a relational database.  Firstly, this 
data model expresses graph connections in a compact way using the adjacency list 
paradigm, as BigTable “wide rows” naturally accommodate such data structures by 
allowing for large sets of sparsely populated columns.  Secondly, rows can be sorted by 
vertex ID to ensure that the graph is partitioned in such a way which allows for better query 
traversal performance.  This leads to the final consideration that as the graph grows, the 
adjacency list can be expanded by distributing node contingency information across 
computational resources, thus making the solution extremely scalable.  This adjacency list 
satisfies the encoding of the graph’s structure, but not the properties of the elements which 
comprise it.  As discussed previously, Titan can reserve these properties for indexing using 
secondary storage technologies such as ElasticSearch.  Key-value maps can also serve as 
light-weight schemas describing the properties of graph nodes and edges, which in turn can 
be encoded as JSON objects for ensuring cross-platform compatibility and transmission 
over RESTful APIs.  As can be demonstrated, the structure of the underlying the Titan 
graph is disjointed from its metadata, unlike conventional triple-store solutions based on 
RDF/SPARQL.  This data model removes the reliance on special node-types to 
accommodate the same types of descriptive metadata, and allows data to be expressed in a 
natural way, supported by discrete and algorithmic mathematics.  Figure 26 depicts these 
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underlying data structures as just discussed.  The top section establishes the path-based 
structure of the graph through Titan’s adjacency matrix BigTable schema in Cassandra, 
and the bottom depicts how node and edge properties are stored in ElasticSearch.  The 
resulting multi-relational and attributed graph in Titan allows users to naturally query its 
path-based structure, as well as node and edge-based properties. 
 
 
 
Figure 26.  Titan Graph structure and metadata models 
 
 
After the data loading process described is completed, a graph containing class-
based properties describing the relationships between biomedical concepts, as well as how 
those concepts relate to various facets of clinical trial protocols, is fully constructed.  This 
allows users to pose novel graph-related questions about the connectivity of these concepts.  
To better understand these principles, the underlying query language used to directly 
interrogate these data structures is now presented, as they represent a relatively new 
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approach for interrogating massive distributed based on their path structure.  This query 
engine is the underlying mechanism for obtaining the relevant graph data, and serves as 
the basis for analysis and subsequent visualizations discussed in the next chapter. 
 
 
Path-based Querying with Gremlin 
 
 
The ability to directly interrogate the massive data formatted by Titan based on 
their path structure represents a relatively new approach to data querying.  In order to 
interrogate the content of a graph, two main types of query languages exist: pattern 
matching and graph traversal.  The former is a declarative language discussed previously 
such as SPARQL, which tests for triples that satisfy sets of specified triple patterns.  While 
graphs can be expressed as sets of triples, this specific type of query language does not 
fully exploit the connective nature of graphs since they do not conventionally allow for 
iterative traversal of nodes along specified paths.  Titan supports a functional query 
language, named Gremlin, which satisfies both language types within a single framework.  
In principle, Gremlin is considered a functional programming language more so than a 
query scripting language since it is based on Groovy, which dynamically compiles to Java 
bytecode and executes on the Java Virtual Machine (JVM).  The functional programming 
paradigm is one which is deeply rooted in lambda calculus, with a hallmark feature being 
the fluent chaining of functions which pipes the logic through series of interconnected 
functions.  This is a critical aspect of Gremlin, as graph traversal instructions and data 
modifiers (side effects) can be logically chained together.  Titan’s Gremlin query language, 
detailed extensively by Rodriguez, introduces the foundational concepts behind such 
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frameworks and is referenced heavily in this section [173,174].  Graph traversal query 
languages on the other hand allow users to accomplish such tasks by programmatically 
specifying how nodes are located by issuing sets of navigational instructions called 
traversals to graph object pointers called traversers.  Here, the foundational concepts of a 
graph traversal language are introduced.  This is not meant to be an exhaustive overview 
of the framework in its entirety, but merely enough to highlight the key differences of a 
graph traversal language. 
Formally, a traversal is denoted as T and represents a series of chained functions 
called steps against the predefined graph G.  A traversal can be structured in two main 
ways: a linear motif, and a nested motif, both of which demonstrate the paradigms of 
functional programming.  A linear motif procedurally chains together a series of steps 𝑇1 ∗
 𝑇2  ∗  𝑇3 such that the input of each successive step is the output of the previous.  A nested 
motif uses a linear step as arguments for another step 𝑇3(𝑇1 ∗  𝑇2) such that the nested step 
is first evaluated and then serves as an argument for the proceeding step.  Since 𝑇𝑖 ∈ 𝑇, a 
single step can be further defined as 𝑇𝑖 ∶  𝑂
𝐴  →  𝑂𝐵, which maps traversers of a specific 
type of object A to traversers of another type of object B.  While Gremlin supports over 30 
unique functions which each step can employ, their capabilities are mainly categorized into 
five high-level functional programming methods: flatMap, map, filter, sideEffect, and 
branch.  When it is stated that a traverser S can take the form of a “specific type of object”, 
these data structures constitute, most basically, a collection of metadata which encodes 
information relating to both a location within a graph as well as a position within the overall 
traversal.  A traverser is formally defined as an element of the following 6-tuple set 𝑆 ⊆
 (𝑈 × 𝑇 × (Ρ(Σ∗) × 𝑈) ×  ℕ+ × 𝑈 × ℕ+), which represents respectively: 1.) U as defined 
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previously as the universal set of node, edge, and property components of a graph, 2.) a 
step within the traversal T, 3.) a labeled path which the traverser has historically traveled 
over, 4.) a natural number indicating the number of copies of the traverser, which is 
reserved for bulk optimization when numerous traversers occupy the same state within the 
traversal, 5.) an additional local data structure referred to as a sack that stores additional 
objects which are the results of sideEffect functions, and 6.) a natural number indicating 
the traverser’s current loop count.  In other words, a traverser is a package of data which, 
behind the scenes, serves as a record of its past activities and current status within traversal 
steps.  Together, the graph, traversers, and traversal instructions allow for the efficient 
computation of path-seeking capabilities as specified by logically-chained sets of 
instructions.  Having now established the basis for a graph-traversal query language from 
a discrete mathematics standpoint, it is now appropriate to introduce it in its application. 
In order to concretely demonstrate the principles of traversers, the Gremlin query 
language merits explanation.  Each query first identifies the target graph from which the 
query is issued against, denoted here by the pointer g, whose data source bindings are 
initially specified in a Rexster configuration file.  From this pointer which references the 
distributed graph g, traversal instructions are issued by subsequently chaining functions to 
the query’s root.  Which the number of functions supported in Gremlin is vast and 
succinctly documented in GremlinDocs20, an example Gremlin query outlining important 
graph-based concepts is provided below in Table 3.  This Gremlin query takes two vertex 
                                                 
20 http://gremlindocs.spmallette.documentup.com/ 
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identifiers, which are specified in the FIND_ID array, and programmatically identifies all 
of the applicable paths which link them together through intermediary concepts. 
 
 
FIND_ID=['OntoAD#C0016967','OntoAD#C0527316']; 
g.V('type','bio_concept').has('uri', T.in, FIND_ID) 
.outE.path.transform{ 
    [it[1].outV.next().uri, it[1].label, it[1].inV.next().uri]}.collect() 
   .filter{['rdfs:subClassOf'].contains(it[1])}; 
 
 
 
Table 3.  An Example Gremlin Path-searching Query 
 
 
To begin, a pointer to the Titan graph is first issued, followed by a traversal step 
V() which specifies all nodes within the graph.  To further narrow down the vertex search 
space, especially when working with a heterogeneous labeled graph, optional inputs ‘type’ 
and ‘bio_concept’ are specified which indicates key-value constraints on the node’s 
properties.  In this example, the traversal process is limited to vertices which satisfy this 
key-value combination to initially reduce the node search space.  It should be noted that as 
the traversal step functions are executed, the current object context of the traverser changes, 
and thus the set of applicable functions changes to the current context as well.  At this point 
in the traversal, the current context applies to a graph’s vertices.  Next, has() specifies a 
two vertices from the graph whose uri fields match the IDs specified in FIND_ID.  The 
T.in argument specifies the specific type of equality match, and the indexing method is 
specified for the uri field in the schema definition described in the previous section.  In this 
example, uri is indexed natively in Titan, as a unique index field does not require any 
special type of full-text indexing deferred to ElasticSearch.  From these vertices, all of 
those which are directly connected as target nodes are selected with the outE() function, 
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and their mutual paths are then selected with the path() function.  At this point, the current 
context is a set of edge paths and their source and target nodes.  The transform() side-effect 
is then issued, which uses the reserved variable it to iterate through the components of a 
set of paths, transforming the path tuple (source, edge, target) to an array of human-
readable triple statements derived from the nodes and edge labels represented by it.  The 
collect() function converts this to an in-memory array, where the filter() function is applied 
to the resulting array for triple statements containing only the label representing a sub-class 
relationship between nodes.  It should be noted that at this point in the query chain, the 
filter is being performed natively in Groovy, as the data has been extracted from Titan at 
the point transform() is called.  On a single 12-core CPU Linux workstation with 32GB of 
RAM, it takes the following query approximately 0.02 seconds to execute against a graph 
of approximately 2.1 million nodes and 1 billion edges. 
Based on this example, it should be clear that a path-based graph traversal query 
language has advantages over pattern matching approaches, in that it enables users to pose 
queries about the graph’s structure, and not just its explicit contents.  One challenge that 
highlights this topic is when complete graph data schemas are not entirely known to the 
user, and makes declarative languages more difficult to employ across federated datasets.  
For example, suppose a user is interested in identifying the shortest path between two genes 
of interest through an exploratory process.  Numerous properties may link genes together, 
such as those indicating whether there is a direct gene interaction, whether they are 
implicated in similar diseases, or whether they participate in the same biological processes.  
Furthermore, for this exploratory process, perhaps the set of possible properties which 
could link these genes are not entirely known.  In order to exploit the shortest-path logic, a 
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graph-traversal query language needs not know the explicit properties it must follow.  
Instead, a graph traversal language may simply specify the iterative path-searching 
instructions needed to research a specific target node.  Contrasting to a declarative style of 
a pattern-matching language, this type of query would be infeasible, as one would have to 
explicitly encode the desired patterns needed to reach the desired node.  Not only does this 
not make intuitive sense, it also does not consider the shortest path needed, which 
obviously cannot be calculated manually.  Other use-cases would involve attempting to 
identify the shortest paths between a large set of nodes, which can be addressed by 
iteratively extracting a sub-graph which minimizes the number of edges connecting the 
complete set of input nodes.  This use case highlights the need for query languages which 
instruct traversers to iterate over both known labeled and unspecified edges. 
As a more applicable example, consider a researcher wishes to understand how 
research organizations are enrolling new subjects into a prodromal AD clinical trial.  Since 
prodromal AD subjects do not yet exhibit signs of cognitive impairment for which they 
would seek professional care, clinical trial enrollment becomes a major challenge.  Further 
suppose this researcher could identify a network of recruitment locations from which these 
studies are currently utilizing to enroll patients.  Unfortunately, the current system only 
captures recruitment locations at the general organizational and state/city levels contingent 
to the United States.  Starting with the concept “Prodromal AD”, a query could be issued 
such that all location links directly connected to clinical trials can be traversed to compile 
a co-occurrence network of locations.  Additionally, the query itself can employ graph 
metrics such as PageRank at query-time once a sub-graph has been extracted, which infers 
location importance for the given type of AD therapy.  
153 
 
The ARRASTRA framework API exposes Titan querying capabilities by 
dynamically compiling Gremlin query scripts at run-time, and issues them against the Titan 
graph instance via a RESTful interface exposed by the Rexster web service.  The scripts 
themselves embed additional instructions for Gremlin called side effects, which specifies 
how result data structures are to be transformed in ways that they can be seamlessly 
encoded by the client software.  The next chapter detailing the ARRASTRA Toolkit will 
discuss the Gremlin query module in more detail, as this functionality ultimately resides 
on the client side. 
 
 
Next Steps 
 
 
 This chapter introduced the concepts underlying the data mining, annotation, and 
storage processes for constructing a massive graph of interconnected biomedical concepts, 
and the relationships they share with various facets of clinical trial protocols.  While the 
data currently stored in Titan, queryable via the Gremlin query language, can already 
provide interesting and unprecedented insights into the interconnected nature of biomedical 
phenomena, it does not yet allow users to explore the data in interactive ways, nor infer 
temporal trends.  As such, a visualization suite was built on top of the Titan graph storage 
such that users can interact with the data in meaningful ways.  Next, the ARRASTRA 
Toolkit which provides a comprehensive API to query, process, and visualize the graph 
data contained in Titan is introduced and dissected in detail. 
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Chapter 6: The ARRASTRA Toolkit 
 
 
 The preceding data loading process through the ARRASTRA Miner module 
described in Chapter 5 serves to construct a queryable graph of integrated biomedical 
concepts and their relationships to clinical trials within the context of their appearance 
within protocol zones.  While this specific capability is unprecedented in that it allows 
researchers to pose novel graph-based inquiries about the interconnected nature of clinical 
research, it does not necessarily provide intuitive and expressive insights about trends and 
patterns over time.  Rather, it merely serves as the basis from which interesting insights 
can be derived.  Indeed, while a graph may be static at the time of query, time-stamped 
nodes such as ones representing clinical trials occur at different points in time.  One 
particular challenge in the information visualization space, specifically with regards to 
graph-based visualizations, is communicating key changes to structures across time 
periods.  These changes ultimately reflect how research fronts form, converge, and diverge 
over time, thus revealing the underlying nature of information diffusion within a domain.  
The ARRASTRA Toolkit is a suite of data processing and visualization tools designed to 
exploit latent patterns and trends which exist within dynamic graphs. It accomplishes this 
with four modules: multi-faceted data dimensionality reduction, manifold learning across 
multiple maps, homogeneous graph reconstruction and slicing, and finally MetroMaps 
visualizations.  The resulting visualizations allow researchers to understand the 
relationship between clinical trial protocols from a high-level cluster perspective, as well 
as providing the ability to “drill-down” into the trials which constitute their respective 
research fronts. 
 
 
Rationale 
 
 
 A framework for conceptualizing information diffusion was established and 
described in the previous chapter.  This was accomplished by operationalizing the 
dynamics of research fronts as changes in graph clusters over time.  However, these graphs 
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must typically be homogeneous in nature, where nodes represent the same type of concept.  
A massive multi-labeled graph containing biomedical concepts, their relationships, and the 
multi-faceted contextual roles they play in clinical trial design was therefore constructed.  
This graph serves as the underlying dataset from which interesting inquiries can be posed 
regarding the interconnected nature of clinical research.  It should be noted that the 
rationale behind the ARRASTRA Toolkit API is influenced by work conducted by 
researchers at the BBC, London.  Raimond and colleagues developed a novel tool known 
as rdfsim, more recently renamed to rdfspace21, as a way to leverage internal RDF storages 
containing metadata regarding station radio programs [175].  Using program content RDF 
metadata, Raimond et al. employ rdfspace to compare archived broadcasts with current 
and relevant news based on the nature of their connectivity to overlapping concepts.  
However, as the project name suggests, rdfspace provides support for symmetric adjacency 
matrices which does not afford for heterogeneous vertices or directed graph edges [176]. 
While understanding how graph metrics can apply to multi-modal graphs is an 
active area of research [177–180], the proposed framework typically relies on well-
established, conventional metrics to quantify the importance of nodes within a network.  
For example, translating PageRank results of a multi-labeled graph extracted directly from 
the underlying Titan graph database are difficult to interpret when attempting to compare 
the score of a node representing clinical trials against another representing the concept 
“Alzheimer’s Disease” [181,182].  Instead, this solution opted to analyze homogeneous 
graphs by purposing target nodes as features of source nodes given a set of directed labeled 
                                                 
 
21 https://github.com/bbc/rdfspace 
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edges.  In other words, clinical trials can be compared directly to each other, given the 
nature of their connectivity to related biomedical concepts.  These features comprise a 
high-dimensional space from which latent themes can be extracted by projecting protocols 
onto lower-dimensional spaces through novel dimensionality reduction and manifold 
learning processes.  The following chapter details this framework which is ultimately 
capable of processing the underlying graph data in such a way that clinical trial protocols 
can be directly compared using graph-based approaches, through both quantitative and 
qualitative means.  This procedural process employed to achieve such output is illustrated 
in Figure 27. The various steps associated with the process flow depicted are subsequently 
incorporated into the structure of this chapter. 
 
 
 
Figure 27.  The ARRASTRA Toolkit client-side graph-construction process 
 
 
Querying Titan Graph 
 
 
 Titan’s Gremlin query language has been introduced previously in Chapter 5 to 
highlight the major concepts behind interrogating graph structures with path-based logic, 
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and is ultimately where the ARRASTRA Toolkit process begins.  The ARRASTRA library 
enables a graph query module which interacts with Titan through Rexster’s RESTful API 
interface.  This module accepts various inputs such as path properties to follow and 
property-based node filters which dynamically compiles Gremlin queries at run-time.  
These queries not only specify the appropriate graph paths which to traverse based on user 
input, but also provide sideEffect instructions for returning the requested graph data in 
platform-independent formats such as JSON.  Overall, there are three high-level types of 
queries which are supported.   
The first type of query allows users to interrogate various aspects of the underlying 
clinical trial protocol graph and is based on the desired protocol zones of interest.  This 
heterogeneous graph provides the basis for the multi-faceted feature space which will be 
visualized as a final output of this process.  In theory, each clinical trial protocol document 
can be expressed as its own sub-graph which constitutes a smaller part of the overall Titan 
graph, formed by biomedical concepts which co-occur within a specified document 
window (in this case, protocol zones).  The second type of query seeks connected concepts 
from those explicitly annotated in each protocol in order to provide full query-expansion 
support in ARRASTRA.  The need for query expansion has been discussed previously in 
Chapter 5, as the content of clinical trial protocols can be augmented by including closely-
connected concepts within conceptual hierarchies.  This query expansion process merits a 
more detailed review in the next section within the context of constructing the input feature 
space.  However, at the query level, this process is crucial in that it demonstrates how path-
based logic can be utilized to identify nodes which connect explicit concepts in meaningful 
ways.  Lastly, a query which requests node and edge-based key-value metadata is 
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supported.  Such queries are useful for providing human-readable labels as well as 
additional data for rendering visualizations.  Consequently,  𝐺 = (𝑉, 𝐸, 𝑃) is satisfied 
locally on the client-side.  Additionally, the ARRASTRA query model employs batch-
querying capabilities in order to reduce the amount of REST calls it makes to Rexster for 
lowering query overhead. 
ARRASTRA provides routines that expose functionality which automatically 
generates these queries and encodes results in such a way that can be directly manipulated 
in Python.  An example of this API capability is provided below in Source Code 1.  The 
list link_types contains all edge properties (i.e. protocol zones) that should be incorporated 
into the initial statement space.  Next, a titan object is instantiated.  It serves as a pointer to 
the underlying Titan graph storage and exposes numerous functions for querying it.  The 
function expand_by_property accepts parameters such as the unique ID field to return for 
each concept (search_field), the links to follow within the Titan graph (to_follow), and a 
node-based property filter (vfilter), which specifies the initial type of nodes to return.  The 
vfilter property is a crucial concept which helps illustrate query optimization practices in 
Titan. Titan does not segment graphs into logical grouping like a relational SQL database 
would, through the use of distinct database and table structures.  It is a single graph storage 
solution, which can contain only a single graph, regardless of its size.  As a result, multiple 
disconnected graphs may exist within the same data space.  Their diversity can be extensive 
and include clinical trial graphs which are the primary subject of this research, a gene-gene 
interaction network, as well as social media graphs.  ARRASTRA imposes additional light-
weight schematic constraints on nodes that essentially serve as namespaces from which 
nodes can be selected or filtered.  In this example, vfilter indicates that initially, only nodes 
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with type of clinical_trial should be considered for future processing.  As a result, nodes 
belonging to namespaces not applicable to the current query context are first filtered. 
 
from arrastra import SERVER_CFG, URI_EDGE_LABELS, G_METRICS, G_CLUSTERS, NODE_WEIGHT 
from arrastra.data.utils import DataUtils 
from arrastra.web import titangraph as tg 
 
#- Link properties to include -# 
link_types = [URI_EDGE_LABELS['CT_DESCRIBES'], URI_EDGE_LABELS['CT_SUMMARIZES'], 
URI_EDGE_LABELS['CT_HASCONDITION'], URI_EDGE_LABELS['CT_HASARM'], 
URI_EDGE_LABELS['CT_MAIN_THERAPY']] 
 
#- Load configuration file, initialize Titan object -# 
titan = tg.TitanGraph(config=SERVER_CFG) 
 
#- Query Titan -# 
graph = titan.expand_by_property(search_field='uri', to_follow=link_types, 
return_property='uri', vfilter=('type','clinical_trial'))['results'] 
 
 
 
Source Code 1. ARRASTRA API demonstrating Titan graph querying capabilities 
 
 
The data which results from this query process, denoted by the graph variable, is a 
graph of clinical trial protocols and biomedical concepts.  This input graph, such as the one 
depicted in Figure 28, is said to be heterogeneous in nature due to the fact that vertices 
represent different types of entities with both vertices indicating clinical trial protocols and 
others representing biomedical concepts.  Since the stated goal of this research is to 
understand the dynamics of clinical trials, their protocols serve as the sole target for 
analysis.  As such, routines for directly comparing clinical trial nodes must be employed.  
One may note, however, that while the input graph itself is characterized by dense edge 
overlaps, when arranging the nodes with an OpenOrd layout, clear communities can be 
visibly detected. 
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Figure 28.  The resulting graph of clinical trials from the Gremlin query process 
 
 
Additionally, users can query for key-value metadata relating to each node to provide 
more descriptive detail about each node within the graph.  In the Source Code 2 example 
below, key-value pair dictionaries are returned for each clinical trial node within the graph 
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returned from the previous API calls, and then filtered for three specific properties using 
an additional DataUtils helper. 
 
all_metadata = titan.get_metadata(uris=list(set([s[0] for s in graph])),  
search_field='uri')['results'] 
ct_metadata = DataUtils.filter_dict(d=all_metadata, 
to_keep=['uri','nctid','brief_title','firstreceived_date','enrollment','overall_status']) 
 
 
 
Source Code 2.  Returning key-value pairs for all clinical trial nodes in the dataset 
 
 
While approaches such as interactive graph tools may prove useful for exploring 
graphs of this general type, they are better suited for considerably smaller graphs.  For 
example, an interactive web-based graph tool was initially developed to visualize the 
output of Gremlin queries against the Titan graph database, constructed with Prototype and 
Foundation JavaScript libraries.  This tool is depicted in Figure 29.  As can been seen, 
central clinical trial nodes are connected to each other through various biomedical 
concepts, such as “MMSE” and “monoclonal antibody”.  However, in comparison to the 
previous figure, exploring connections are considerably more challenging in larger graphs.   
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Figure 29.  Visualizing heterogeneous graphs of clinical trials through an interactive 
tool 
 
 
There is a clear need for further consolidating the information contained within this 
graph in order to directly compare clinical trials.  As a result, the graph in its current form 
must undergo additional transformations to accomplish that goal.  The following sections 
detail this process through the routines exposed by the ARRASTRA Toolkit.  The degrees 
to which clinical trials are compared are based on their connectivity in the graph to similar 
biomedical concepts, weighted by relative importance.  The next part of this process 
involves operationalizing clinical trial protocols such that these comparisons can be made 
through text mining and latent theme detection algorithms.  
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Text Mining and Latent Theme Detection 
 
 
Vector Space Models and Graph Weighting 
 
 
In order to fully understand the nature of information diffusion within a research 
domain, direct comparisons must be made to the entities which represent the source from 
which the information is derived – in this case, clinical trial protocol documents.  
Expressing research fronts as clusters of interconnected clinical trials demands that the set 
of documents be converted to a directed graph of homogeneous entities.  Past research has 
focused on calculating similarities between documents in a variety of ways as will be 
described.  However, in order to quantify the degree to which documents share similarities, 
they must be operationalized in a way such that is supported by discreet mathematical 
paradigms.  The following section details selected conventional approaches which propose 
to solve this specific problem while employing a novel similarity metric which expresses 
clinical trial protocol documents as sub-graphs of the underlying Titan graph.  This first 
step involving the operationalization of document contents is crucial in order to accurately 
compare documents by imputing pairwise similarity-based metrics.  At the heart of this 
process is establishing ways in which to weigh the importance of concepts at both corpus 
and document levels. 
Conventional information retrieval (IR) practices conceptualize text-based 
documents such as biomedical research papers as a bag-of-words, or an unordered 
collection of extracted keywords which comprise the main text.  This collection is 
operationalized into a vector space as an array of values where each cell represents a 
unique keyword.  The value for each keyword-specific cell represents, most simply, 
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whether that keyword exists within the document.  This is operationalized by a logical 
Boolean value where one indicates the presence of the term in the document and zero 
otherwise.  However, this standard approach does not take into consideration that certain 
keywords may be more important than others, both within the context of the individual 
document and at the corpus level.  Therefore, the vector space approach can be extended 
to weigh keywords based on their prevalence at these two levels by calculating the Term 
Frequency Inverse Document Frequency (TF-IDF) of each keyword [183].  In theory, a 
keyword within a document represents that document well if that keyword appears 
numerous times within it (term frequency).  The term frequency (TF) for each term is first 
normalized to the number of total terms within the document.  However, to ensure that the 
word is not over-expressed continually across the entire corpus, each term frequency is 
penalized by multiplying it by the keyword’s log inverse document frequency.  As a result, 
keywords which are highly expressed within documents, but not across the entire corpus, 
are weighted higher as they tend to be most descriptive for those documents.  TF-IDF can 
be expressed by the following formula, where t represents a specific term for each d 
document, N the total number of documents in the corpus, tdoc the number of times t appears 
in the document, ttotal the number of total terms within the document, and tN the number of 
documents containing term t. 
 
𝑇𝐹(𝑡) =
𝑡𝑑𝑜𝑐
𝑡𝑡𝑜𝑡𝑎𝑙
, 𝐼𝐷𝐹(𝑡) =  log (
𝑁
𝑡𝑁
) 
𝑇𝐹𝐼𝐷𝐹(𝑡) = 𝑇𝐹(𝑡) ∗ 𝐼𝐷𝐹(𝑡)  
Equation 1.  TF-IDF Equation for Normalizing Term Frequency to Document and 
Corpus 
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While TF-IDF has long been considered the conventional gold standard for 
weighting term importance within documents, it fails to account for additional document 
and corpus-level variables that may influence term importance.  As such, TF-IDF has since 
been expanded with a set of heuristics which improve upon the term frequency scoring 
function by accounting for these document and corpus-level variables [184,185].  A log-
based concave function adjusts the weight of a keyword appearing in a document multiple 
times such that its gain as a function of the times it appears in the document is not linear 
(Equation 2).  Pivoted document length normalization adjusts weights based on the 
varying lengths of documents (Equation 3).  Finally, lower-bounding regularization is 
used to widen the weight difference between keywords which exist and those that do not 
in larger documents (Equation 4).  These functions are successively applied to raw term 
frequency scores to produce an adjusted TF-IDF score, which brings further clarity to the 
importance of a keyword by accounting for these factors.  Let (𝑡, 𝑑) equal the term 
frequency of term t in document d, the constant k equal to the maximum possible gain for 
multiple term occurrences (default set to 1.2), 𝑏 ∈ [0,1] the slope tilting parameter for 
pivoted normalization (default set to 0.03), |𝑑|equal the length of the document d, and avdl 
equal the average document length of the corpus. 
 
𝑇𝐹𝑘(𝑡, 𝑑) =  
(𝑘1 + 1) × 𝑡𝑓(𝑡, 𝑑)
𝑘1 + 𝑡𝑓(𝑡, 𝑑)
 
Equation 2.  Log-based concavity TF function 
 
TF𝒍(𝑡, 𝑑) = 1 + ln(1 + ln(𝑡𝑓(𝑡, 𝑑))) 
Equation 3.  Pivoted document length normalization TF function 
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𝑇𝐹𝑝(𝑡, 𝑑) =
𝑡𝑓(𝑡, 𝑑)
1 − 𝑏 + 𝑏 ×  
|𝑑|
𝑎𝑣𝑑𝑙
 
 
Equation 4.  Lower-bounding regularization TF function 
 
 
Two approaches which purpose these TF functions in specific ways are an 
“augmented” TF-IDF (referred to herein as aTF-IDF to differentiate it from conventional 
TF-IDF), and BM25.  aTF-IDF first applies lower-bounding regularization to the raw term 
frequency score and then pivoted document length normalization, which is denoted as 
𝑇𝐹𝑝∘𝑙 × 𝐼𝐷𝐹.  BM25 on the other hand first applies log-based concavity to the raw term 
frequency score, and then pivoted document length normalization, which is denoted 
as 𝑇𝐹𝑘∘𝑝 × 𝐼𝐷𝐹.  The respective formulas in their entirety are provided in Equation 5 and 
Equation 6.  These different variations of TF-IDF subsequently play pivotal roles in 
weighing biomedical concepts in documents expressed as graphs of interconnected 
documents. 
𝑎𝑇𝐹𝐼𝐷𝐹(𝑡, 𝑑) =  
1 +  ln(1 + ln(𝑡𝑓(𝑡, 𝑑)))
1 − 𝑏 + 𝑏 ×  
|𝑑|
𝑎𝑣𝑑𝑙
 ×   log (
𝑁
𝑡𝑁
) 
 
Equation 5.  aTF-IDF Formula 
 
 
𝐵𝑀25(𝑡, 𝑓) =  
(𝑘1 + 1) × 𝑡𝑓(𝑡, 𝑑)
𝑘1 ×  (1 − 𝑏 + 𝑏 ×  
|𝑑|
𝑎𝑣𝑑𝑙)
× 𝑡𝑓(𝑡, 𝑑)
 ×  log (
𝑁
𝑡𝑁
) 
Equation 6.  BM25 Formula 
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One shortcoming of the conventional bag-of-words approach to modeling the 
context of documents is based on the assumption that word appearances are independent 
of each other, when in fact they tend to logically co-occur.  In other words, an unordered 
collection of keywords weighed individually by their appearance within documents and 
across a corpus does not adequately capture the nature of how those keywords exist within 
the context of others.  Therefore, recent work has focused on weighing functions that are 
based on the interaction between keywords utilizing graph theory, by first expressing each 
document as a graph of interconnected keywords.  Since edges communicate some 
information about a pair of concepts, it is appropriate to operationalize the nature of this 
relationship.  The concept of co-occurrence has been discussed previously in the context 
of co-citations.  Much like co-citations, term co-occurrence can be represented as the 
appearance of two distinct terms appearing together within a sliding window of fixed 
length.  A sliding window in this case can represent a fragment of text as small as a 
sentence, a paragraph, or a specific zone (heading) within the document.  Next, term 
weights can be imputed, which represents some graph-based metric measuring a node’s 
influence in a document – namely node out-degree strength and betweenness centrality.  It 
should be apparent that this metric serves as a paralog to a term’s importance based on a 
bag-of-words approach and conventional TF-IDF, but now includes additional information 
about each term’s importance based on their relationship with other terms. 
Two past efforts succinctly illustrate this important concept. For example, Valle 
constructed document graphs based on term dependencies [186].  The concept of term 
dependency extends term co-occurrence by filtering initial edges based on linguistic 
relationships using the Stanford Dependencies parser [187].  Valle then used conventional 
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graph-based metrics to weight the importance of each concept within each document, 
specifically node centrality measurements, denoted as 𝑇𝐶(𝑡, 𝑑).  However, influenced by 
conventional TF-IDF metrics, Valle also introduced the concept of inverse corpus 
centrality, denoted as 𝐶𝐶(𝑡), which imputes each term’s weight based on their connectivity 
within the global corpus graph.  The resulting equation named term centrality inverse 
corpus centrality (TC-ICC) is expressed below in Equation 7.  These imputed weights 
then serve as the final term weights for the input vector space for each document. Valle 
empirically compared term co-occurrence and term dependency TC-ICC metrics against 
TF-IDF metrics using the Reuters-21578 news article collection dataset to accurately 
cluster labeled articles together.  Overall, TC-ICC outperformed TF-IDF (0.6375), with co-
occurrence document graphs (0.6875) slightly outperforming dependency variants 
(0.6763).  ARRASTRA currently supports TC-ICC and can be selected as the term 
weighting method by specifying this setting in the configuration settings. 
 
𝑇𝐶𝐼𝐶𝐶 =
𝑇𝐶(𝑡, 𝑑)
𝐶𝐶(𝑡) + 1
 
Equation 7.  Term Centrality Inverse Corpus Centrality  
 
Another approach proposed by Rousseau similarly uses a sliding window approach 
to establish co-occurrences between keywords (nodes) if they occur within the same 
sentence, employing edge directionality to indicate ordered term appearance within the 
sentence [188].  Rousseau then imputes numerous graph-based metrics for each keyword 
represented within the resulting word-graph of each document, referred to as a term weight 
and denoted by 𝑡𝑤(𝑡, 𝑑).  Here, Rousseau ultimately uses node in-degree to 
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represent 𝑡𝑤(𝑡, 𝑑), citing performance and compression complications when scaling to 
larger graphs.  The concept of term-weight inverse document frequency is introduced in 
order to maintain similar heuristics from which TF-IDF are founded upon. However, 
instead of relying on a simple term frequency, Rousseau opts for a more expressive metric 
which captures relationships between terms.  It should be noted the following equation 
leverages 𝑇𝐹𝑝 described previously as a means of regularizing node weights, and then 
applies inverse document frequency, again similar to TF-IDF.  This metric is expressed 
below in Equation 8. 
 
𝑇𝑊𝐼𝐷𝐹 =  
𝑡𝑤(𝑡, 𝑑)
1 − 𝑏 + 𝑏 ×  
|𝑑|
𝑎𝑣𝑑𝑙
× log (
𝑁
𝑡𝑁
)  
Equation 8.  TW-IDF with lower-bounding regularization 
 
 
Based on the approach proposed in this dissertation, windows were selected based 
on protocol zones to construct document graphs, since clinical trial protocol texts are 
generally curt and may also be expressed as bulleted lists of phrases.  This is reflected in 
the current input graph described in the previous section, where biomedical concepts are 
connected to clinical trial nodes based on their zone appearance.  The rationale is that, for 
example, biomedical concepts describing trial arms are largely distinct for describing the 
specific context of how patient treatment populations are structured.  Additional concepts 
which span multiple zones may serve as key unifying concepts in document-based graphs.  
Currently, there is no built-in support to alter these relationships based on varying window 
sizes.  However, it would be possible to encode n-gram distance metrics for every zone-
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based edge linking concepts, such that higher-level edges can be filtered in subsequent 
iterations of the Titan graph.  As an alternative, document-based graph edges can be filtered 
based on how frequently those terms co-occur within the scope of the corpus itself.  For 
example, two concepts Cx and Cy may occur within a single zone of a specific document, 
yet very infrequently in the overall collection of documents, suggesting a spurious 
relationship within the document.  The ARRASTRA Toolkit allows users the ability to 
additionally view each document-converted graph based on these zone constraints.  Three 
clinical trial protocols expressed as graphs are depicted below in Figure 30. 
 
 
 
 
Figure 30.  Protocol documents expressed as term co-occurrence graphs, pre-edge 
filtering 
 
 
This term weighting process results in a vector space model in which a term’s value 
for each document reflects its importance based on its connections.  However, as has been 
discussed, the concept of query expansion plays a pivotal role in augmenting scant clinical 
trial protocol texts with implicit biomedical concepts, based on ontological connections.  
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Consequently, discussion of an optional expansion process which injects or replaces 
concepts within the feature space follows. 
 
 
Vector Space Expansion 
 
 
 Since the process of text-mining the contents of clinical trial protocols suffer from 
various pitfalls such as short segments of text, synonyms, and company-specific compound 
identifiers, it is crucial that the ARRASTRA framework is able to accurately capture key 
concepts throughout the corpus.  As such, the graph-based framework presented previously 
allows users to programmatically search for inter-connected concepts given a set of 
annotations, and exposes functionality to incorporate “implicit” information based on these 
relationships in a seamless manner.  These concepts, based on their hierarchical 
relationships (ex. “parent-child”, “instance of”, “same as”) to explicit terms extracted from 
text can be injected directly into the feature space in various ways.  For example, the two 
concepts “galantamine” and “donepezil” are generic names for “acetylcholinesterase 
inhibitors” (AChE) prescribed to AD patients alone or in combination.  This relationship 
is not readily known if it is not explicitly stated in the text of the protocol.  Indeed, in order 
to identify latent themes in a collection of documents by clustering similar clinical trials, it 
would be appropriate if these clinical trials appeared relatively close to each other.  These 
documents currently do not share key features found in common biomedical concepts.  As 
depicted below in Figure 31, by using the transitive property of equality, if a clinical trial 
mentions the generic name “donepezil” in the protocol title, it can also be inferred that the 
title encompasses the broad drug class “acetylcholinesterase inhibitor”. 
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Figure 31.  Inferring biomedical concepts to augment text feature spaces 
 
  
Adding to the complexity and as discussed in Chapter 5, therapies being tested in 
Phase 1 clinical trials are often initially identified using company-specific compound 
identifiers prior to the assignment of a generic name.  In the example provided, Eli Lilly 
and Company’s compound “LY450139”, was used in clinical trial protocols prior to the 
assignment of the generic name “semagacestat”.  Indeed, it is crucial that this information 
be consistent between protocols as they progress throughout their clinical development 
lifecycle. 
Using the entire clinical trial protocol corpus of 1,139 documents, 22,500 
statements can be directly extracted from the information that results from the annotation 
process of the explicit text for each protocol.  After being semantically augmented, the 
statement space describing each clinical trial expands to 36,400 statements.  This number 
reflects implicit high-level parent concepts (ex: “Thing”, “Drug”, “Disease”, “Patient”, 
etc.) filtered from the results, as well as those which do not appear enough times based on 
a preset threshold, in this case three times.  This process is seamless in the ARRASTRA 
API.  Given a set of “seed” concepts from the explicit ontological annotation of each 
clinical trial protocol, users can query for all concepts which share hierarchical 
connections.  These inferred concepts are then injected into the set of statements for each 
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protocol document and subsequently become a part of the augmented vector space from 
which latent themes are extrapolated.  Current research is focused on evaluating how this 
added information performs when compared simply to the explicit annotated statements.  
A snapshot of the code which achieves this in the ARRASTRA API is provided below in 
Source Code 3.  The follow_links list specifies which ontological properties to follow 
within the Titan graph and the to_expand list captures all biomedical entities for possible 
expansion.  The titan object is a pointer to the Titan graph storage, and exposes an 
expand_by_field method, which dynamically generates a series of Gremlin queries to 
retrieve statements relating to 1-degree connections between the concepts specified in 
to_expand.  Lastly, a new set of statements, indicated by new_graph, is generated by 
merging the resulting set of expanded statement with the initial set of explicit statements 
using the ARRASTRA DataUtils module. 
 
follow_links = [URI_EDGE_LABELS['RDFS_SUBCLASS'], URI_EDGE_LABELS['RDF_TYPE'], 
URI_EDGE_LABELS['OWL_SAMEAS'], URI_EDGE_LABELS['CT_DRUG_TARGET']] 
#- Collect all biomedical concepts of the graph, query, and expand -# 
to_expand = sorted(list(set([c[2] for c in graph]))) 
expanded = titan.expand_by_field(uris=to_expand, to_follow=follow_links)['results'] 
new_graph = DataUtils.merge(x=graph, y=expanded,  
mappings=(URI_EDGE_LABELS['CT_MAIN_THERAPY'], URI_EDGE_LABELS['CT_DESCRIBES'])) 
 
 
 
 
Source Code 3.  Expanding the feature space with the ARRASTRA API 
 
 
The resulting process produces a weighted, sparse, and high-dimensional matrix 
expressed as 𝐷 =  {𝑋1, 𝑋2, 𝑋3 , … 𝑋𝑚 ∈  ℝ
𝑚×𝑛} , where m indicates the number of objects 
being analyzed (i.e. clinical trial protocol documents) and n denotes the number of unique 
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features extracted from the corpus (i.e. biomedical concepts).  The term D herein refers to 
this initial input matrix.  This data structure serves as the basis for the rest of the analysis.  
Efficiently processing and visualizing high-dimensional datasets to respectively quantify 
and qualify latent themes contained within in them is currently a very active area of 
research.  The next sections detail the routines ARRASTRA employs to obtain lower-
dimensional estimates of this complex data in order to identify underlying latent themes. 
 
 
Dimensionality Reduction 
 
 
  The quantification and qualification of complex and sparse high-dimensional 
datasets is an active area of data mining and information visualization.  Data dimensionality 
refers to the number of variables which encode aspects of its observations: numerical 
values, categorical groupings, time occurrences, etc.  The nature of how effectively 
relationships between a large set of variables is communicated is based both on the number 
of coordinates available for mapping values to, as well as other visual esthetics.  The desire 
to extract and subsequently depict high-level patterns and trends from these types of data 
ultimately leads to the interplay of two data mining approaches which address the “curse 
of dimensionality”: high-dimension information visualization and dimensionality 
reduction.  While the two approaches are certainly not mutually exclusive, the former 
approach attempts to map as much of the original data to a visualization representation as 
possible.  The latter, which is the focus of this section, aims to find meaningful and 
summative overlapping components within the feature space.  In other words, through this 
approach, the original data is reduced to a manageable set of dimensions which reflect the 
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most salient, or latent, overarching themes.  These approaches contend that while data is 
high-dimensional, the majority of their dimensions can be accurately summarized by only 
a few variables.  Perhaps the most well-known example of dimensionality reduction is that 
of Principle Component Analysis (PCA).  Using PCA, observations are factorized into 
discrete components based on the nature of their linear correlations, where each component 
attempts to account for the most possible variability while maximizing orthogonality to the 
other components.  As a result, a high-dimensional dataset can be effectively consolidated 
into a number of discrete components which, for example, could be visualized as a 3-
dimensional scatterplot.  Another popular approach is Singular Value Decomposition 
(SVD) [189].  Briefly, SVD is an eigendecomposition approach which factorizes a matrix 
through a series of three operations: an 𝑚 × 𝑚 unitary matrix, an  𝑚 × 𝑛 diagonal matrix, 
and an 𝑛 × 𝑛 unitary matrix.  These statistical approaches however are more suitable for 
linear relationships within the data.  More recently, enhanced non-linear factorization 
procedures have been devised which apply non-linear transformations to sparse high-
dimensional datasets.  One such example is that of Non-Negative Matrix Factorization 
(NMF) [190], which plays a crucial data pre-processing role within the ARRASTRA 
Toolkit. 
Non-Negative matrix factorization is a factorization approach which approximates 
a lower-dimensional matrix of rank k, where 𝑘 ≪ 𝑚𝑖𝑛(𝑚, 𝑛), by identifying the most 
salient blocks or components within the high-dimensional dataset.  NMF can be denoted 
as 𝐷 ≈ 𝑊𝐻, where the non-negative input high-dimensional matrix D is best approximated 
by the solution’s basis matrix denoted as 𝑊 = {𝑊1, 𝑊2, 𝑊3, … 𝑊𝑚 ∈  ℝ
𝑚×𝑘} and its 
mixture matrix denoted as 𝐻 = {𝐻1, 𝐻2, 𝐻3, … 𝐻𝑚 ∈  ℝ
𝑛×𝑘}.  This approximation is 
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achieved through an optimization function which minimizes the difference between D and 
WH, which can be expressed as the bound-constrained optimization problem provided in 
Equation 9.  The degree to which NMF accurately approximates the original input matrix 
can be quantified through metrics such as Euclidean distance or Kullback-Leibler (K-L) 
divergence. 
 
𝑓(𝑊, 𝐻) ≡
1
2
∑ ∑(𝐷𝑖𝑗 − (𝑊𝐻)𝑖𝑗)
2
𝑛
𝑗=1
𝑚
𝑖=1
 
 
Equation 9.  NMF general optimization function 
 
 
While NMF is a factorization solution in itself, it is extensible due to the fact that 
different objective functions can be devised and accuracy metrics implemented, which are 
tailored to different types of data.  Numerous variants of NMF exist which extend, improve 
upon, or modify the core NMF approach [191].  Specifically, ARRASTRA employs the 
bound constrained optimization NMF variant Alternating Nonnegative Least Squares 
Matrix Factorization Using Projected Gradient method for solving sub-problems 
(LSNMF) [192].  LSNMF first employs a regularization method to the data that has 
demonstrated faster convergence in estimating the lower-dimensional space compared to 
other approaches.  Additionally, LSNMF has been demonstrated to be less sensitive to 
noise and more to true signals than other NMF variants based on how it incorporates 
uncertainty estimates into the update rules of its optimization function [193].   
In general, NMF is superior to other factorization approaches in that it enforces 
non-negativity constraints on the data.  There are numerous practical pattern recognition 
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applications which require non-negativity constraints such as pixel-based sub-structures 
within digital images [194,195], microarray gene expression [196], signal processing 
[197], and word occurrences in text [198] as such is the focus of this research.  NMF differs 
from other decomposition methods such as PCA and SVD due to the fact that NMF does 
not attempt to identify components that are orthogonal or independent, but rather seeks 
parts-based representations of the underlying data.  One major advantage of NMF is that 
observations can be classified into multiple clusters if those observations exhibits 
characteristics from multiple clusters.  This is due to its additive nature in identifying key 
overlapping components in sparse high-dimensional datasets.  As will be discussed, this is 
a critical design concept, especially when attempting to construct graph-based 
representations of similar objects factorized through NMF.  Indeed, forcing objects into 
distinct and non-overlapping groupings is not intuitive to graph theory, as nodes with high 
betweenness centrality scores may be influential within a network due to the fact that they 
serve as essential linkages which connect clusters.   
In order to process the large feature space of weighted document terms while 
retaining important information contained within the data, LSNMF is employed to reduce 
the feature space into a manageable lower set of k dimensions.  The lower-dimensional 
space is then used as the basis for constructing similarities between clinical trial protocols 
based on this latent information.  The ARRASTRA Toolkit utilizes the NIMFA Python 
library for NMF functionality [199], which supports over 10 NMF variants, as well as 
different matrix initialization approaches and quality metrics.  However, while NMF and 
its LSNMF variant play a critical role in pre-processing the clinical trial protocol feature 
space in ARRASTRA Toolkit, it is actually only the first step which is followed by another 
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process called manifold learning.  The protocol corpus manifold reveals the overall 
structure of the corpus itself, as it is projected into a lower-dimensional surface.  In order 
to accomplish this, the manifold learning method t-Distributed Stochastic Neighbor 
Embedding (t-SNE) is introduced and improved upon using LSNMF as a pre-processing 
step.  Additionally, the concept of multiple manifolds is explored through multiple maps 
t-SNE (mm t-SNE), which attempts to map multi-dimensional manifolds into a series of 
2-dimensional scatterplots.  As will be discussed in the following sections, this manifold 
reveals the structure of the underlying protocol corpus which ultimately dictates the 
structure of the homogeneous clinical trial graph, the intended graph-based representation 
which then can be employed to directly compare clinical trial influence over time. 
 
 
Manifold Learning 
 
 
 As discussed, attempting to visualize high-dimensional data spaces can present 
numerous challenges due to limitations on the number of coordinates and facets that are 
available to encode information associated with relationships within the data.  
Dimensionality reduction techniques are first applied to the input data in order to 
confidently reconstruct the dataset into a more manageable lower-dimensional space.  The 
daunting challenge remains however, as to how to most effectively describe the 
relationships between the set of objects through visual means.  For linear data as an 
example, the use of PCA is straight-forward, where objects are mapped to a coordinate-
based scatterplot, dictated by their loadings along the extracted components.  However, for 
more complex and non-linear data, additional approaches are needed to map objects 
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relative to each other using an array of pair-wise distance metrics.  The general process of 
mapping a set of objects to a 2-dimensional or 3-dimensional surface is known as manifold 
learning.  While manifold learning may be considered a form of dimensionality reduction 
in itself, it encompasses a set of additional routines such as constructing surface-based 
representations of the non-linear relationships between objects in a dataset for visualization 
purposes.  Two conventional approaches of manifold learning are Multi-Dimensional 
Scaling (MDS) [200] and Isomaps [201].  Relatively newer approaches such as t-
distributed stochastic neighbor embedding (t-SNE), however, propose machine learning 
algorithms designed for non-linear dimensionality reduction.   
 t-SNE is a manifold learning method that employs pairwise similarity metrics (i.e. 
K-L divergence) converted to a joint probabilities matrix, in order to visualize high-
dimensional objects [202].  In this way, objects can be plotted as a point in a lower 
dimensional space.  t-SNE overcomes the traditional crowding problem, where points are 
plotted too closely to each other after being projected onto a lower-dimensional space, by 
opting for a heavy-tailed distribution rather than a Gaussian distribution when constructing 
the joint probability matrix.  The joint probability between objects x and y using a heavy-
tailed distribution is specified in Equation 10. 
𝑝𝑥𝑦 =
(1 + ‖𝑠𝑥 − 𝑠𝑦‖
2
)
−1
∑ ∑ (1 + ‖𝑠𝑘 − 𝑠𝑙‖2)−1𝑘≠𝑙𝑘
 
 
Equation 10.  Student-t distribution for joint probabilities between two objects 
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As a result, points which are merely slightly similar to others are plotted much 
further away, ensuring that the closest points gravitate more closely to each other.  It is 
contested that this algorithmic design decision can more clearly elucidate clear cluster 
structures within the manifold.  Recently, t-SNE has gained popularity within the machine 
learning community, specifically in bioinformatics applications, to visualize gene 
variations found within single nucleotide polymorphisms (SNPs) [203], clustering 
preclinical AD subjects based on cortical thickness of various brain regions [204], and 
identifying docking targets for protein-ligand binding [205].   
One limitation of the original t-SNE implementation is that for large datasets, 
imputing the final manifold is 𝑂(𝑁2) complex due to the fact that it imputes all pair-wise 
distances between objects.  As a solution, Barnes Hut t-SNE (BH t-SNE) was developed 
to improve processing performance time to O(𝑁 log 𝑁) [206].  BH t-SNE introduces two 
improvements to accomplish this.  First, it employs PCA as a pre-processing step to reduce 
the number of dimensions of the original data to a more manageable set of features (authors 
use 50 components).  Second, it employs vantage point trees [207] to efficiently search 
for nearest neighbors, rather than performing pair-wise comparisons to all points.  Vantage 
point trees (vp-trees) partition similarity matrices by constructing a hierarchical tree-based 
structure that reduces the computational cost of nearest neighbor searches over large 
datasets.  However, recent research suggests that the use of PCA as a pre-processing step 
potentially removes vital information from the input high-dimensional space.  As such, 
Augmented Barnes Hut t-SNE (aBH t-SNE) was developed as a collaboration between 
Drexel College of Computing and Informatics (CCI) and Wuhan University [208].  Most 
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notably, aBH t-SNE replaces the PCA pre-processing step, with NMF to more accurately 
reconstruct the high-dimensional input dataset. 
The superiority of aBH t-SNE compared to MDS and Isomap has been established 
through this collaborative research effort.  The nature of this research was to understand 
which manifold learning approaches could most efficiently construct accurate 
representations of microbial phylogenetic and taxonomic data extracted from 5 anatomical 
regions and 18 sub-structures from over 4,700 people.  Microbiome research is a new and 
extremely active area of bioinformatics research aimed at understanding how microbial 
colonies, identified by their DNA sequences, can influence human health.  One of the most 
interesting learnings from this research was that aBH t-SNE is able to not only accurately 
cluster microbes of similar body sites, but was, from a qualitative standpoint, more 
sensitive to subtleties in underlying body site sub-structures.  As such, it was concluded 
that aBH t-SNE could elucidate subtle, albeit meaningful variations within sparse data at a 
finer degree of resolution.  For example, one source of extracted microbes was those that 
colonize the oral cavity.  However, the anatomical location of the microbes extracted could 
be further segmented into seven additional sources, including saliva, tongue, and hard 
palate.  Not only did the aBH t-SNE manifold reveal one super-structure relating to oral 
microbes, but could also discriminate the cluster into finer groupings based on the specific 
site of the oral cavity.  Although perhaps not intuitively obvious, this research establishes 
an important consideration when attempting to model multi-faceted information contained 
within clinical trial protocols. 
Another complication with manifold learning, explicitly noted by the initial authors 
of t-SNE, is that 2-dimensional projections may suffer from the fact that pair-wise point 
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distances do not always space dissimilar objects from one another, especially when objects 
relate to other objects in different contexts.  Known as the triangle inequality, Van Der 
Maaten provides the following example to depict this issue.  Consider a word co-
occurrence matrix being projected onto a 2-dimensional manifold using t-SNE.  The word 
“tie” can be used in a variety of contexts and is dictated by the words it co-occurs with.  It 
may be highly similar to words such as “suit” or “tuxedo”, but also “rope”, “shoelaces”, or 
even “sports”.  In a neighbor embedding exercise, it would not be appropriate to place 
“rope” near “suit” for the sake of both being similar to different contexts of “tie”.  Instead, 
a series of maps in which these distinct embeddings are rectified is a more appropriate 
approach.  In order to accomplish this, a multiple maps t-SNE (mm t-SNE) 
implementation strategy was also explored [209].  Simply stated, the mm t-SNE approach 
projects the neighborhood embedding across multiple maps.  Referring back to the word 
co-occurrence example, one embedding may map “tie” closer to “suit” and “tuxedo”, while 
another may map it closer to “rope” but never both.  In this way, “suit” and “tuxedo” will 
not appear anywhere near the point representing “rope”.  mm t-SNE is similar to the 
original t-SNE implementation, except for two key differences stemming from the fact that 
point spacing must be distributed across multiple maps. 
Firstly, embedded points within each manifold are weighted by importance such 
that the sum of their weights across all maps is equaled to 1. This then redefines the joint 
probability of two points as the weighted sum of their pairwise similarities across all maps.  
Referring back to the previous equation. the student-t distribution function can be updated 
to account for point weights across multiple maps, as established in Equation 11.  The 
weight of point x for map m is also defined below as 𝑤𝑥
𝑚, which is akin to the normalized 
183 
 
exponential softmax function, as a means of distorting a distribution of values such that 
higher values are weighted significantly more than smaller values. 
 
𝑤𝑥
𝑚 =
𝑒−𝑢𝑖
𝑚
∑ 𝑒−𝑢𝑖
𝑚′
𝑚′
  𝑝𝑥𝑦 =
∑ 𝑤𝑥
𝑚 𝑤𝑦
𝑚
𝑚 (1 + ‖𝑠𝑥
𝑚 − 𝑠𝑦
𝑚‖
2
)
−1
∑ ∑ ∑ 𝑤𝑘
𝑚′𝑤𝑙
𝑚′ (1 + ‖𝑠𝑥
𝑚 − 𝑠𝑦
𝑚‖
2
)
−1
𝑚′𝑘≠𝑙𝑘
 
 
Equation 11.  A multiple maps implementation of the student-t distribution 
 
 
Secondly, the number of appropriate maps to generate which best captures the 
relationships within the manifold is required.  Although this process is computationally 
intensive, total map numbers can be tested individually in order to determine the optimal 
number.  The optimal number of maps is determined by maximizing the neighborhood 
preservation ratio (NPR).  NPR is a measurement of how faithfully the lower-dimensional 
manifold reconstructs the high-dimensional data, which is the percentage of nearest 
neighbors which agree with those from the original dataset [210]. 
 The ARRASTRA Toolkit in its current state supports aBH t-SNE natively.  The 
following code provided in Source Code 4 outlines the approach of computing the 2-
dimensional manifold of the clinical trial corpus.  Processing the initial high-dimensional 
clinical trial protocol dataset is controlled through an instance of the AsymSpace2 object.  
The input variables new_graph and ct_metadata have been established previously in this 
chapter and serve as the graph statement and entity metadata dictionary, respectively.  The 
ARRASTRA configuration object contains user-specified settings which tune data mining 
parameters.  Options can also be modified programmatically by accessing them through 
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the AsymSpace2 instance.  In the example below, note that the node-weighting method has 
been specified as aTF-IDF.  This method was introduced in the previous chapter.  The 
method init initializes an empty matrix D of m protocol documents and n unique features 
based on the input statement graph, and generate_vector_space populates the matrix with 
weighted values based on the settings supplied in the configuration.  The factorize_bhtsne 
method first factorizes the input matrix using LSNMF and then constructs the lower-
dimension manifold using BH-tSNE. 
 
from arrastra.config import ArrastraConfig as cfg  
from arrastra.data import asymspace2c as ar 
 
#- Load client-side configuration file 
config = cfg.ArrastraConfig().get_configuration("./config/ct31_v1.json") 
 
#- Generate feature space and impute document term weights 
aspace = ar.AsymSpace2(statements=new_graph, metadata=ct_metadata, config=config) 
aspace._node_method = NODE_WEIGHT.ATF_IDF 
aspace.init() 
aspace.generate_vector_space() 
 
#- Generate feature space and impute document term weights 
aspace.factorize_bhtsne() 
 
 
 
Source Code 4.  Instantiating new weighted feature space and generating its 2D manifold 
 
This process results in a 2-dimensional manifold, which can be accessed through 
the AsymSpace2 instance and visualized as a scatterplot.  This basic visualization paradigm 
is a straight-forward approach to exploring the structure of the corpus manifold, where each 
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point in the scatterplot represents a clinical trial protocol.  The position of a point within 
the manifold relative to others, as well as point sub-structures which form coherent clusters.  
Both communicate vital types of information, which will be discussed in the next section 
when converting the manifold to directed graphs.  The ARRASTRA Toolkit provides both 
native Python visualization capabilities using Matplotlib22 and scikit-learn23 libraries.  
Additionally, the ARRASTRA Toolkit API enables the ability to export data to web-based 
visualization tools such as Plotly24, which subsequently allows for dynamic exploration of 
the manifold.  Source Code 5 demonstrates the two scatterplot solutions in the 
ARRASTRA Toolkit – the first generating a native Python visualization, and the second a 
web-based Plotly scatterplot.  These visualizations are depicted in Figure 32 and Figure 
33 33, respectively.  Note the structure of the 2-dimensional manifold, and how points 
representing distinct clinical trials forms visible clusters within the scatterplot.  The output 
of the manifold learning process is an excellent approach for providing basic visualizations 
for exploring large collections of high-dimensional objects. 
 
 
 
 
 
                                                 
 
22 http://matplotlib.org/ 
23 http://scikit-learn.org/stable/ 
24 https://plot.ly/ 
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#- Native scatterplot 
aspace.scatter_plot(aspace._ldata, labels=aspace.get_labels(), 
category_labels=None, color_map="Paired", level=1, label_categories=False, 
highlight=None, highlight_only=False, lbl_combine=False) 
 
#- Upload interactive scatterplot to Plotly 
aspace.plotly_scatter_plot(aspace._ldata, aspace.get_labels(), 
scatter_categories, level=1, color_map="Spectral", alpha=0.5, export_name='ct-
plot') 
 
 
 
 
Source Code 5.  Constructing two scatterplot visualizations of the protocol manifold 
 
 
 
 
Figure 32.  Visualizing the aBH t-SNE manifold in native Python with Matplotlib 
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Figure 33.  Visualizing the aBH t-SNE manifold in Plotly for interactive visualizations 
 
 
 While scatterplots represent one basic approach to visualize the structure of a 
manifold as well as the relationships between distinct clusters and the points which 
comprise them, the goal of this research is to express this structure in terms of information 
diffusion.  A scatterplot, or a series of scatterplots, do not particularly afford this type of 
information.  It should be reiterated that the goal of translating these insights within the 
context of information diffusion requires that manifolds be converted to graphs.  Indeed, 
the manifold itself reveals the structure of the corpus, or rather how protocols relate to each 
other based on their multi-faceted content, but not the temporal dynamics between the 
objects.  As such, the following section specifically focuses on how the corpus manifold is 
used to construct a temporally-directed graph of clinical trials.  Consequently, a novel 
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visualization will be devised which summaries the dynamics of these graph clusters 
(research fronts) over time. 
Temporal Graphs 
 
 
Rationale 
 
 
Currently, the majority of the work conducted thus far in this chapter has focused 
on imputing proper low-dimensional representations of the high-dimensional dataset 
consisting of expanded biomedical concepts for the clinical trial protocol corpus.  The 
manifold space, imputed by various flavors of t-SNE, projects this information onto a 2-
dimensional plane by mapping protocols as points of a scatterplot.  The manifold visualizes 
the shape and structure of the corpus, where individual points can be investigated, as well 
as larger sub-structures which reveal community structures.  As noted previously, the 
concept of communities is a key conceptualization required to understand the existence of 
research fronts within a domain.  In the case of manifolds, closely grouped objects 
projected onto a lower-dimensional surface can represent these distinct sub-domains.  For 
instance, ARRASTRA Toolkit allows users to cluster the aBH t-SNE manifold into 
embedded hierarchical groupings with routines such as hclust [211].  Source Code 6 
outlines the ARRASTRA Toolkit API calls which visualize the lower-dimensional space 
as an embedded set of clusters, with each successive level representing more general 
groups of objects.  The API function renders a dendrogram highlighting 10 clusters, 
depicting an adjacency matrix linked by similarity groupings based on Euclidean distance, 
provided below in Figure 34. 
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#- Native dendrogram with cluster information 
clusts = aspace.dendrogram(aspace._ldata, 
labels=aspace.get_labels(lbl_field='nctid'), csize=10, method='complete', 
metric='euclidean') 
 
 
Source Code 6.  Using the ARRASTRA Toolkit to generate static protocol clusters 
 
 
 
 
Figure 34.  The dendrogram depicting hierarchically-clustered clinical trial protocols 
 
 
There is, however, one crucial shortcoming of the manifold visualization.  In order 
to understand how research fronts evolve over time, information must also encode changes 
over time.  Indeed, the points within the manifold occur at different time points – clinical 
trials are filed, completed, or terminated over the course of nearly two decades.  The 
manifold communicates the current state of the protocol corpus in its entirety, where every 
clinical trial protocol is represented regardless of its status at some given point in time.  As 
190 
 
such, other visualization approaches must be explored which faithfully captures the 
information of the manifold, but can also accommodate additional data dimensions which 
account for time.  
High-dimensional visualizations were mentioned as a complementary approach to 
dimensionality reduction techniques in the previous section.  With this approach, multiple 
dimensions of a data set are mapped to meaningful visualization heuristics such as object 
position, size, color, shape, and grouping [212].  Additionally, functions such as filtering, 
jittering, grouping, etc. can be applied to a visualization in order to reduce clutter among 
plotted objects [213].  An adequate visualization will utilize the heuristics previously 
mentioned to clearly depict patterns that exist between the multiple facts of a dataset.  One 
well-known example of this type of visualization is a parallel plot [214,215].  Parallel 
plots are a type of visualization which weaves together a series of coordinate plots of 
continuous variables, with multiple colored lines representing a categorical facet.  Another 
example is a Circos plot, which captures connectivity-based information of multi-faceted 
components, specifically geared for comparative genetic analyses [216].  Yet another 
example is that of VlaaiVis, which is popular for visualizing multi-faceted pie charts, 
particularly for comparing multiple drug compounds and their affinities for binding with a 
drug target [217].  While these visualization approaches are useful due to the fact that they 
capture as much of the original data as possible, they are designed more towards specific 
research applications. Additionally, they do not employ visualization paradigms which 
accommodate changes in time.  As a result, additional visualization options must be 
explored, which has led to the implementation of graph-based data representations in 
ARRASTRA. 
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The conceptual basis for using graphs as a data structure representing a protocol 
corpus is that graphs can naturally map a great deal of information to its nodes and edges.  
This allows for expressive representations for both temporal and multi-faceted data: 
1. Graph edge directionality can be purposed to encode temporal information, such 
that the source node predates the target node; for this context, a directed edge 
conceptualizes the probability that the source node has “influenced” the creation of 
the target node. 
2. Numerical and categorical values can be bound to both nodes and edges.  
3. Node importance can be easily operationalized based on various graph metrics such 
as betweenness centrality. 
4. Nodes can be clustered into groups to summarize higher-level themes and 
relationships within the data. 
These qualities of graph-based data models justify their use when conceptualizing 
information diffusion.  Due to these considerations, and aligned with the concept of 
evolving research fronts through information diffusion, focus is now given to converting 
the protocol manifold to a directed network graph.  This graph serves as the basis for which 
changes in research fronts are quantified and qualified once it is subset by time. 
 
 
Graph and Graph Series Construction 
 
 
In order to construct a directed graph from the protocol manifold that was generated 
through steps discussed in the previous section, two concepts must be considered: the 
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nearest neighbors of each point within the manifold, and time directionality.  Firstly, the 
nearest neighbors of a point within the manifold are those which lie the closest to that 
given point based on some distance metric.  Points which are very close to each other in 
the manifold are very similar to each other content-wise.  Recall in the previous section 
that t-SNE and its variants utilize a student-t distribution to construct the joint-probability 
matrix.  This overcomes the overcrowding problem by forcing points which are only 
slightly similar to be plotted further away from each other.  As such, the first step of 
constructing a graph of clinical trials is establishing each point as its own vertex and then 
converting the nearest neighbor information of the manifold into an edge-list.  This is 
achieved by selecting n-nearest neighbors of each point within the manifold and 
establishing an edge between them.  There are three ways of constraining the nearest-
neighbor search process.  The first approach is to set a limit to the number of n edges that 
can be formed between each point.  Another approach is to set a normalized distance limit 
d where 𝑑 ∈ [0,1], such that regardless of how many neighbors a point may have, the 
distance of any of its neighbors will not exceed some threshold.  This ensures that neighbors 
are not being assigned to edges simply due to the fact that a static parameter is being 
enforced.   
The multiple maps t-SNE manifold version of this process is similar.  The major 
difference is that the nearest neighbors are selected across multiple manifolds.  Suppose 
the n-nearest neighbor value is set at 15, for a set of manifolds containing 3 maps.  
Naturally, 5 nearest neighbors would be selected for each point across all maps.  This can 
be illustrated in the following way as depicted in Figure 35 and Figure 36.  Recall the 
word co-occurrence multiple maps example discussed in the previous section to highlight 
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issues constructing a single manifold when points appear in different contexts.  The need 
for multiple maps is that a single 2-dimensional map may force similar points close to each 
other which violate the triangle equality.  Node colors reference specific word co-
occurrence clusters discussed previously (ex. words relating to “suit”, “games”, “rope”, 
respectively).  The red node refers to the word “tie”, which has three different contexts.  
Figure 35 depicts the n-nearest neighbor search of a single manifold.  Note that some blue 
nodes are linked to nodes belonging to other clusters as a result of this nearest neighbor 
search.  Indeed, connecting a blue node to a yellow node, simply for the sake that they both 
share a mutual nearest neighbor does not intuitively make sense.  Instead, a multiple maps 
approach searches for neighbors within individual maps, and as such, spurious edges 
realized in the single maps example (indicated as dotted red lines) do not occur in the 
multiple maps example, since these nodes appear in vastly different contexts (Figure 36).  
Also note that the overall importance of the word “tie” becomes more clear through the 
multiple maps process, as the node representing “tie” is more “between” each of the 
clusters.   
 
 
Figure 35.  Graph construction using n-nearest neighbors from a single map 
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Figure 36.  Graph construction using n-nearest neighbors from multiple maps 
 
 
The second consideration when establishing edges within an edge-list, is that the 
edge-list must be sorted temporally.  As mentioned previously, the directionality of an edge 
is conceptualized as the source node “influences” the creation of the target node.  As such, 
the source node pre-dates the target node.  It should be noted that while the unit of temporal 
resolution for this research is currently set to yearly time slices, this sorting process uses 
the full timestamp to ensure protocols are appropriately sorted within time slices.  There 
are numerous date fields from which this information could be derived within clinical trial 
protocols.  For this example, the “first received date” field, or the date when the clinical 
trial was first filed with the FDA, is selected.  While other options such as the date when 
the clinical trial first started may also be appropriate, the current scope of this research is 
aimed at understand the genesis of the idea, and not necessarily the execution of the idea.  
This value is referred to as time-of-origin.  However, the ARRASTRA framework allows 
users to specify any date field which has been bounded to the current graph network, 
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provided that the field is a discrete integer.  Based on the information contained within the 
time specified field, the entries of the edge-list are sorted accordingly.  ARRASTRA 
utilizes the Python wrapper of the igraph25 C library for all client-side graph processing.  
The sorted edge-list is used to construct an initial graph of all available clinical trials and 
their connections, referred to as the source graph.  In other words, the source graph contains 
all of the available information up to the most recent time contained within the specified 
date field and represents the most recent state of the research domain.   
As mentioned previously, a graph pruning process can also be applied to the source 
graph in order to remove unimportant or redundant edges.  Numerous graph pruning 
techniques have been developed in the past.  Minimum spanning tree (MST) for example 
finds the smallest possible set of weighted undirected edges which connect all nodes, while 
minimizing the total weight of those edges [218].  Pathfinder is another which removes 
those edges that violate triangle inequality, which states that a direct path between two 
given nodes must be less than or equal to any paths which connect them through a set of 
intermediary nodes [219].  These routines were briefly introduced previously in Chapter 3 
as two pruning approaches supported by CiteSpace.  Recall that approaches such as MST 
tend to be too liberal in the removal of edges.  In fact, MST ultimately reduces the graph 
to a unitary hierarchical tree structure which effectively disconnects meaningful clusters.  
While MST is appropriate for some applications, the concept of information diffusion 
through evolving research fronts requires that salient graph clusters be detected and tracked 
over time.  Due to these considerations, a global null model (GLoSS) pruning method for 
                                                 
 
25 http://igraph.org/ 
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both directed and undirected weighted graphs was implemented in ARRASTRA [220].  
Briefly, GLoSS is a graph pruning algorithm that removes redundant and/or spurious edges 
while ensuring consistent topological structures and distributions of edge weights.  It 
accomplishes this by comparing the graph to a null graph model.  This is established by 
the null hypothesis that states a node of degree k with a weight x corresponds to a 
probability distribution of normalized edge weights, defined by Equation 12. 
 
𝑝(𝑥)𝑑𝑥 = (𝑘 − 1)(1 − 𝑥)𝑘−2𝑑𝑥 
Equation 12.  GLoSS probability density function for a node of degree k 
 
 
Edges are filtered according to this density function based on a disparity filter, 
specified by a significance threshold 𝛼.  Edges are removed from the original graph which 
do not reject the null hypothesis at the specified significance level, and can be expressed 
as the relation in Equation 13.  Simply stated, the GLoSS approach is more accurate in 
filtering “noisy” edges due to the fact that it considers both the node’s degree and the 
incidental edges weights, and uses this information to determine whether or not the edge 
should appear by random chance. 
 
𝛼𝑖𝑗 = 1 − (𝑘 − 1) ∫ (1 − 𝑥)
𝑘−2𝑑𝑥 < 𝛼
𝑃𝑖𝑗
0
 
Equation 13.  GLoSS disparity filter for significance level 𝜶 
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The full graph construction process is provided below in Source Code 7, where 
aspace._lspace references the low-dimensional manifold imputed previously.  In this 
example, the 10 nearest neighbors are selected for each node, edge distance threshold is set 
to 0.55, and the edge significance level for the GLoSS filtering significance level 𝛼 is set 
to 0.05.  The graph node time-of-origin values are specified by the year input field, in this 
case, the date the trial was first filed.  The source graph, in its entirety, can be accessed by 
specifying the maximum time-of-origin value from the resulting array of graphs, and is 
depicted in Figure 37.  While ARRASTRA supports native igraph visualizations, it also 
provides graph export features to applications like Gephi26 for interactive exploration.  
Additionally, note that the last two lines of code identify clinical trials which have become 
disconnected from the source graph after the pruning process.  These clinical trials may 
represent those which have, even after the query expansion process, not enough descriptive 
information about them or are “one-off” clinical trials which currently cannot be placed 
near other trials in the manifold. 
 
 
 
 
 
                                                 
 
26 https://gephi.org/ 
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#- Generate a graph of trials, filter graph based on GLoSS 
aspace._efilter, aspace._nneighbors, aspace._sig_level = 0.55, 10, 0.05 
graphs = aspace.to_directed_graphseries(labels=aspace.get_labels(lbl_field='uri'), 
groups=None, years=[d['firstreceived_date'] for d in ct_metadata], prune=True) 
 
#- Bind metadata to network nodes 
graphs[2015].bind_data_dict(dict=ct_metadata, dict_idx_name='uri', 
idx_name='label', pidx_names=['glabel','overall_status']) 
 
#- Remove detached nodes 
disconnected_idx = graphs[2015].remove_disconnected_nodes() 
 
#- Refresh graph after removing detached nodes 
aspace.update_labels_and_categories(disconnected_idx) 
 
 
Source Code 7.  Generating the source graph and graph series in ARRASTRA from the 
manifold 
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Figure 37.  The clinical trial source graph, containing all clinical trials from 2000 - 
2015 
 
 
It is crucial to note that by calling to_directed_graphseries, the ARRASTRA 
Toolkit returns an array of graphs.  Recall, that the goal of this research is to construct not 
a simple static graph of clinical trial protocols, but a series of graphs which have been 
segmented by its time-of-origin.  As the method name would suggest, the concept of a 
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graph series is one which represents a set of successively increasing graphs as the time 
span between current time window and time-of-origin span of time is increases.  The 
construction of a graph series from the source graph serves as the basis for quantifying and 
qualifying cluster dynamics across the time series.   
 A graph series is established by incrementally increasing the time-of-origin window 
for each sub-graph, based on the original source graph.  A graph series GT is conceptualized 
as a set of graphs, where T is a strictly increasing set of time values, such that 𝐺𝑇 =
[∑ 𝐺𝑇+𝑇′𝑇′=0 ].  The dataset captures clinical trials from the years 2000 to 2015.  A graph 
series covering years 2000 to 2015 contain 16 graphs: G2000, G2000-2001, G2000-2002, …, G2000-
2015.  In ARRASTRA, each sub-graph can be accessed from the graphs array by specifying 
the upper limit of the desired year.  In this case, the source graph can be accessed as 
graphs[2015].  One major design decision that was considered when constructing 
ARRASTRA framework was whether to remove or deprecate clinical trial nodes which 
occurred within a period of elapsed time.  Indeed, like co-citation networks, it would not 
make intuitive sense to remove nodes from a graph based on the fact that science is 
inherently iterative, with each study possibly giving life to new ideas, regardless of whether 
it succeeded or not.  The beauty of science itself is that seemingly old or outdated ideas can 
spawn new ideas in light of new knowledge. 
 While a set of incremental sub-graphs may be useful in that they can be individually 
interrogated by a user, the approach does not address the issue of focus-versus-context.  As 
the term suggests, an appropriate visualization will allow users to focus on a specific part 
of the visualization while still being able to understand how that part relates to the overall 
context of the visualization itself.  Users lose this ability when having to continuously 
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switch between a series of disconnected images.  Figure 38 depicts a sample of the graph 
series sub-space from 2000 – 2015.  Note that while it can be easily demonstrated that the 
graph is increasing in size, it is difficult to understand how clusters form and change over 
time.  Shortly, previous approaches which have been developed to address the issue of 
focus-versus-context in regards to dynamic temporal graph changes will be discussed, 
culminating to the creation of a novel graph-summarization visualization.  This 
summarization communicates graph changes at the cluster level.  Indeed, since the concept 
of research fronts has been operationalized previously as clusters of closely-related ideas, 
this visualization ultimately depicts how streams of ideas evolve over time.  However, it is 
appropriate to first understand the processes used to identify these community structures, 
as ARRASTRA supports two different clustering methods. 
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Figure 38.  The AD clinical trial graph series from 2005 – 2015  
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Graph Clustering 
 
 
A directed graph containing all clinical trial protocols across all years has been 
constructed as described in the preceding section.  The directed graph in its entirety can be 
analyzed to identify the most salient themes throughout time via clustering routines.  These 
groups of tightly-connected protocols, when identified, represent larger bodies of research 
that are founded on common knowledge.  Previously, this has been translated within the 
context of information diffusion, where graph clusters represent research fronts.  As such, 
it is vital that these communities be accurately identified.  Since numerous methods exist 
to detect communities within graphs, numerous graph clustering routines were assessed.  
These include both Walktrap [221] and Infomap [222] clustering algorithms.  Since 
minimal priori information about the clinical trial space is assumed, clustering routines 
such as ones which specify the number of clusters do not serve as ideal candidates for 
community detection.  Additionally, random walk paradigms serve as an accurate paralog 
for networks such as co-citation networks, as it mimics the real-world process which a 
researcher may take in attempting to identify a paper of interest, given a starting point. 
 Both Walktrap and Infomap are clustering solutions which use random walks 
across graph nodes to assess the frequency in which the walk stays within densely 
connected communities of nodes, as opposed to those outside other clusters.  The rationale 
is that a random “walker” tends to traverse edges within a community than those which 
span across different communities.  Here, a “walk” refers to the iterative process in which 
a random start node is selected, and the process moves to an adjacent neighbor based on 
that node’s incidental edges (either undirected or directed).  Walktrap represents the 
simplest approach in that it only requires a random walk duration be specified before the 
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traversal completes.  Infomap on the other hand extends the concept of random walks by 
augmenting the process with information theory.  Infomap enforces an information cost on 
the random walker as it traverses edges, and attempts to minimize the description length of 
the graph traversal process.  It states that the edge-based partitions of the graph which 
minimize this information cost best describe the community structures within the graph.  
The degree to which these clustering methods both agree with each other varies.  Based on 
the clinical trial source graph, both clustering routines are compared.  In general, Walktrap 
consistently detects a larger set of communities than Infomap.  At the node-level Walktrap 
and Infomap tend to identify similar community structures by assessing cluster 
membership correlation (r = 0.41, p < 0.01), and similarly confirming with a comparative 
graph assortativity of 0.34.  While users can specify which clustering method to use in the 
ARRASTRA configuration settings, the following examples use Infomap as its the 
community detection routine, since this is the same clustering method employed by 
Alluvial Flow diagrams. 
 After identifying all communities within the source graph, two open issues still 
remain: firstly, understanding the contextual nature of the community itself, and more 
importantly, how those clusters have evolved to the current point within the source graph.  
Firstly, in ARRASTRA clinical trial clusters can be further analyzed by extracting major 
therapeutic themes that are most representative of each cluster.  Users can select n most 
representative concepts from the original vector space which are, on average, weighted the 
highest for all nodes within the specified community.  As a result, the concept of a cluster-
summary graph is introduced.  Simply stated, a cluster-summary graph is constructed by 
connecting those terms which co-occur within each cluster.  Not only does this describe 
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the contextual nature of each cluster, but also how clusters share similar concepts within 
these different contexts.  An example cluster-summary graph is provided below in Figure 
39.  Note that key concepts can be identified in this graph, such as MRI Imaging, 
Monoclonal Antibody, and Sleep Disturbances – all of which describe key aspects of 
current AD research.  Additionally, the cluster-summary graph can be automatically 
generated in ARRASTRA using the API call provided in Source Code 8. 
 
 
 
Figure 39.  The cluster-summary graph reveals context of clusters from source graph 
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#- Extract cluster information from all cluster and generate MetroMap 
cluster_details = aspace.graph_summary(ntop=3, membership=G_CLUSTERS.INFOMAP) 
 
 
 
Source Code 8.  Generating the cluster-summary graph in ARRASTRA 
 
 
While clustering of the source graph and subsequent cluster-summary graphs reveal 
interesting information about the current state of the research domain by providing context 
about each research front, this still does not allude to how these fronts have evolved over 
time.  In other words, this does not necessarily quantify the actually diffusion of 
information between research front over time.  Recall, that from the source graph, a set of 
n-year sub-graphs form a graph series.  For each sub-graph, the clustering process is 
executed and cluster membership for each node is tracked over time.  As a result, a 
collection of directed sub-graphs with cluster information is constructed.  The overall goal 
of this research is to understand how those clusters change over time.  Quantifying and 
qualifying these changes finally and fully links the notion of information diffusion across 
research fronts through a concrete graph framework.  Understanding the visual aspects of 
dynamic graphs is an active area of information visualization with far-reaching applications 
such as social media [223–225] and transportation [226] networks.  Consequently, it is 
beneficial to considers selected historical approaches employed to capture time-based 
graph dynamics through visual means. 
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Approaches to Dynamic Temporal Graphs 
 
 
 The ability to map the evolution of the clinical trial space within a particular 
therapeutic area dictates the need to quantify and qualify changes in time-based sub-graphs.  
Recall that ARRASTRA begins with a source graph, or a complete graph of all objects 
spanning the entire duration of time, and incrementally sub-sets the graph to form a graph 
series.  Indeed, while the overwhelming majority of graph-based research has focused on 
analyzing static snapshots of graphs, such as a social network at a single time point, there 
is a growing body of research dedicated to developing approaches to visualize graph 
changes over time.  These approaches can be categorized into three high-level categories: 
animation-based approaches, large-scale merged networks, and high-level summary 
visualizations. 
Previously, the clinical trial graph series was expressed as a set of static images, 
each representing a graph sub-set by an increasingly expanding time window.  The goal of 
extending this set of static images is to satisfy the trade-off of focus-versus-context.  
Naturally, animating these static images by “stitching” them together as a single animated 
image or video for the purpose of visually highlighting changes is a logical first-step to 
address this need.  Farrugia and Quigley empirically test graph layouts that best arrange 
nodes in ways that these changes can be easily detected by users [227].  Overall, they 
demonstrated that users were able to answer questions about specific graph changes more 
accurately when they occurred in a video compared to those changes that occurred across 
a static set of images Additionally, properties such as total nodes and edge density were 
determined to influence the ability of the user to accurately determine changes associated 
with a graph.  In this study, the sample graphs in question were considerably small – 
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approximately 32 total nodes.  The associated accuracy will obviously degrade as a graph 
grows exponentially.  Consequently, an approach is not appropriate for large graphs such 
as the one being used in this research. 
Another strategy for capturing the dynamic nature of a time-based graph is the 
large-scale graph approach.  This method typically focuses on devising novel layout and 
visual graph properties such as node and edge size and color to elucidate key changes.  This 
is generally accomplished by merging graph information from across the graph as it exists 
at different time points.  For example, a Massive Sequence View (MSV) is a temporal 
layout method, originally proposed by van den Elzen et al., which initially arranges nodes 
vertically along the y-axis and time segments along the x-axis.  This layout is also referred 
to as the lexicographic order of a time-based graph [228].  When two nodes are connected 
to each other within a given time period, an edge is drawn between them at that specific 
point on the x-axis.  Naturally, this layout style requires that edge density be addressed, 
especially for larger networks, since both nodes and edges are being replicated multiple 
times based on their occurrence within time periods along the x-axis.  To address this, van 
den Elzen et al. proposed two visual heuristics which address this issue: an edge-coloring 
routine, and a node resorting process.  MSV was tested with edges of continuous color 
gradients, representing edge length and weight.  Aside from lexicographic order, MSV also 
reorders nodes along the y-axis based on degree, in-degree, and out-degree in order to 
create areas of high activity for a given point in time.  Another example is 
TimeSpiderTrees (TST), proposed by Burch et al., which similarly arranges a series of 
temporally-merged networks [229].  However, TST layouts differ from MSV layouts 
primarily in two key ways: firstly, the they do not fully render edges, and secondly they 
209 
 
arrange nodes in a circular and hierarchical layout.  TST layouts employ, what the authors 
refer to as half-links. Half-links represent edges which do not completely connect nodes 
but rather provide general size and trajectory.  The concept of half-links is based on the 
premise that users can visually approximate the location at which nodes and edges join 
based on only this minimal amount of information.  This ultimately reduces visual clutter 
caused by dense areas of edge overlaps.  The other interesting aspect of a TST layout is the 
manner in which nodes are arranged in a hierarchical circular format.  This layout generates 
a series of increasingly outward-growing rings, represented by a specific time period – the 
larger outside rings representing more recent time periods.  Time-based nodes are stacked 
along their own axis, similar to those of a radial plot.  In some respects, a TST layout can 
be envisioned as a “warped” MSV layout that has bent inward on itself.  However, 
examples such as TST and MSV attempt to capture graph changes at the individual 
component level.  The last type of dynamic graph visualization category supposes that 
communicating these individual changes are not always necessary.  Instead, the next 
approach aims to summarize the evolution of high-level themes (i.e. graph structures such 
as clusters), rather than individual granular components of the graph. 
Rather than overload the user with multiple copies of individual nodes and edges 
as a result of merging graph information across different time points, another dynamic 
graph visualization strategy depicts only the high-level thematic changes which occur.  The 
term “high-level” is used here to describe summarized aspects of a graph, particularly 
graph communities.  Graph clustering algorithms were presented in the previous section, 
and it is these clusters of tightly-connected nodes which represent the aforementioned 
“high-level” themes.  Therefore, these strategies focus on changes in graph 
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macrostructures.  Perhaps one of the most well-known examples which embodies this style 
of approach is that of the Sankey diagram.  Introduced first by Captain Matthew Henry 
Phineas Riall Sankey to visualize the energy output of a steam engine, and the inspiration 
behind Edward Tufte’s classic “Napoleon’s March” visualization, Sankey diagrams are 
used to visualize the quantity of flow between various entities, such as the flow of natural 
resources through various types of energy transfer systems [230,231].  Sankey diagrams 
indicate flow quantity and directionality using edges of proportional thickness between 
these interacting entities.  In Figure 40, a simple example of a Sankey diagram is generated 
with a web-based tool (http://sankey.csaladen.es/), depicting the flow of natural resources 
to various outputs.  Coal, natural gas, and oil are three initial nodes given a combined 
weight of 85 (relative units).  Their flow is distributed across two nodes, fossil fuels and 
electricity.  It is clear that based on this graph, 30 (units) of coal comprises the total weight 
of fossil fuels, while 20 (units) to electricity.  While this may not appear like a conventional 
network such as the ones discussed throughout this research, a Sankey diagram is in fact a 
network in the most basic sense.  This is due to the fact that Sankey entities can be 
conceptualized as nodes, and their respective flows as weighted edges. 
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Figure 40.  An example Sankey diagram visualizing flow of energy resource outputs 
 
 
 The notion that Sankey diagrams, at their core, express underlying data as directed 
and weighted network is an important concept.  These types of visualizations were the 
inspiration behind Alluvial Flow diagrams, which fully extend Sankey diagrams into the 
realm of network visualizations [232].  Devised by Rosvall, the researcher who also 
developed Infomap, Alluvial Flow diagrams employ Sankey diagram esthetics to 
communicate change within graph structures at the macroscopic level.  In order to 
accomplish this, an Alluvial Flow diagram first summarizes the structure of a large network 
using a random graph traversal process, similar to the Infomap algorithm discussed 
previously.  Recall that this random walk process uses information theory to minimize the 
total traversal “cost” within a random walk process in order to identify cohesive structures 
within a graph.  An Alluvial Flow diagram first identifies these high-level structures, 
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referred to by the creators as modules, which encapsulates all the nodes which belong to it.  
This process is repeated against a series of bootstrapped graphs based on the original data, 
where edge weights are resampled from a Poisson distribution.  This bootstrapping process 
tests for statistically significant clusters, by assessing the degree to which multiple 
bootstrapped graph samples agree on cluster membership.  Again, these statistically-
significant modules are said to contain sets of closely-connected nodes due to the fact that 
they share key similarities.  To translate, Alluvial Flow modules represent the research 
fronts which share some over-arching research theme, similar to the cluster-summary graph 
presented in the previous section. 
Similar to a Sankey diagram, the nodes of an Alluvial Flow diagram represent the 
extrapolated graph modules from the random walk process.  A module is labeled after the 
node which has accepted the highest amount of flow through it during the random walk 
process.  Also like a Sankey diagram, the thickness (weight) of the edges within an Alluvial 
Flow diagram represent the amount of flow that passed through the cluster based on the 
random walk process.  In Alluvial Flow, the concept of “flow” is operationalized as the 
total PageRank score for all nodes within an identified module.  The question that remains 
then is how Alluvial Flow diagrams map actual changes within a graph.  Much like the 
implementation in ARRASTRA, Alluvial Flow begins with a set of graphs, which was 
previously referred to as a graph series.  The random walk process detects changes in 
modules across the series based on the flow connectivity of the module’s members.  For 
instance, the random walker may detect connections between nodes existing within two 
different and disconnected modules which did not exist within the previous graph.  This 
suggests that the initially isolated modules have, to some degree, merged together.  The 
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relative amount of flow which is now realized between the two modules is reflected in the 
Alluvial Flow diagram, merging the two streams together.  In terms of information 
diffusion, it can be said that some amount of information between these two modules has 
fused, potentially forming a new research area.  
 
 High-level graph summary visualizations present relatively new and intriguing 
areas of information science.  This novelty is due to the fact that they communicate only 
the most important changes in a graph and effectively removes clutter within the 
visualization.  Additionally, these approaches break conventional graph paradigms while 
still maintaining the heuristics that make graphs easy to interpret by the user.  As discussed, 
low-level visualization solutions, for example, still largely rely on established graph 
conventions in that they are graph-based extensions of the data, with temporal information 
simply merged together.  These innovation strategies accomplish this by incorporating 
additional time-based data into the graph and arranging their components in various ways 
which elucidate the temporal order of node appearance.  The high-level approach operates 
at the cluster level, but still draws from network visualization paradigms to depict network 
flow between clusters.  In other words, the summarized graph approach communicates only 
the changes that exist within high-level themes, not individual graph components such as 
individual nodes and edges.  Since identifying changes in research fronts within collections 
of clinical trial protocols is the primary research goal of this dissertation, the high-level 
summary approach is more appropriate than historical strategies described.  As such, the 
final step of this overall process as currently supported within the ARRASTRA Toolkit, 
involves the construction of a high-level graph change summary visualization from the 
information contained within the graph series.  This visualization strategy is referred to as 
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a MetroMap.  As the name implies, MetroMaps borrow well-established visual heuristics 
for constructing simplified maps of complex urban subway rail routes.  As will be 
developed, the potential application of this visualization strategy to dynamic changes 
associated with research fronts is both novel and intriguing. 
 
 
MetroMaps –  Extending Temporal Graphs 
 
 
Alluvial Flow diagrams are currently the preeminent standard for visualizing flow-
based information across high-level graph communities.  However, more recently, newer 
visualization strategies have been devised which exhibit the potential to extend the 
concepts embodied in flow-based diagrams.  Most notably is that of MetroMaps, a 
visualization style which draws from simplified, color-coded maps of interconnected 
subway stations, junctions, and rail lines in large metropolitan settings [233].  This style of 
visualization is effective due to the fact that it employs numerous well-known and easily-
understandable visual heuristics that have seen the adoption of such map styles around the 
world.  First introduced by Shahaf et al., MetroMaps were originally designed to visualize 
the connectivity between news articles with varying facets of topical overlap within a time-
sorted corpus [234].  Shahaf et al. originally applied this visualization technique to news 
articles highlighting the 2008 financial debt crisis in Greece, and is depicted in Figure 41.  
In this graphic, each node within the MetroMap represents an explicit news article, sorted 
horizontally along the x-axis according to the article’s publication date.  Articles are 
temporally connected by colored “tracks”, linking together similar articles which occur at 
different periods of time.  These tracks represent logical transitions between similar articles 
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and succinctly form intuitive chains of events.  Articles are connected by tracks based on 
similarity metrics.  Note the consistent visual aesthetics MetroMaps employs in order to 
succinctly demonstrate how new article topics, or “tracks” of similar story concepts, form 
a coherent map that outlines both the temporal and thematic relationships between news 
articles.   
 
.   
 
 
Figure 41.  An Example MetroMap summarizing the debt crisis in Greece 
 
 
However, document similarity alone cannot fully dictate the appropriate deviations 
which form new thematic tracks of stories of varying but coherent facets.  Shahaf et al. 
employs three metrics to address the overall quality of the MetroMap: coherence, 
coverage, and connectivity.  “Coherence” measures those terms that are the most 
representative concepts of a document cluster.  This metric, in its current implementation, 
uses tf-idf as a means to weighting a term w.  Coherence is calculated across documents 
which are chained together along a metro track, comparing each document d with its 
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successive document in the given track such that 𝑑𝑖 → 𝑑𝑖+1 .  “Coverage” measures how 
representative the topic is within the context of the entire corpus, and encourages article 
diversity across the MetroMap.  Coherence and coverage are represented below, 
respectively, in Equation 14 and Equation 15.   
 
𝐶𝑜ℎ𝑒𝑟𝑒𝑛𝑐𝑒(𝑑𝑖 , … , 𝑑𝑛) = 𝑚𝑖𝑛𝑖=1…𝑛−1 ∑ 𝑖𝑚𝑝𝑜𝑟𝑡𝑎𝑛𝑐𝑒(𝑤|𝑑𝑖 , 𝑑𝑖+1)
𝑤
 
Equation 14.  Coherence of a chain of documents within a MetroMap 
 
 
𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑀(𝑤) = 1 − ∏ (1 − 𝑐𝑜𝑣𝑒𝑟𝑑𝑖(𝑤))
𝑑𝑖𝜖𝑑𝑜𝑐𝑠(𝑀)
 
 
Equation 15.  Coverage of a word within a MetroMap 
 
 
Shahaf et al. also introduced one additional quality metric, connectivity, which 
counts the number of overlapping edges that exist within a MetroMap.  Indeed, this layout 
property is vital to the visual aesthetics, such that users can easily follow tracks and identify 
their interactions with others.  Together, these three concepts are employed in an objective 
function due to the trade-offs of maximizing one metric over the other.  For example, 
maximizing coherence tends to minimize coverage, as all the documents selected for the 
MetroMap tend to be very similar.  The objective function uses coherence as a fixed 
constraint, including only those tracks which meet or exceed some threshold.  The authors 
chose to maximize coverage and connectivity in their objective function, in order to 
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provide a highly comprehensive set of articles which represent different facets of the article 
corpus, displayed in such a way that makes following tracks easy on the eye. 
Currently, the work of Shahaf et al. expresses individual news articles as nodes 
within the MetroMap, which would be akin to mapping similarities across distinct clinical 
trial protocols.  Recall, however, that the theme of this research is to map not the 
relationships between individual documents, but the overarching themes that those 
documents comprise.  This should be apparent after the introduction of the Alluvial Flow 
diagram, where temporal flow is mapped based on the links between graph clusters, as 
dictated by a graph traversal process.  As such for the purpose of this dissertation and the 
desire to map changes in research fronts, ARRASTRA extends MetroMaps to represent 
collections (or clusters) of documents as the nodes which jointly represent over-arching 
themes, rather than individual entities.  Simply put, the MetroMaps rendered by 
ARRASTRA illustrate the formation of connections between previously isolated clusters 
of ideas that establish between time periods.  While the visualization itself uses the original 
MetroMap technique as developed by Shahaf et al., the process in which ARRASTRA 
maps the flow of information across time is considerably different.  Within the context of 
graph theory, a MetroMap “track” can be conceptualized as a graph cluster, extended 
across time.  Each point on a given track represents the current state of a cluster at that 
given time point.  These states are linked together by ascending time, left to right, by a 
colored track.  Tracks ultimately communicate the interactions between clusters as they 
interact over time, as determined by a random node walk process, which will now be 
discussed. 
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The construction of the MetroMap in ARRASTRA, more akin to the Alluvial Flow 
diagram, uses a random graph walk process for every clustered (Infomap or Walktrap) 
graph within the graph series.  The random walker keeps track of node cluster membership 
across time periods, while actively checking for new paths which, when traversed, connect 
previously isolated clusters from the preceding graph in the series.  This process is depicted 
in Figure 42 against a test subset of clinical trial protocols representing eight key sub-
therapies.  The image on the left depicts a simple random graph walk routine which initially 
traverses within the blue cluster, which is jointly represented by the blue track in the 
MetroMap on the right.  Each cluster is represented in the MetroMap by a combination of 
a colored track and a white circle “metro station”, aligned to the x-axis representing time.  
The “station” size is indicated by the percentage of directed information which passes 
through it.  This is where the differentiation is made between a static graph cluster and that 
of a temporally-salient research front, as the notion of a research front in a MetroMap is 
conceptualized as individual “tracks” of similar themes which extend through time.  Each 
“metro station” at the current year of the x-axis represents a snapshot of that cluster at that 
given point in time.  These points within the MetroMap are also the locations where graph 
cluster interactions can occur.  For example, at some time point (in this example, 2011), 
the random walker discovers an edge-based path linking the blue cluster to the brown 
cluster, which is reflected by the merging of the two colored tracks.  Additionally, an 
orange track continues throughout the MetroMap without any interactions between other 
tracks, and thus is completely isolated from the overall network throughout the entirety of 
the sampled graph series.   
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Figure 42.  Identifying new connections between two clusters (blue, brown) with a graph 
walker 
 
 
At the heart of the random walk process, ARRASTRA is actually constructing a 
new graph in which each temporally-bound node indicates a traversed graph cluster, and 
the edges summarize discovered interactions between clusters across time.  A linear chain 
of nodes in this underlying graph, when sorted by ascending time period horizontally, 
creates a track on the MetroMap, with each node representing a cluster state at a particular 
period of time.  This graph is then converted to the MetroMap JSON format for rendering 
in the D3 JavaScript visualization library. 
Additionally, during this process the overall flow of each node within a cluster is 
calculated using individual betweenness centrality and out-degree strength scores.  In order 
to identify the most interesting clinical trials across time (nodes), Kleinberg’s burst 
algorithm is applied against these graph metrics over time.  This algorithm identifies 
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“bursts” of activity within windows of time to identify the emergence of pivotal nodes 
[235], by expressing the node as a vector of these graph metric values across each time 
segment.  The nodes which exhibit bursts within the calculated graph metrics are marked 
as those which may be influential to the overall corpus.  It is hypothesized that the most 
influential nodes are those not just characteristic of having high individual metric scores, 
but which also exhibit periods of increasing activity of those metrics over time.  The 
application of burst algorithms to individual nodes within clusters along MetroMap tracks 
will be discussed in more detail in the next section.  It will be demonstrated that not only 
do they reveal novel clinical trial profiles, but also that graph metrics can be used to predict 
the success of a track over periods of time.  
In addition to the overall MetroMap, users are also given the ability to view details 
of individual clinical trials within specific clusters, including individual protocols.  In other 
words, MetroMap nodes which appear along individual tracks can be thought of as “super 
nodes”, which encapsulate individual protocol members. Therefore, users are able to drill 
further down into each cluster in the MetroMap to view individual clinical trial members 
of that group, as depicted below in Figure 43.  Graph node sizes can represent either 
supplied metadata such as total enrolled subjects (such as in this case), or imputed 
information such as a node’s betweenness centrality within the current time period.  This 
feature satisfies the focus-versus-context problem.  It does so by capturing the manner in 
which these nodes fit into the overall context of the map thereby providing various levels 
of granularity to explore.  As will be discussed in Chapter 8, one key next-step to this 
research is pulling together all of its web-based visualization capabilities to a cohesive 
functional reactive dashboard model [236].  Source Code 9 below depicts the step of the 
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ARRASTRA Toolkit API instructions which generate the MetroMap.  Note that the 
MetroMap constructor also accepts the sets of cluster concept summary graphs, such that 
each MetroMap track can be quantified with the set of concepts which best describe the 
nature of the protocols included in that track.  Next, an in-depth look at other reporting 
features supported by ARRASTRA will be taken.  These added capabilities allow users to 
understand the nature of the individual components with the MetroMap at granularities of 
both the individual protocol and high-level clusters. 
 
 
Figure 43.  An embedded diagram of clinical trials comprising an example metro 
“station” 
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from arrastra.graph import metro 
from arrastra.ui import graphstyle as gs, dashboard 
 
mmap = metro.MetroMap(summaries=graphs, concepts=cluster_details, 
years=list(range(2000,2015)), cluster=G_CLUSTERS.INFOMAP) 
mmap.generate_map() 
mmap.write_json(f='metro.json') 
 
#- Launch the ARRASTRA embedded browser  
dashboard.UI(metromap=mmap).show() 
 
 
 
Source Code 9.  Using ARRASTRA Toolkit to construct a MetroMap 
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Extracting Meaning from MetroMaps 
 
 
In order to fully understand the dynamics of evolving research fronts in accordance 
with the goals outlined by this dissertation research, it is critical that the qualitative changes 
captured within MetroMaps be quantified at both the individual protocol level, as well as 
at the thematic levels.  To review, the research thus far has mined a corpus of clinical trial 
protocols based on the interconnectivity of the biomedical concepts which they contain, 
imputed a temporally-directed homogeneous graph of protocols, and visualized the key 
structural changes of that graph over the course of 15 years. Previously, it was hypothesized 
that converting the information captured within a therapeutic space through the principles 
of information diffusion via evolving research fronts can be operationalized as changes in 
appropriate graph metrics. As such, the solution imputes multiple graph metrics from 
which protocol “influence” or “importance” is operationalized based on its position within 
the network, described previously as betweenness centrality and out-degree strength.  
Furthermore, these metrics are calculated for each node across the time-segmented graph 
series.  As a result, graph metrics are not represented merely as single static points of data, 
but vectors of values for each time period a clinical trial is present within the time-subset 
graph.  In other words, these vectors of data provide key insights into the roles each node 
plays within a network not just at any given point of time, but also across multiple periods 
of time.   
To accomplish this, the imputed graph metrics are first harnessed in order to 
quantify the key clinical trial protocols, using the previously mentioned Kleinberg burst 
algorithm.  It is theorized that “influential” clinical trials exhibit “bursts” of activity within 
betweenness centrality and/or out-degree strength metrics.  To reiterate, the concept of 
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“betweenness” is translated as a node which potentially connects multiple graph clusters 
(i.e. research fronts), thus serving as one which unifies ideas and forms new research fronts.  
The out-degree strength calculates the weighted sum of all directed edges of a node, 
translated as a protocol directly influencing the creation and/or design of future clinical 
trials based on similar protocol content.  Burst activities are interesting in that they can 
span different durations of time, and either immediately influence the network or serve as 
lagging indicators based on when a trial first appeared.  These metrics have the potential, 
at the very least, to filter thousands of clinical trials and direct researchers to only the ones 
which may be of importance to a given research context.  Further, one can visualize and 
compare the burst activities of these key trials using Sparkline plots, popularized by 
Edward Tufte.  Figure 44 and Figure 45 use this graphical approach to depict the burst 
activities of 20 random clinical trials which were determined to exhibit burst traits based 
on the Kleinberg’s Bursty and Hierarchical Structure in Streams algorithm, for out-degree 
strength and betweenness centrality metrics respectively.  Graphs are sorted vertically in 
ascending order based on when that clinical trial first appeared, and the start of its burst 
time period.  For each individual graph, the x-axis represents time, and the y-axis represents 
the quantity of the graph metric being measured, specific to the current protocol context.  
The minimum and maximum values within each stream of values are depicted by red and 
blue points, respectively.  Source Code 10 demonstrates the ARRASTRA API call for 
detecting bursts for a graph series and exporting the results for further analysis in statistical 
programming software such as R.  The graphs were rendered in R using the Tufte-inspired 
stylistic guidelines outlined in the excellent “Tufte in R” digital guide by Lukasz Piwek27. 
                                                 
27 http://motioninsocial.com/tufte/ 
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Figure 44. Out-degree strength “burst” activity sorted by time duration 
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Figure 45. Betweenness centrality “burst” activity sorted by time duration reveals 
 
 
Sparklines are an aesthetically pleasing approach to plotting data using Tufte 
visualization heuristics to cleanly and clearly demonstrate the continuous relationships 
between a collection of multi-faceted objects. The actual interpretation of these results and 
their applicability to the current state of the art will be deferred to the discussion section of 
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the following chapter.  However, this approach to quantifying the activities of individual 
objects within a research front is a starting point to validate the utility of the ARRASTRA 
platform, by demonstrating that not only does it produce interesting visualizations from an 
initial set of documents, but also ones which are meaningful in accurately describing 
relevant themes and events within the therapeutic space.  Additionally, the top 50 clinical 
trials exhibiting burst activities for both out-degree strength and betweenness centrality 
have been compiled in Appendix C and Appendix D respectively.  The explanation of the 
relevance of these identified clinical trials, specifically the 10 trials which appear in both 
results, is deferred to the discussion section of Chapter 8, as the individual clinical trials 
identified through this process reveal much about the clinical trial space.  Overall, this 
aspect of the research addresses the clinical utility of the approach ARRASTRA has 
employed for mining and understanding the collection of clinical trial protocols relating to 
AD research. 
In order for ARRASTRA to truly serve as a translational layer between the clinical 
research space and information sciences, a predictive model which integrates endpoints 
obtained from the clinical space with those imputed within the graph space must be 
devised.  Recall that a primary goal of this research is to understand the vitality of a research 
front given the amount of information that flows through it.  Throughout this process, novel 
metrics have been calculated which has never yet been applied to the context of clinical 
trial research in such ways.  Next, the topic of formulating predictive models based on the 
totality of the data both compiled and imputed will be discussed in the form of survival 
analyses through Kaplan-Meier estimators and Cox proportional hazards models. 
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bursts = aspace.calculate_bursts(metric=G_METRICS.BETWEENNESS_CENTRALITY, 
from_slice=2000, to_slice=2015, s=2, gamma=0.2) 
aspace.metric_to_sparklines(file="sparklines_between.csv", trials=[l[0] for l in 
bursts], id_field='uri', from_slice=2000, to_slice=2015, 
metric=G_METRICS.BETWEENNESS_CENTRALITY) 
 
 
Source Code 10. Calculating and extracting burst activity of metrics across a graph 
series 
 
 
In order to answer questions relating to the applicability of how ARRASTRA 
conceptualizes a therapeutic space and operationalizes it as a stream of graph importance 
metrics over time, these terms are tested as covariates in various survival models to 
determine their significance in predicting the overall “health” of a sub-therapy.  As the 
burst activity analysis discussed previously inspects the dynamics of individual documents 
contained within a research front, the survival analysis compares the survivability of the 
actual research fronts over time.  Firstly, the Kaplan-Meier estimator approach is discussed, 
followed by a series of Cox proportional hazard models which integrate both graph metrics 
and protocol metadata specified in ClinicalTrials.gov as covariates.  Briefly, these analyses 
quantify the hazard, or risk, that would be expected between two groups as a function of 
time.  From a clinical perspective, this analysis would equate to whether the risk of entering 
a specific therapeutic sub-space is worth the reward, based on the historical performance 
of similar clinical trials within their respective clusters. 
Traditionally, these analyses have been used as a means to quantify the statistically 
significant difference in, for example, cancer population groups being treated with a novel 
drug versus the current standard of care.  The dataset encodes this phenomenon as 
measuring a time-to-event from baseline for each subject within the treatment and placebo 
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groups.  For this example, the event would be encoded as the time of death of a patient 
from the baseline assessment.  Kaplan-Meier plots can additionally be generated to 
visualize the rate of survivability between two populations, capturing percentage of 
subjects not yet reaching that event as a function of time.  The distinct population tracks 
should in principle reveal, in the event of a successful therapeutic effect, that the two 
populations significantly diverge over time, with the current standard population 
decreasing at a steeper rate. In order to express cluster-based metrics data over time in this 
same framework, ARRASTRA first compiles a normalized data set as a CSV file, applying 
the following transformations to the graph data: 
1. Categorize clinical trial “overall status” labels into three high-level factors, in order 
to make this dependent event covariate more coarse-grained: Ongoing (0), 
Completed (1), and Terminated (2).  For example, “Withdrawn” and any variation 
of “Terminated” are encoded with the value 2, while “Ongoing”, “Recruiting”, and 
“Enrolling” are encoded with the value 0 
2. Correct the trial’s primary completion date with the earliest clinical trial first 
received date within its cluster, in order to align all clusters to a zeroed baseline 
time, in order to compare research fronts on same timeline 
3. Categorize trial phase into a Boolean value representing whether the trial has passed 
the critical Phase 2 stage of testing in humans, where anything before (inclusive) 
“Phase 2” is denoted as “false”, and anything beyond “Phase 2/Phase 3” (inclusive) 
is denoted as “true” 
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ARRASTRA exports results to a flat CSV file where each row captures a single clinical 
trial, its cluster membership, it’s cluster-adjusted time-to-event, the last event status, and 
the following covariates, grouped by theme: 
1. Graph: The trial’s betweenness centrality (Numeric) and out-degree strength 
(Numeric) at the time period of its completion/termination event, or its current state 
if still ongoing 
2. Burst: Burst metrics such as whether it exhibited burst behavior (Boolean), and the 
duration of its longest burst phase (Numeric) 
3. Meta: Additional variables obtained from ClinicalTrials.gov, including trial phase 
(Boolean) and number of patients successfully enrolled (Numeric) 
A Kaplan-Meier analysis is performed to test whether survival function estimates are 
significantly different between two groups.  This chapter has previously focused on 
qualifying the dynamics of research fronts, or individual “tracks” within a MetroMap.  
However, MetroMaps cannot answer, quantitatively, the nature of how “healthy” a track is 
from a historical standpoint.  Recall that MetroMaps, like Alluvial Flow diagrams, do not 
actively remove objects from the visualization.  While it seems intuitive to remove a 
clinical trial from the MetroMap after it has been completed, this does not negate the fact 
that the information it contains has the potential to influence the direction of future 
research.  As such, a Kaplan-Meier plot can be used to compare the viability of MetroMap 
tracks, based on the status of the trials which comprise them.  The following analyses utilize 
the survival library of the R statistical programming environment.  Figure 46 depicts such 
a plot which compares two MetroMap tracks over time, one capturing the behavior of 
symptomatic therapeutic solutions, and the other disease-modifying solutions.  This 
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analysis uses trial completion as the event to indicate the final state of a clinical trial.  
Ideally, trial termination would serve as a more useful event for comparison to suggest 
critical issues in key topics such as trial design and enrollment.  However, the occurrences 
of trial terminations were too sparse across clusters to ultimately be useful for this specific 
analysis.  Trial completion is still an interesting event type to analyze, as it can indicate 
whether research organizations are still interested in conducting similar studies within a 
sub-therapeutic space, alluding to the industry’s overall confidence in such approaches.  
The rationale is that regardless, a track which does not have a robust pool of active ongoing 
trials may indicate that the overarching ideas which embody that track have since been 
abandoned within the therapeutic space.  As Figure 46 suggests, the two clusters being 
compared exhibit slightly different survival behaviors, which are evident by their distinct 
trajectories.  The transparent red and blue areas around each trajectory denote 95% 
confidence intervals, indicating that the true survival estimates lie within those areas. 
233 
 
 
Figure 46.  Kaplan-Meier plot comparing the overall survivability of two research fronts 
 
 While it’s undoubtedly interesting to first impute latent themes within a collection 
of protocols and take the added step of integrating that data with ClinicalTrials.gov 
metadata to empirically demonstrate the viability of those themes over time, Kaplan-Meier 
estimates do not elaborate on the factors which influence success or failure.  For this, a Cox 
Proportional Hazard Model (CPHM) is employed to the same dataset.  Similar to logistic 
regression models, CPHM models are employed to identify the covariates which explain 
the survival function to a level of statistical significance.  Graph metric, burst data, and 
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protocol metadata are included for this analysis.  This is where the truly translational aspect 
of the ARRASTRA framework is demonstrated.  CPHM models are employed to determine 
the utility of imputed graph metrics by empirically testing their ability to predict survival 
estimates.  In other words, CPHM models can be used to elaborate if the linear 
combinations of graph metrics calculated by ARRASTRA hold any significance in 
predicting the survival of ideas within a research domain.  The overall process for 
validating the approaches ARRASTRA utilizes to convert a collection of clinical trial 
protocols to a series of directed protocol networks is described in detail in the next chapter, 
as a method of evaluation.  Source Code 11 depicts the ARRASTRA API call which 
exports the imputed graph space to an analysis-ready dataset in R. 
 
 
#- Compile dataset for survival analysis 
aspace.to_cox_proportional_hazard_model(file=”cphm_walktrap_between.csv", 
from_slice=2000, to_slice=2015, cluster_type=G_CLUSTERS.INFOMAP) 
 
 
 
Source Code 11.  Exporting the graph series to a CPHM dataset for further analysis 
 
 
This chapter has outlined the data processing pipeline of ARRASTRA: 1.) querying 
a massive graph of interconnected clinical trial statements, 2.) weighting and constructing 
an expanded feature vector space, 3.) reducing the high-dimensional space to a set of 
manageable latent themes, 4.) revealing the manifold structure of the clinical trial protocol 
statements, 5.) constructing a homogeneous edge-filtered source graph of interconnected 
protocols, 6.) sub-setting the source graph by time into a graph series, 7.) mapping cluster 
changes within each graph of the time-based series, 8.) rendering a MetroMap to highlight 
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high-level changes across the graph series, and 9.) quantifying these changes by applying 
novel graph-based metrics to burst analyses of individual protocols and survival analyses 
to clusters of documents.  Overall, the ARRASTRA Toolkit API is a novel approach for 
visualizing the evolution of those relationships between homogeneous entities from an 
initial set of heterogeneous statements.  It is anticipated that this framework has additional 
applications beyond clinical trials, such as identifying biological processes and disease 
associations which are enriched within sets of genes, and will be discussed in further detail 
in Chapter 8.  Having now presented the ARRASTRA framework in its entirety, it is 
appropriate to briefly evaluate aspects of the overall solution, as well as translate findings 
contained within the final MetroMap into current understandings of the current AD 
therapeutic space.  
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Chapter 7: ARRASTRA Evaluation 
 
 
 Thus far, a novel framework which mines clinical trial protocol data through a 
pipeline of data reduction, manifold learning, and dynamic graph-based visualization 
routines have been presented.  In order to defend the appropriateness of this solution, it 
must be empirically validated through both quantitative and qualitative means.  
Unfortunately, as is evident by the comprehensive literature review in the first chapters, 
there is not a precise set of works which can be directly compared to the presented 
capabilities, as this research fills a relatively new space in which its underlying data source 
is largely overlooked.  As such, the processes can be logically decomposed from three high-
level technological perspectives which have dependencies with each other.  Firstly, the 
appropriateness of graph clusters identified by ARRASTRA is compared with latent topics 
imputed by a conventional LDA topic modeling routine. Second, the rendered MetroMap 
is qualitatively compared and contrasted to an Alluvial Flow diagram in its ability to 
communicate key graph changes across time. Finally, the utility of temporal graph metrics 
is tested using a novel cluster-survival model which integrates ARRASTRA outputs with 
metadata supplied by ClinicalTrials.gov. 
   
 
Evaluating Extracted Themes 
 
 
In order to empirically demonstrate the performance of the manifold and graph-
construction process within the ARRASTRA Toolkit, the validity of its outputs must be 
quantified.  Unfortunately, there is currently no gold standard from which to directly 
compare the solution to in order to establish which aspects of the research exhibit superior 
enhancements over its predecessors.  Instead, the novelty of the proposed ARRASTRA 
solution and its applications which fulfill current unmet needs of the pharmaceutical 
industry should stand for itself.  However, in order to assess the overall ability of the data 
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mining approach to extract meaningful latent themes from untidy, terse, and unstructured 
protocol texts, results are compared to that of LDA, a conventional standard for identifying 
latent topics within collections of documents.  The rationale for this evaluation exercise is 
to compare and contrast the latent themes identified by a conventional LDA process to 
those extracted by ARRASTRA as captured in the cluster summary graph, described in the 
previous chapter.  Ideally, a successful mining approach will be sensitive to latent themes 
not detected by established gold standards.  LDA identifies themes by calculating weighted 
linear combinations of features which best segment objects into discrete classes.  It is 
hypothesized that a conventional LDA process cannot adequately identify subtle topics due 
to the sparse nature of protocol texts as they are currently supplied on ClinicalTrials.gov. 
Specifically, thematic labels were generated for groups of protocols by extracting 
text of each protocol included in the current dataset, and exposing the content to the LDA 
implementation of the Gensim28 Python library.  This process uses the explicit textual 
context of each protocol, devoid of any additional data that ARRASTRA employs, such as 
semantically-expanded concepts, synonym resolution, or weighted protocol zones.  Raw 
text for the “brief title”, “brief summary”, “eligibility”, “arm group” fields of the same 
protocol IDs utilized throughout this analysis (1,139 total) was acquired through Eli Lilly’s 
LCOI API, and merged to form individual document vectors.  Stop words were then filtered 
from each text.  The number of clusters was selected to be comparable with that of the 
number of clusters ARRASTRA identified through Infomap (48 clusters), and was set to 
50.  The process was executed for 100 iterations.  The 50 themes identified by LDA is 
                                                 
 
28 https://radimrehurek.com/gensim/ 
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provided in Table 4 and is expressed as the top normalized term weights for each theme 
(in this case, the top 5 features of each document).  Of the 50 themes identified, over 56% 
of the corresponding protocols were assigned to the first cluster (646 protocols).  This 
suggests that the overwhelming majority of clinical trial protocols, as they exist in 
ClinicalTrials.gov, do not contain enough descriptive information to be considered useful, 
and thus can only be binned into a general group of protocols. Of the other clusters, 
excluding the first, the average cluster size was 45 ± 42 documents, with a maximum value 
of 257 members and a minimum value of only 1 member. 
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0.024*study 0.014*18f 0.014*tau 0.014*dementia 0.014*imaging 
0.014*changes 0.011*study 0.011*disease 0.01*may 0.01*brain 
0.017*alzheimer 0.017*disease 0.017*s 0.014*patients 0.013*ad 
0.015*as 0.011*dementia 0.011*investigators 0.011*imaging 0.01*pet 
0.03*amyloid 0.03*pet 0.019*scan 0.018*18 0.017*florbetapir 
0.025*fnirs 0.022*vsep 0.021*vagus 0.019*early 0.017*nerve 
0.023*ad 0.021*type 0.017*by 0.015*changes 0.015*activity 
0.04*18f 0.022*brain 0.02*imaging 0.02*nachr 0.018*pet 
0.038*ad 0.014*disease 0.013*by 0.01*s 0.009*cognitive 
0.02*ad 0.019*ftd 0.013*by 0.013*patients 0.012*agitation 
0.03*care 0.02*caregivers 0.015*their 0.015*intervention 0.014*dementia 
0.031*dha 0.02*ad 0.018*epa 0.018*carriers 0.017*apoe4 
0.015*dementia 0.015*group 0.012*intervention 0.012*study 0.009*test 
0.026*dementia 0.013*agitation 0.012*life 0.011*quality 0.011*care 
0.082*alzheimer 0.081*s 0.078*disease 0.072*study 0.051*patients 
0.021*ad 0.021*as 0.02*patients 0.013*memory 0.012*disease 
0.016*ad 0.009*group 0.009*as 0.009*early 0.008*life 
0.019*mg 0.018*4 0.018*5 0.016*by 0.015*treatment 
0.025*patients 0.021*ad 0.017*retinal 0.017*dimebon 0.016*rivastigmine 
0.035*brain 0.021*study 0.017*memory 0.016*s 0.016*disease 
0.018*mci 0.018*hope 0.015*cognitive 0.012*stimulation 0.012*clinical 
0.014*patients 0.013*quality 0.012*life 0.012*ad 0.011*study 
0.029*pet 0.019*imaging 0.017*amyloid 0.015*emission 0.015*tomography 
0.025*dementia 0.015*study 0.013*by 0.011*groups 0.011*from 
0.025*bpsd 0.011*stage 0.011*symptoms 0.011*patients 0.01*as 
0.024*patients 0.015*dementia 0.012*from 0.011*study 0.01*treatment 
0.018*ad 0.012*knowledge 0.012*dementia 0.011*care 0.01*adults 
0.017*as 0.013*bbb 0.013*study 0.011*an 0.009*families 
0.04*insulin 0.026*brain 0.021*study 0.012*participants 0.01*single 
0.041*dementia 0.023*disease 0.017*stroke 0.014*brain 0.014*depression 
0.024*ad 0.013*disease 0.01*study 0.009*risk 0.008*blood 
0.011*as 0.011*s 0.011*alzheimer 0.01*have 0.01*adults 
0.012*depression 0.012*by 0.011*caregiver 0.011*cognitive 0.01*disease 
0.044*study 0.033*subjects 0.029*placebo 0.02*weeks 0.017*randomized 
0.046*rivastigmine 0.046*patch 0.024*memantine 0.017*probable 0.016*transdermal 
0.013*study 0.012*scan 0.011*brain 0.01*tracer 0.009*pet 
0.041*therapy 0.033*group 0.027*behavioral 0.021*patients 0.017*hearing 
0.088*cognitive 0.028*exercise 0.027*training 0.022*brain 0.022*impairment 
0.046*sleep 0.019*cognitive 0.014*investigators 0.014*as 0.013*disease 
0.014*disease 0.014*ad 0.013*brain 0.011*amyloid 0.011*patients 
0.022*if 0.02*effective 0.017*ad 0.016*safe 0.009*patients 
0.022*disease 0.022*s 0.02*alzheimer 0.012*an 0.012*impact 
0.025*ad 0.019*disease 0.019*genetic 0.013*study 0.012*alzheimer 
0.015*imaging 0.014*pet 0.014*ad 0.011*ivig 0.008*services 
0.02*disease 0.019*ad 0.013*an 0.011*brain 0.009*s 
0.051*ad 0.035*mci 0.033*cognitive 0.024*impairment 0.021*disease 
0.031*brain 0.021*beta 0.021*see 0.02*alzheimer 0.02*amyloid 
0.026*study 0.012*rsg 0.012*apoe 0.012*subjects 0.011*who 
0.032*patients 0.019*Alzheimer 0.014*disease 0.013*rtms 0.01*treatment 
0.021*s 0.02*study 0.019*participants 0.016*their 0.016*disease 
 
Table 4.  The latent themes extracted from the LDA mining process 
 
 
 Consequently, ARRASTRA identified 48 clusters based on the Infomap clustering 
routine, described in the previous chapter.  To reiterate, a cluster summary graph is 
constructed by taking the top-n concepts (in this case 5 concepts) which maximize term 
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weights for each cluster, previously depicted in Figure 39.  First, cluster membership is 
compared to the LDA approach based on the number of clinical trials belonging to each 
cluster.  The distribution of clinical trial protocols across imputed clusters were more 
evenly distributed.  For the ARRASTRA graph, the average cluster size was 22 ± 25 
documents with a maximum value of 120 members and a minimum value of 2 members.  
This suggests that ARRASTRA is more sensitive in identifying latent themes from text 
data which does not easily afford the ability to do so using conventional approaches.   
Additionally, the input manifold space generated by the augmented t-SNE process 
in ARRASTRA was assessed using a silhouette coefficient.  This is an important data 
structure to assess, as the low-dimensional manifold is used as input to construct the initial 
source graph used for this analysis.  A silhouette coefficient measures the average distance 
of points within a cluster compared to the average distance of the closest neighboring 
cluster.  Values of the coefficient range from -1, which indicates a complete mislabeling of 
nodes within a cluster, to 1, which indicates a perfect separation of clusters.  The distance 
matrix derived from the low-dimensional manifold and used to construct the source graph 
was compared against labels imputed from a hierarchical clustering routine depicted in 
Figure 34, yielding a silhouette coefficient of 0.41.  This suggests that the input manifold 
contains discernible clusters which area appropriately distanced from each other. 
These clusters include topics covering both pharmacological and non-
pharmacological solutions.  For example, general pharmacological solutions are apparent 
through topics including a cluster representing imaging modalities (imaging studies, 
Imaging modality, Diagnostic Imaging, Radionuclide Imaging, fMRI, emission 
tomography, and Magnetic Resonance Imaging). Nicotinic acetylcholine receptor 
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agonists, symptomatic treatments, immunotherapy, Histamine H1 Antagonists, and 
Antipsychotic Agents identify areas of symptom-masking therapeutic solutions.  Specific 
compounds which appear in the results include Galantamine, Memantine, Dimebolin, N-
Methylaspartate, Escitalopram, Pioglitazone, Risperidone, and Mirtazapine.  Disease-
modifying concepts are present in clusters indicated by concepts such as subdermal, 
immunotherapy, and Amyloid beta-Peptides.  Non-pharmacological solutions include 
topics such as Primary caregiver, Supportive care, Discipline of Nursing, and Sites of Care 
Delivery.  Key biomedical topics such as Hyperphosphorylated tau, Amyloid beta-
Peptides, cerebrospinal fluid, MAP kinase activity, Brain tissue, regional part of cerebral 
cortex, and Intracranial structure are also present, representing areas of key AD drug 
targets.  Additionally, topics including secondary neurological symptoms such as 
Behavior, Sleep Wake Disorders, Hallucinations, Apathy, and Diminished motivation are 
present.  Topics such as Epidemiology and Risk Factors suggest observational clinical trials 
aimed at understanding the disease at the population level.  Overall, these topics are well-
represented based on the literature review of the current state of the AD clinical research 
space outlined in Chapter 1, by identifying a diverse set of both observational and 
interventional trials which represent both pharmacological and non-pharmacological 
solutions. 
However, these results also suggest that while the clustering processes devised by 
this research is sensitive to subtle latent themes not identified by LDA, it’s not entirely 
specific to other key biomedical concepts.  For example, terms such as Population Groups, 
Evaluation, Treating, chemical compound, Fluid, onset quality, and organism substance 
are also present within this analysis.  This can be explained primarily by the ontological 
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expansion process detailed in Chapter 5, since these concepts originate mostly from higher-
level ontologies.  It’s plausible that this expansion process, when identifying implicit 
connections between concepts within the feature space, also applies this to top-level 
ontological concepts, thus introducing additional generic terms to the feature space.  
Additionally, concepts such as Mental deterioration and Cognitive impairment, while not 
entirely synonymous with each other from a semantic standpoint, capture similar meanings.  
These relationships do not contribute to the feature space equally, and may drive further 
distance between similar documents once their parents are added to the feature space after 
the semantic expansion process.  In the future, this can be addressed by including additional 
information regarding the position of the concept within the ontology during the Titan 
graph data loading process in order to determine whether the concept is appropriate for 
expansion.  A more brute-force approach would be to specify high-level ontology concepts 
which should be filtered from the input statement space and remove them before 
constructing the weighted vector space. 
Additionally, the cluster summary graphs themselves can be directly compared.  
Recall that the cluster summary graph captures concept co-occurrences for each cluster.  
Conceptually, topic coverage in its entirety can be operationalized using this data structure, 
based on the modularity score of its underlying cluster summary graph.  Graph modularity 
is a metric which quantifies how segmented sets of nodes are to each other, by comparing 
the density of edges within a cluster against a random distribution of edges between all 
nodes within the graph.  Highly modular graphs exhibit edges which are denser within 
clusters than that of a random set of edges.  While there is no standard which dictates what 
an optimal modularity score should be for this specific application, a few guidelines are 
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suggested.  A perfectly modular summary graph (modularity score of 1) is not expected, 
nor should be, due to the fact that merges occur throughout the duration of the map’s 
timeline, and thus clusters may share multiple concepts.  Additionally, the nodes of the 
resulting cluster summary graph should not be completely connected, as this implies the 
discovered clusters are completely convoluted, and distinct themes were not successfully 
identified.  Instead, a balanced modularity score is desired, which indicates a variety of 
detected themes, while still accounting for overlaps.  For this example, the resulting 
modularity score of the cluster summary graph produced by ARRASTRA is 0.80.  A 
similar approach was applied to construct a cluster summary graph for the LDA results.  
The resulting LDA cluster summary graph yielded a modularity score of 0.36, much less 
modular than the one produced by ARRASTRA.  This process was executed an additional 
15 times for both summary graphs in order to test for robustness.  The modularity scores 
for the LDA summary graph was 0.213 ± 0.061, while the ARRASTRA summary graph 
averaged 0.77 ± 0.03 (p < 1 x 10-10).  Cluster summary graphs support the notion that 
distinct community topics can be discerned, and serves as a visual to support the value of 
its modularity score.  Based on the fact that LDA cannot accurately classify the majority 
of clinical trials into specific groups, as well as yield a cluster summary graph of 
appropriate modularity, it is logical to conclude that the clustering process employed by 
ARRASTRA is superior in identifying overarching themes from collections of clinical trial 
protocols.  Having now established the ability of ARRASTRA to identify a range of themes 
extracted from the graph clusters, the next logical step is to evaluate the nature of how these 
themes evolve over time, through the use of MetroMaps. 
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Figure 47.  The cluster summary graph of the LDA topic model 
 
 
 
 
 
Comparing MetroMaps to Alluvial Flow Diagrams 
 
 
The current MetroMaps implementation in ARRASTRA was designed to articulate 
two major concepts, founded in information diffusion theory: 1.) when concrete areas of 
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thought emerged, conceptualized by tightly-connected clusters of similar clinical trial 
protocols, and 2.) how their interactions evolve them over time, conceptualized by track 
events within these groups.  As a result, ARRASTRA adopted the visual aesthetics 
proposed by a solution devised for depicting transitions between individual documents, 
and translated this design to capture changes in flow between clusters of interconnected 
documents over time.  The Alluvial Flow diagram is the current approach which most 
closely fills this gap for dynamic flow-based graph visualizations at the cluster level. 
Firstly, key high-level areas where the two solutions differ is briefly discussed.  
Most notably, it can be argued that especially for complex networks, Alluvial Flow 
diagrams can suffer from high areas of dense edge overlaps. The construction of 
MetroMaps, when rendered, has the ability to reduce these overlaps by providing higher-
level insights at the individual cluster level.  MetroMaps also employ well-known visual 
design heuristics that have, for decades, served as informative maps that commuters rely 
on for navigating complex transportation systems: stops (clusters), junctions (cluster 
merges), and tracks (salient temporal themes).  Additionally, the nature of each track can 
be contextualized based on their representative concepts extracted from the cluster 
summary graph.  Alluvial Flow diagrams label each module based on its most prevalent 
node, typically with the vertex ID.  Since vertex IDs serve as short and unique identifiers, 
these module labels may not readily communicate human-readable and contextual labels.  
For example, in this dissertation Alluvial Flow modules are labeled by NCT identifiers.  
While it’s possible to manually cross-reference these identifiers by searching for that 
specific protocol in ClinicalTrials.gov and imply the given module ID is most 
representative, or influential, of the nodes contained within that module, this approach is 
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not entirely intuitive.  Instead, ARRASTRA augments MetroMap tracks with the concepts 
most representative of its clinical trial members, derived from the imputed summary graphs 
introduced in Chapter 6.  This provides important context to the user when interactions 
between map tracks are being assessed.   
ARRASTRA can easily import the contents of its current graph series to the 
Alluvial Flow generator, by iterating through each graph in the graph series and exporting 
it in the Pajek format.  The resulting files can then be manually uploaded in the Alluvial 
Flow UI29 based on the temporal order of each graph.  The ASpace2 class in ARRASTRA 
exposes an alluvial_flow_export method for this purpose.  A comparison of the two 
solutions is conducted by briefly identifying common traits of the visual output.  Indeed, it 
is vital to demonstrate that the two solutions produce visualizations that, at some level, 
share an agreeance on vital components identified across the series of graphs.  These 
components are identified by briefly comparing module features in Alluvial Flow, with 
those present in the MetroMap visualization. 
 Each graph slice was uploaded sequentially to the Alluvial Flow generator 
individual directed networks, where the application imputes clusters (modules), and the 
most representative components of those modules.  The resulting visualization, depicted 
below in Figure 48, indicates changes in “flow” between modules using PageRank as the 
metric of analysis.  The size of each module is proportional to the amount of flow which 
passes through it.  Modules can be “tracked” across time periods by manually highlighting 
its top components using different color pallets.  In this example, module components 
                                                 
 
29 http://www.mapequation.org/apps/MapGenerator.html 
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which exhibit network flows greater than 1% are indicated with red, green, blue, and purple 
tracks.  Note how these colors serve as aids to visually guide the eye to key module 
transitions along the flow diagram.  Module merges are identified by areas where colors 
overlap.  Additionally, Alluvial Flow diagrams render module graphs, which summarize 
the connections between key module components. 
 
 
 
Figure 48.  The Alluvial Flow diagram’s interpretation of the directed clinical trial space 
 
 
 ARRASTRA similarly visualizes the flow of information throughout the evolving 
network, but one key difference is noted.  Recall that the relationships between clinical 
trials is directed only by ascending time.  The directionality of edges is vital to 
understanding how past clinical trials influence the creation of new clinical trials.  Because 
of this, operationalizing flow with PageRank metrics, which considers edges of both 
directions (in-links and out-links), does not make sense for this specific application.  This 
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is the rationale for ARRASTRA to employ out-degree strength, which captures this specific 
type of temporal-directionality.  As a result, it may not be possible to directly compare 
ARRASTRA outputs with those provided by Alluvial Flow, however, intersections of key 
features will be discussed. 
Referring back to MetroMap visualization, note that much like Alluvia Flow, the 
flow starts with two initial clusters identified in 2000, as they represent the small areas of 
therapeutic solutions being tested at that time.  The entire flow of the network is calculated 
as the sum of the out-degree strength of all edges within the network.  As new clusters 
form, the overall flow is distributed proportionally to the total out-degree strength of the 
nodes within that cluster.  The metro “station” size indicates this value.  ARRASTRA also 
reduces the amount of overlapping edges by communicating only the key structural 
changes which occur over time, based on a specified threshold of the tracks responsible for 
a percentage of the overall flow (in this case, 10%).  This removes information about 
clusters which are responsible for small fractions of a percentage in the evolving network, 
which Alluvial Flow actively shows.  The opacity of metro tracks is set to 50%, in order to 
show where track intersections occur, similar to Alluvial Flow merging different colored 
tracks together.  Most notably is the added information provided by MetroMaps, with labels 
which indicate the nature of the metro “station” at a given time point.  These labels are 
derived from the top weighted concepts of the cluster summary graphs discussed 
previously, and provide context about the nature of each “station”. 
While features of the MetroMap in the context of the current state of the AD 
research space will be outlined in the previous chapter, some notable overlaps in 
visualization features are apparent.  These features take the form of identified key module 
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features identified by both frameworks.  Again, it should be iterated that the two solutions 
utilize different graph metrics to operationalize information flow within a graph, since 
ARRASTRA is only interested in one edge direction based on the logical progression of 
time.  These assessments can be acquired in Alluvial Flow by inspecting individual 
modules and noting the components which are specified as exhibiting the highest flow 
amounts.  Some interesting observations can be realized.  Alluvial modules were exported 
from the web application as plain-text map files, a modified Pajek format, which captures 
high-level module membership.  The intersection of identified trials between the Alluvial 
module exports and the top 50 clinical trials listed in the Appendix for both betweenness 
centrality and out-degree strength was assessed.  This metric measures the ability of 
ARRASTRA to recall the same clinical trials as identified by a third-party application.  
Based on out-degree strength, ARRASTRA and Alluvial Flow agree on 15 total clinical 
trials (recall 30%).  For betweenness centrality, there is an agreement in 18 total clinical 
trials (recall 36%).  By highlighting these examples, it can be demonstrated that both 
ARRASTRA and Alluvial Flow agree on some key features within the current clinical trial 
protocol dataset.  Table 5 and Table 8 capture these trials and compares their Alluvial 
module membership to the time periods in which they exhibited burst activity for out-
degree strength and betweenness centrality, respectively. 
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NCTID Start Year Alluvial Time Range Burst Time Range 
NCT00024531 2001 2001 2001-2009 
NCT00403520 2006 2006 2009-2012 
NCT00433121 2007 2007 2007-2009 
NCT00500500 2007 2007-2008 2009-2011 
NCT00715858 2008 2008 2008-2010 
NCT00594269 2008 2008-2011 2009-2011 
NCT00862940 2009 2009-2010 2010-2012 
NCT00916617 2009 2009-2012 2012-2015 
NCT00934050 2009 2009-2011 2012-2015 
NCT00955409 2008 2009 2012-2015 
NCT01000038 2009 2009 2014-2015 
NCT01117181 2010 2010-2011 2010-2011 
NCT01409694 2011 2011-2012 2011-2012 
NCT01565356 2012 2012 2012-2013 
NCT01624389 2012 2012 2013-2014 
 
Table 5. Trials which ARRASTRA and Alluvial Flow agree based on out-degree strength 
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NCTID Start Year Alluvial Time Range Burst Time Range 
NCT00211159 2005 2005 2005-2006 
NCT00249080 2005 2005 2005-2009 
NCT00106899 2005 2006 2005-2011 
NCT00403520 2006 2006 2006-2010 
NCT00287742 2006 2006 2006-2011 
NCT00409279 2006 2006-2008 2007-2010 
NCT00366288 2006 2006 2007-2011 
NCT00762411 2008 2008-2009 2008-2011 
NCT00706186 2008  2008 2009-2012 
NCT00715858 2008 2008 2010-2015 
NCT00842920 2009 2009 2009-2010 
NCT00862940 2009 2009-2010 2009-2011 
NCT00869817 2009 2009-2011 2012-2014 
NCT00991419 2009 2009-2010 2013-2014 
NCT01117181 2010 2010 2010-2011 
NCT01320527 2011 2012-2013 2013-2015 
NCT01565356 2012 2012 2012-2014 
NCT01962753 2013 2013-2014 2013-2014 
 
Table 6.  Trials which ARRASTRA and Alluvial Flow agree based on betweenness 
centrality 
 
 
Improvements can also be made to future iterations of the MetroMap, most of 
which stem from enhanced visual aspects of its current design.  Firstly, overlapping tracks 
caused by merges between clusters can be better represented visually, by concatenating 
colored tracks together, rather than stacking them on top of each other, forming a single 
newly-colored track.  Additionally, the use of curved lines, where changes in track 
direction occur, can be used to make smoother transitions between cluster states.  Sharp, 
angled changes in track directions which cut across other tracks is not entirely appealing 
to the eye.  Lastly, the edge-overlap issue is not entirely solved by first applying a force-
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atlas layout to the underlying graphs.  The interplay between minimizing edge overlap and 
appropriately arranging map tracks along the y-axis in the order in which the track first 
appears, is a considerable consideration that requires further work. These visual aspects of 
the MetroMap will require enhanced layout logic, for more appropriately arranging its 
components in the ways described. These changes would require considerable retooling of 
the MetroMap Javascript library, beyond what was already done for this research.  
Regardless, this aspect of the ARRASTRA framework introduces a novel approach to 
visualizing high-level changes in graph structure over time, using repurposed visual 
heuristics from transportation system maps, which were previously applied to visualizing 
faceted connections between individual news articles.  While MetroMaps establish an 
intriguing precedent for communicating changes in graphs over time, understanding how 
properties of individual tracks may predict the overall success of a theme, is perhaps an 
even more valuable capability for research organizations.  Next, the ability to assess the 
characteristics of individual tracks and their ability to “survive” over time, by supporting a 
robust collection of on-going clinical trials being tested over time, will be reviewed. 
 
Evaluating Framework Covariates Predicting Track Health 
 
 
 As discussed in the previous chapter, the final and truly translational piece of this 
dissertation involves identifying the role that novel graph metric endpoints exhibit in 
determining the overall success of identified temporal clusters.  Should the 
conceptualization of information diffusion through graphs of interconnected protocols be 
sufficient in explaining how ideas evolve in reality, these endpoints must be empirically 
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tested against unrelated performance endpoints supplied by ClinicalTrials.gov.  This is 
achieved through survival analyses, specifically Cox Proportional Hazard Models, which 
are used to determine the factors that are predictive in the time-to-event survival of some 
phenomenon – in this case, the primary completion of a clinical trial protocol.  Recall from 
Chapter 6, that the “health” of a track within a MetroMap is determined by the number of 
active and ongoing clinical trials within it.  A track which is quickly being abandoned by 
the research industry as a whole can be thought of as a high-level idea, such as a specific 
drug target, in which organizations are no longer actively engaging in.  These models 
ultimately cannot elaborate exactly why a track is not performing well, but rather elucidate 
on key variables which predict the outcome of that track.  This is the final step in 
demonstrating that graph-based approaches employed by ARRASTRA are well-founded 
and can articulate the nature of the phenomena under scrutiny as they occur within the real-
world. 
For this evaluation, six models were created and tested against variables imputed by 
ARRASTRA against the two clusters identified previously in Chapter 6.  These models are 
described below, and structured in such a way that tests combinations of covariates 
representing the three endpoints categories – graph, burst, and meta endpoints.  For 
example, the third model, graph.burst, can be expressed in R using the survival package 
with the following formula, similar in syntax to a linear regression model: Surv(time = 
offset_time, event = i_event_type) ~ mclust_id + ((g_between * is_bursty) + burst_dur). 
1. graph.between – the node’s betweenness centrality as the sole covariate in 
predicting time-to-event 
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2. graph.strength – the node’s out-degree strength as the sole covariate in predicting 
time-to-event 
3. graph.burst – the nature of a node’s burst activity, including whether the node 
exhibited burst behavior, the duration of the burst, as well as an interaction term 
between betweenness centrality and presence of burst activity within that metric 
4. trial.enroll – the number of successfully enrolled subjects as specified on 
ClinicalTrials.gov 
5. trial.phase – the most recent clinical trial phase, or the phase at time of event 
6. all – a linear combination of all terms described above 
 
Table 7 depicts the statistical significance of each covariate for the six models tested, 
with significant p-values satisfying p<0.05 italicized.  Interestingly, the graph and burst 
covariates imputed by ARRASTRA have stronger statistical significance in predicting the 
vitality of a cluster when compared to conventional endpoints derived from 
ClinicalTrials.gov metadata.  It would make sense, however, that tracks which contain 
clinical trials that either actively merge together new areas of thought (betweenness 
centrality), influence the design of future within-cluster clinical trials (out-degree strength), 
and/or do so in a way which exhibits extreme behavior (bursts), are more likely to promote 
the genesis of new ideas.  As a result, these influential nodes keep tracks “active” by serving 
as major conduits from which information flows and/or merges with previously disparate 
clusters of ideas.  This further suggest that certain clinical trials can have influence on 
future trajectories of the industry as a whole.  The cluster term was not significant in the 
case of trial phase and enrollment models, suggesting that regardless of the tracks being 
compared, these covariates are better indicators of survival overall, and there were no 
255 
 
significant differences between the two clusters being compared.  The importance of graph 
metrics, specifically out-degree strength, are further supported by the linear combination 
model of all available covariates.  One may argue that graph metrics perform as superior 
predictors of survival due to the fact that, since cluster membership was selected as the 
main independent covariate, those discrete groups may already contain information about 
the structure of the network utilizing those metrics which quantify node influence.  In order 
to account for this, recall that cluster membership was imputed against the final graph in 
the graph series, while the supplied graph metrics for each node originated from the graph 
slice at the time which a target event first occurred. 
 
Model Cluster G.Between G.OutStrength B.Burst B.Duration G.B.Ix C.Enrolled C.Phase 
graph.between 0.026 0.0044 NA NA NA NA NA NA 
graph.strength 0.0002 NA 0 NA NA NA NA NA 
graph.burst 0.024 0.001 NA 0.772 0.683 0.031 NA NA 
trial.enroll 0.161 NA NA NA NA NA 0.005 NA 
trial.phase 0.12 NA NA NA NA NA NA 0.044 
all 0.002 0.191 0 0.00023 0.305 NA 0.004 0.752 
 
 
Table 7. Covariate significance for six Proportional Hazard Models determining cluster 
health 
 
 These initial results are promising in two ways.  Firstly, data from clinical trials 
have not yet been expressed in terms of survival analyses before, especially enabled 
through the integration of novel graph-based endpoints derived from protocols available 
on ClinicalTrials.gov.  This novel approach has potential industry applications for assisting 
organizational strategies in the future.  These initial results suggest that a series of graph 
metrics can be used to actively monitor for “pivotal” trials in the future which could 
potentially spawn new areas of research.  The current state of ClinicalTrials.gov would 
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never afford such analyses, even with diligent manual inspection of a set of relevant 
documents.  Secondly, this exercise establishes an evaluation approach which demonstrates 
that graph metrics of importance do have the ability to translate real-world phenomena, 
based on the labeled time events which occur across the artifacts produced within the 
research domain being analyzed. 
Some shortcomings to the current implementation of this approach are noted, 
however, and should be considered for future iterations of this framework.  Firstly, this 
approach is appropriate for clusters of considerable size.  Recall that the “Terminated” 
event could not be reliably analyzed due to the fact that such events were sparse within 
clusters.  This suggests that clinical trial failures and/or enrollment issues aren’t isolated to 
one specific sub-therapeutic space, but is a challenge within the clinical research domain 
itself.  Additionally, the current implementation only allows for pair-wise comparison of 
two groups, and events indicated as binary values (“ongoing” vs. “completed”).  While 
multi-variate solutions do exist using linear mixed effects models, these will be considered 
for future iterations of the framework.  Regardless, this work undoubtedly serves as an 
initial and promising step for repurposing data from ClinicalTrials.gov in order to glean 
temporal insights from the plain-text protocols it currently contains. 
 To summarize, the ARRASTRA Toolkit allows users to seamlessly convert a 
collection of documents to a novel flow-based MetroMap diagram, which communicates 
key graph structural changes that occur over time.  The factors which influence these 
changes can be quantified through survival analyses including Cox Proportional Hazard 
Models.  While there are currently no established standards from which to directly and 
empirically test ARRASTRA outputs, this evaluation has systematically 
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compartmentalized the process in order to incrementally quantify and qualify the validity 
and utility of its outputs.  Firstly, the ability of ARRASTRA’s augmented mining process 
to detect subtle therapeutic themes was compared and contrasted to that of a conventional 
LDA mining routine.  Secondly, the qualitative traits of the resulting MetroMap were 
assessed against an Alluvial Flow diagram rendered by the same graph series data.  Lastly, 
the utility of the imputed graph metrics used to explain the survivability of tracks which 
span across the MetroMap are evaluated using survival analyses.  These three steps 
demonstrate the overall utility of the ARRASTRA framework in identifying clusters of 
similar clinical trial themes, visualizing the genesis and evolution of these themes through 
MetroMaps, and finally empirically testing the ability of graph metrics to predict the 
performance of MetroMap themes over time.  Indeed, this research sets an exciting 
precedent which establishes a cohesive framework for organizations to leverage in the 
future in order to better understand the role key clinical trials historically play within a 
therapeutic space. 
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Chapter 8: Translation of Novel Toolkit to Real World Observations 
 
 
A novel framework for analyzing trends in dynamic data, coined ARRASTRA, was 
developed and described in Chapters 5 and 6 by adopting, adapting and codifying a highly 
diverse assortment of visualization strategies including MetroMaps.  The primary goal of 
ARRASTRA is to provide data processing and visualization tools that articulate how 
information diffuses within a research domain as apparent through the dynamics of 
changing research fronts.  Having validated the ARRASTA framework output as described 
in Chapter 7, the logical culmination of this research is to translate findings acquired 
through MetroMap visualizations and its individual components, illustrating examples of 
real-world observations associated with past and current states of AD research.  Since 
MetroMaps infer the interplay between research fronts, it is appropriate to link these 
observations to sentinel events that have historically occurred within the space.  
Additionally, it is demonstrated that correlates can be identified between pivotal trials and 
conventional bibliometric endpoints such as total citation counts of the published literature 
they produce.  This serves as further evidence that the framework can identify pivotal 
clinical trials which translates to influential published research output for the general 
research community. Lastly, the foundation for future applications of the ARRASTRA 
framework for additional is briefly explored.  Closing remarks envisioning currently 
unexplored aspects of this dissertation will be briefly discussed with the intent of further 
spurring interest in this area of research. 
 
 
Discussion 
 
 
In order to narrate a cohesive story about how graph logic employed by 
ARRASTRA can ultimately translate to real-world phenomenon within a research space, 
results of the example run provided in Chapter 6 will now be discussed.  As has been 
established, graph clusters represent collections of similar ideas, referred to as research 
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fronts, which are encoded within collections of research artifacts such as clinical trial 
protocols.  Having established the rationale and validity of ARRASTRA’s technological 
foundations, it is appropriate to briefly translate key features of the rendered MetroMap to 
the state of AD research as it is currently understood, based on the comprehensive literature 
review in Chapter 1.  First, features of the MetroMap example discussed in Chapter 6 are 
reviewed and mapped back to key pieces of AD literature.  Second, clinical trials which 
exhibited burst activities within their betweenness centrality and/or out-degree strength are 
discussed based on their perceived importance with the research space. 
The rendered MetroMap discussed in the previous chapter also reveals some 
insights into the nature of the AD space.  For example, in 2002 a pink track is first formed, 
with the initial summary concepts “mood stabilizing” and “atypical antipsychotics”, 
suggesting a track which maps to clinical trials with secondary neurological condition 
themes.  This is later confirmed in 2005, where the track then merges with an orange track 
originating from 2000, resulting in a set of summary concepts including “confusion”, 
“delirium”, and “hallucinations”.  The next year, in 2006, the concept “risperidone” 
appears, furthering the theme of antipsychotics.  Also in 2002, a purple track appears 
containing the terms “Radiological Imaging” and “diagnostic”, supporting the notion that 
this track initially captures early clinical trials involved in studies for diagnosing AD based 
on imaging biomarkers.  In 2007, the track merges with a cluster indicating “Amyloid beta-
peptides”, suggesting a fusion of imaging approaches for observational purposes, to new 
applications for identifying efficacy of a therapeutic intervention based on its engagement 
with disease pathology.  The use of MetroMaps, with added contextual information, allows 
users to visually follow tracks of ideas, and not just inspect their interactions with other 
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clusters, but also how those events change the contextual summary concepts of those ideas 
across time. 
 The ARRASTRA framework operationalizes a therapeutic space as a dynamic set 
of research artifacts which potentially influence the genesis of new ideas over time.  This 
approach effectively filters large collections of protocols by identifying pivotal clinical 
trials, the year which those protocols first appeared, and the time periods in which they 
exhibited spikes in importance.  Recall that in the evaluation section of this work, the 
metrics which encode node importance were found to be highly significant covariates in 
predicting a survival function between two clusters.  The two graph metrics tested, 
betweenness centrality and out-degree strength, offer different explanations which define 
the nature of their importance.  Out-degree strength is a weighted summation of all out-
directed edges of a node.  Briefly, it is a metric which indicates how many clinical trials 
have been influenced in future periods of time. Betweenness centrality on the other hand 
quantifies the number of shortest paths which run through a node.  An appropriate 
translation of this metric identifies protocols which are central to a number of tightly 
interconnected clusters. This suggests that a node with a high betweenness centrality score 
unifies distinct clusters, and thus, is responsible for synergistically forming new research 
fronts.  One would expect a highly between protocol to exhibit a set of multi-faceted 
concepts, such as combining a novel therapeutic agent with an imaging modality.   
 In order to identify those protocols which were most influential over time, the 
Kleinberg burst algorithm was applied to each node in the graph series, focusing on the 
two metrics discussed previously.  The top 50 protocols for each metric were exported from 
the ARRASTRA environment, and are provided in Table 8 and Table 9 in the Appendix.  
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The two tables are briefly elaborated upon to demonstrate further insights that 
ARRASTRA can provide about the historical evolution of the AD space.  First, the out-
degree strength results include clinical trials which are suspected to serve as nodes which 
influence the formulation of similarly-themed clinical trials in the future.  The results 
provided in this result suggest a diverse range of topics ranging from symptomatic 
therapies, proposed disease-modifying therapies, therapies for secondary neurological 
symptoms such as antipsychotics, exercise and games, and imaging studies.  For example, 
the earliest study in this result set, “Genetic Studies in Alzheimer's Disease” 
(NCT00001235), serves as an initial basis for future genome-wide association studies – 
ones responsible for identifying the domain’s hallmark genetic risk factors such as APOE, 
TOMM40, CLU, and PSEN1 and PSNE2 for familial AD.  Other early studies include 
“Lipitor as a Treatment for Alzheimer's Disease” (NCT00024531), which tested an early 
hypothesis that lowering cholesterol with statins could delay the onset of AD symptoms.  
The use of vitamin extracts is also present in the protocol “Effect of EGb 761 on Patients 
With Mild to Moderate Alzheimer's Disease” (NCT00500500), which tests the therapeutic 
benefits of ginkgo biloba.  Symptomatic disease solutions are found in “The Effect of 
Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients” 
(NCT00255086) and “Long-term Safety and Efficacy of Galantamine in Alzheimer's 
Disease” (NCT00304629).  The surge of disease modifying therapeutic strategies can be 
noted at the appearance of two bapineuzumab clinical trials: “Bapineuzumab in Patients 
With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier/ApoE4 Carrier)” 
(NCT00574132 and NCT00575055).  The current state of AD disease-modifying therapies 
currently being evaluated, BACE inhibitors, is represented by the clinical trial “The Study 
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of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 1 
(BACE1)” (NCT01819545).  Comparative diagnostic imaging modalities are also present 
for accurately identifying disease pathology in the brain, in trials such as “Study of MRI 3 
Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and 
Comparison to the FDG-PET” (NCT02058043).  More recent trials, in accordance with 
the current state of AD research, have shifted focus to prodromal/early-stage AD.  
Specifically, the clinical trial “Measurement of Retinal Nerve Fiber Layer Thickness - a 
Biomarker for the Early Detection of Alzheimer's Disease?” (NCT02051244), seeks to 
identify pathology in the retina, which is predictive of the presence of early AD.  This area 
of research is critical for non-invasive and cost-effective screening methods for next-
generation clinical trials which propose to intercept the disease before it progresses.  
Interestingly, none of the major observational studies such as ADNI, AIBL or DIAN appear 
in these results, as they are major observational research initiatives which have influenced 
research based on the fact that they are the premier longitudinal observation studies within 
the space.  Instead, one must look to the betweenness centrality results in order to better 
understand this observation. 
Betweenness centrality results provide additional insights about the AD clinical 
trial space.  Notably, the official ClinicalTrials.gov entry for the observational ADNI 
longitudinal does in fact appear, starting in 2005: “ADNI: Alzheimer's Disease 
Neuroimaging Initiative” (NCT00106899).  Since ADNI contains a comprehensive set of 
observational arms involving the collection of biospecimens (blood, cerebral spinal fluid), 
imaging assessments (MRI, PiB-PET, FDG-PET, etc.), and cognitive assessments, it has 
clear potential to unite multiple areas of research which are representative of these distinct 
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themes.  Additionally, an observational trial of similar scope to ADNI, the Dominantly 
Inherited Alzheimer’s Disease Network (DIAN), also appears in this dataset: “Dominantly 
Inherited Alzheimer Network (DIAN)” (NCT00869817).  Another clinical trial, 
“Hippocampus Study: Comparative Effect of Donepezil 10 mg/d and Placebo on Clinical 
and Radiological” (NCT00403520), evaluates the efficacy of a therapeutic intervention 
against its impact on an imaging modality, again merging two areas of research together to 
form a new idea.  Some clinical trials test the efficacy of combinations of multiple drugs 
“Donepezil and Memantine in Moderate to Severe Alzheimer's Disease” (NCT00866060), 
which has the potential of linking clusters representing those respective trials.  Another 
example links depression, AD disease pathology, and PET imaging in the trial “Depression 
in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives 
Symptoms and Amyloid Plaques (ASAP)” (NCT01962753).  Additionally, there was an 
intersection of 10 clinical trials which appeared in both datasets, and are highlighted in 
each table: NCT00001480, NCT00182897, NCT00403520, NCT00715858, 
NCT00594568, NCT00753662, NCT00862940, NCT00904683, NCT01117181, and 
NCT01565356.   
Finally, one additional analysis was conducted which sought to quantify the 
relationship between the imputed graph important metrics and the number of resulting total 
citations the resulting literature received, as mapped by PubMed entries within each 
protocol entry in ClinicalTrials.gov.  Again, it should be stressed that protocol metadata is 
not always accurately maintained in a timely fashion.  This analysis ultimately relies on 
the quality of the provided metadata for each protocol.  For each clinical trial entry 
identified as exhibiting burst behavior, an additional dataset was compiled which captured 
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the citation count of the highest published work produced by that trial.  ClinicalTrials.gov 
specifies an optional “Publication” field which links these pieces of literature to PubMed 
entries.  Of these entries, Google was used to determine the citation count of the highest 
cited work for each protocol.  The hypothesis is that importance metrics will exhibit some 
correlation with disparate measurements of influence acquired elsewhere – in this case, 
citations of published outputs.  Indeed, it would make intuitive sense to assume that an 
identified “pivotal” clinical trial would also be influential within the context of 
bibliometrics based on the publications it produced.  Table 10 and Table 11 in the 
Appendix capture these citation counts for out-degree strength and betweenness centrality 
respectively.  PubMed ID, citation count, and an additional “Status” column captures the 
data for this analysis.  The status column indicates the current status of the clinical trial, 
and is used to identify possible false-positives in the results.  For example, an identified 
clinical trial which does not indicate any published literature and was terminated 
prematurely is clearly not characteristic of an “influential” node.  To reiterate, this does not 
definitively mean that the protocol did not yield published works – just that none has been 
specified in the ClincialTrial.gov entry.  Indeed, the fact that protocols are identified which 
do have this field populated is an achievement in itself, since less than half of the entries 
in the dataset do not provide any mappings to PubMed. 
For the out-degree strength metric, the identified citation counts were highly 
variable (355 ± 779 citations).  Of the trials which did not receive any citations, 6% were 
still ongoing, while 12% were marked as having an “Unknown” status, which the 
framework assumes as “Terminated” due to lack of better information about the trial’s final 
status.  Betweenness strength was highly variable (274 ± 299 citations) as well.  Of the 
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trials which did not receive any citations, 20% were listed as “Ongoing”, 8% were listed 
as “Terminated”, and 10% were listed as “Unknown”.  Correlations between these graph 
metrics and citation counts were also assessed.  Interestingly, out-degree strength 
correlated well with associated citation counts (r=0.59, p=0.004).  Betweenness centrality, 
however, performed poorly for this analysis (r=0.03, p=0.89).  This could be attributed to 
the fact that a higher percentage of trials were more recent and still ongoing, and did not 
yet yield any published works.  It’s not unbelievable that an ongoing trial could influence 
the genesis of new trials if it is supported by preceding basic research that is highly regarded 
by the industry as a whole.  In addition, clinical trials marked as “Unknown”, while 
considered “Terminated” by the framework, may not actually be terminated.  Indeed, 
clinical trials marked as “Unknown” have produced publications in the past.  This suggests 
that the criterion for identifying “false-positive” results is much more stringent than what 
is to be expected in reality.  It is promising to further validate at least one metric with an 
additional endpoint obtained from a disparate source, by demonstrating its utility in 
accurately translating research points from other points of reference, such as citation 
counts. 
While the insights which the ARRASTRA framework reveal, once translated to 
current research knowledge as expressed within scholarly literature is undoubtedly a novel 
improvement to the current capabilities of clinical trial protocol repositories, there are other 
areas in which the outlined solution can be extended and/or improved upon.  As with all 
research of merit, its current state inspires new ideas and possibilities for future exploration.  
Lastly, additional areas of improvements which were not implemented due to either time 
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or resource constrains is reviewed and discussed with the intention of spawning new 
interests for prospective doctoral students.  
 
 
Future Directions 
 
 
Platform Extension 
 
 
The framework presented allows users to programmatically mine and visualize 
large collections of temporally-ordered documents in novel ways, specifically as the 
subject of this dissertation, clinical trial protocols.  The specific solution fills a major 
functionality gap that has been apparent in ClinicalTrials.gov for years.  As with all 
valuable research, there are areas where the work can be expanded upon to further improve 
the solution, as well as apply to new applications.  Firstly, it should be stressed that the 
ARRASTRA Toolkit is currently an API that serves as a back-end data processing 
component.  As is evident by the extensive API examples in Chapter 6, these functions 
give users the ability to programmatically configure and control the mining process.  
However, in order to gain wider acceptance from the research community, a front-end 
interface would be desired, specifically for researchers with medical backgrounds who are 
unfamiliar with computer programming.  While Python was chosen as the platform to build 
ARRASTRA due to its excellent library support and active bioinformatics communities, 
its design was carefully considered for additional extensions by adopting support for 
numerous web-based standards.  As a result, the ARRASTRA libraries can be integrated 
directly with REST-based frameworks such as Flask or Django, which provide web 
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wrappers that encapsulate backend ARRASTRA logic.  A light-weight proof-of-concept 
web interface has been developed, as presented previously in Chapter 6, which allows users 
to build Titan queries and visualize results.  Additional user interface features would 
include form fields which allow users to tune ARRASTRA client-side configuration 
settings and serve as an integrated and interactive dashboard for all output visualizations. 
Secondly, as has been mentioned in the previous section, the original intent of this 
thesis was to additionally understand the impacts which evolving research fronts have on 
real-world prospective patient populations.  This is the rationale behind accurately 
capturing numeric values for biological measurements and assessment scales during the 
NLP step of the ARRASTRA Miner process in order to map those values back to endpoints 
captured in, for example, an observational study such as ADNI.  The rationale is that 
changes in research fronts reflects some knowledge which either directly impact traits of a 
disease population, or is influenced by some biomedical trait or quality within targeted 
disease populations.  Recall from Chapter 1 that current AD research has now shifted 
towards preventing the proliferation of amyloid plaques in patients not yet exhibiting 
symptoms of the disease.  This has clear impacts on recruitment patient populations for 
future disease-intercepting AD clinical trials.  However, well-documented biases in the 
ADNI dataset including those in education and APOE status suggest populations which are 
not indicative of real-world populations.  More appropriate datasets used for this 
comparison may be found in electronic health records (EHRs) obtained at points of clinical 
care.  However, it is appropriate to outline how these features could be implemented into 
future iterations of the ARRASTRA platform. 
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Recently, initial research has been conducted in this area from Dr. Weng’s 
laboratory at Columbia University.  This work aims to quantify the degree of external 
validity reflected within a clinical trial design eligibility criteria compared to target disease 
populations from EHRs [237].  In this work, Weng et al. use Type 2 Diabetes as an 
example, focusing only on age and HbA1C levels in 1,761 applicable clinical trials against 
outpatient EHR records from Columbia University Medical Center.  Patient distributions 
were imputed for age and HbA1C separately, for both the clinical trial and clinic 
populations.  For these distributions, the x-axis represents discrete bins of increasing 
endpoint quantity ranges.  For example, the x-axis of an age range from 20 to 30, inclusive, 
would be binned as (20,21], (21,22], (22,23], (23,24], (24,25], (25,26], (26,27], (27,28], 
(28,29], (29,30).  A clinical trial with an age range of 20 – 23 would be added to the first 
four bins, since they satisfy this range of values.  The y-axis represents the percentage of 
clinical trials and patients who would fall within that specific bin.  Most simply yet 
effectively, visually superimposing the clinical trial and real-world patient distributions 
together allows for qualifying the amount of agreement a set of trial protocol eligibility 
criterion have with real-world clinical measurements based on the degree of overlap 
between distributions.  The Generalizability Index for Study Traits (GIST) was 
developed as a metric to quantify the overlaps in patient population distributions as a means 
to operationalize the external validity of clinical trials.  This is depicted below in Equation 
16 where T is the total number of clinical trials, P is the total number of patients, ilow and 
ihigh are the minimum and maximum range of values for the endpoint quantity being 
assessed, and 𝐺𝐼𝑆𝑇 ∈ [0,1] where 0 indicates no intersection between populations, and 1 
indicates perfect intersection.  Weng et al. also sub-categorizes the trial distribution into 
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distinct phases to identify generalizability in patient distributions based on different facets 
of clinical trials. 
 
 
𝐺𝐼𝑆𝑇 = ∑
∑ 𝐼(𝑖𝑙𝑜𝑤 <= 𝑤𝑗 <= 𝑖ℎ𝑖𝑔ℎ)
𝑇
𝑗=1
𝑇
𝑁
𝑖=1
×
∑ 𝐼(𝑖𝑙𝑜𝑤 <= 𝑦𝑘 <= 𝑖ℎ𝑖𝑔ℎ)
𝑃
𝑘=1
𝑃
 
Equation 16.  The Generalizability Index for Study Traits (GIST) metric 
 
 
While the approach outlined in this work focuses on a static set of basic 
demographic and clinical endpoints, Weng et al. sets the stage for future enhancements in 
this area, with a general GIST framework which makes quantifying the external validity of 
clinical trial eligibility criteria possible.  It is envisioned that the GIST framework be 
automated in future iterations of the MetroMaps, where clinical trials within tracks of 
interest be automatically compared to the trials contained within a cluster at a given time 
period.  It may be useful to include a GIST covariate to the current survival models, in 
order to understand the role protocol generalizability plays in determining the fate of 
MetroMap tracks.  As mentioned previously, this will unfortunately take considerable 
amounts of work to accomplish, and rightly a comprehensive study on its own.  However, 
the current solution provides a sufficient platform from which these capabilities can be 
extended for future research, especially since the current solution has extracted 
demographic and clinical endpoint value ranges as discussed in Chapter 3.  Additionally, 
Weng et al. compare a single variable in each distribution.  In expanded iterations of this 
solution, interesting combinations of criteria can be combined through a bitwise 
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conjunction (ANDed) in order to form intersections of clinical criteria for further 
population refinement. 
 
 
New Applications 
 
 
Lastly, there are other potential applications for ARRASTRA beyond text-mining 
which are actively being explored.  One example involves understanding gene-gene 
interactions within disease pathways.  The ARRASTRA framework has also amassed and 
integrated gene information relating to disease and biological processes (i.e. 
GeneOntology), as well as direct gene interactions (i.e. bioGRID).  It is anticipated that this 
multi-faceted set of data can assist in detecting whether a candidate set of genes from, for 
example, the results of a genome-wide Association Study (GWAS) is specifically enriched 
for any particular underlying disease process.  Gremlin-based querying allows users to 
intuitively pose gene-gene interaction queries using its path-based syntax to reveal, for 
example, the shortest paths which connects a pair of genes across a massive graph of gene 
relationships.  While exploring viable paths between two candidate genes may provide 
some interesting and serendipitous insights, the process becomes more challenging when 
attempting to compare a larger set of genes.  Much like multi-faceted zone-based 
information can be used to construct a manifold and then build a graph based on nearest 
clinical trial protocols, the same can be applied to genetic data.  The rationale for this 
approach is that a given set of seed genes may provide enrichment for specific biological 
pathways that when altered or disrupted, lead to disease.  Figure 49 depicts this extended 
application of ARRASTRA for constructing an expanded gene interaction manifold of 
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eight key seed genes involved in the RAS pathway and implicated in colorectal cancer, as 
inferred and validated by Olsen et al. [238].  The initial dataset was seeded with the same 
eight genes listed in the Olsen manuscript: CDK5, HRAS, MAP2K1, MAP2K2, MAPK1, 
MAPK3, NGFR, and RAF1.  Figure 50 depicts the subsequent undirected gene-gene 
interaction network constructed from this manifold. 
 
 
 
Figure 49.  The gene manifold reveals clusters of genes implicated in colorectal cancer 
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Figure 50.  The resulting gene-gene interaction graph 
 
 
While these types of interaction relationships do not suggest temporal directionality 
which is the hallmark feature of ARRASTA MetroMaps, it is anticipated in the future that 
other types of gene data can afford such directionality by analyzing longitudinal gene 
expression profiles of patients as they progress with a certain disease.  While this type of 
longitudinal data is not widely available, The Allen Brain Atlas has published a 
“Developing Human Brain Tissue Gene Expression Profile” microarray dataset, which 
measures expression levels in 26 different brain regions at 27 different points of time within 
subjects of varying ages [239].  It is envisioned that in the future, MetroMaps may reveal 
key changes in high-level genetic expression themes within specific brain structures as the 
brain develops. 
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One additional example uses DBPedia, the SPARQL query endpoint for Wikipedia, 
which allows users to directly interrogate its page and semantically-enhanced link structure 
to generate statements regarding sets of related entities.  Users can compile a set of 
statements regarding data about entities relating to virtually any topic.  Take, for example, 
the topic of classic video games, each of which are expressed as their individual page and 
linked to related wiki pages through labeled hyperlinks.  DBPedia can be queried, which 
returns a set of statements that describe this link structure in the form of triple statements.  
Supplemental literal data provided by DBPedia such as timestamps which denote release 
dates can also serve as temporal information which stratify entity similarities along 
MetroMap tracks.  Visualizing the temporal evolution of popular cultural topics, such as 
video games, by automatically generating interactive MetroMaps from pre-existing data 
sources would undoubtedly be a welcomed tool spanning across diverse user communities, 
giving expanded visibility and applicability to the ARRASTRA Toolkit. 
 Overall, refactoring and development of the ARRASTRA framework will continue 
after the successful completion of this dissertation defense.  It will be released under GPLv3 
open source software license, hosted on GitHub, and produced through the joint 
collaboration between Drexel CCI and The Andrew W. Mellon Foundation (iFellows).  
Any prospective doctoral student at Drexel CCI expressing interest in the synergies 
between bioinformatics and/or clinical research and data mining and/or information 
visualization is encouraged to generate dissertation topics further extending the principles 
outlined in this dissertation. 
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Conclusion 
 
  
In closing, a framework was developed and tested which aims to span the gap 
between natural sciences and information sciences, by developing visual information 
landscapes which succinctly describe how research domains evolve over time.  It is 
contended that the contributions of this dissertation research are three-fold.  The first 
contribution, and arguably the most tangible one to the overall clinical research 
community, is providing a comprehensive toolkit for mining collections of protocols 
hosted on ClinicalTrials.gov, as well as the underlying data structures which allow for 
querying the data at finer granularities.  The second contribution is the creation of an 
extensible graph-based mining framework for brief pieces of biomedical text, specifically 
applied to clinical trial protocols.  The third is an evaluation framework which quantifies 
the events which occur within these graphs in two ways: first, by expressing node influence 
as streams of “bursty” graph metrics, and second by integrating imputed graph metrics and 
protocol metadata for Kaplan-Meier and Cox Proportional Hazard Model survival 
analyses. 
A vital functionality gap for clinical trial research has been addressed by extending 
the capabilities of clinical trial protocol repositories.  ClinicalTrials.gov is a vital resource 
for clinical research due to the fact that filing a new trial in the United States is mandatory 
in the interests of regulatory transparency.  As a result, the timestamped documents 
represent the active “pulse”, not just as the industry as a whole, but also for specific 
therapeutic areas.  Unfortunately, in light of this mandatory requirement, ClinicalTrials.gov 
is oft maligned for a plethora of reasons, particularly stemming from its plain-text search 
and full-document retrieval features and its dearth of descriptive data outlining topics such 
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as drug mechanisms.  This dissertation addresses this gap, apparent for nearly two decades, 
by expressing coarse-grained plain-text data at the document field level as a series of 
statements expressing the relationships between trial design and biomedical concepts, as 
well as metadata which quantify/qualify them.  This data format can be naturally expressed 
as a massive directed labeled graph, persisted by the distributed graph storage technology 
Titan, from which interesting path and property-based queries can be issued using the 
functional query language Gremlin.   
While these queries can provide some insightful aspects about clinical trial design, 
the overall goal of this dissertation is to better understand how to quantify and qualify the 
diffusion of information throughout a therapeutic area, specifically AD, and how this 
shapes bodies of related works known as research fronts.  This too is an added feature for 
enhancing the capabilities of ClinicalTrials.gov, which can currently only analyze 
protocols at the individual document level.  Indeed, manually interrogating clinical trial 
protocols from a corpus does not afford a great deal of contextual information about how 
it fits into the overall research landscape.  The notion that documents contain latent 
thematic information based on their textual content can be extended to account for how 
those themes emerge and changes over time.   
In summary, the ARRASTRA Toolkit was devised as a result, which exposes 
comprehensive API functionality for querying, processing, and visualizing clinical trials 
based on biomedical concepts contained within multi-faceted protocol zones.  Due to the 
brief plain-text nature of the current AD clinical trial corpus, a novel data mining routine 
which employs a sparse variant of NMF and non-linear manifold learning methods found 
in t-SNE variants has been devised.  The resulting manifold is then constructed to a 
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temporally-directed graph using an n-nearest neighbors search approach and optionally 
pruning the graph to remove redundant and spurious edges.  This homogeneous source 
graph, which contains all available clinical trial protocols across all years, is then 
incrementally sub-set by year to form a collection of graphs, or a graph series.  Using 
parameter-less random-walk clustering routines such as Walktrap and Infomap over each 
graph within the graph series, the dynamics of node communities can be tracked and 
mapped over time.  In order to properly communicate these key changes in graph structures 
over time, a MetroMap visualization was developed.  MetroMaps depict how clusters, in 
this case conceptualized as individual research fronts, form and fuse with other fronts to 
generate new ideas and consequently new areas of research.  With this approach, a 
collection of timestamped plain-text documents can be analyzed and processed in such a 
way that allows for descriptive, summative, high-level visualizations. 
It is anticipated that such data mining approaches can assist clinical researchers in 
better understanding how a given therapeutic area has evolved to its current state, by 
temporally arranging protocol documents in intuitive and meaningful ways based on their 
textual content.  A secondary side effect, it is hoped, is that this work will allow researchers 
to realize the hidden potential of clinical trial protocol repositories, thus leading to better 
annotated and curated sources of data.  Indeed, the area of clinical research applied to key 
therapeutic areas such as Alzheimer’s Disease is complex, where the origins of current gold 
standards are not always entirely understood from historical perspectives.  It is vital that 
the clinical research community rethink how old paradigms be challenged when faced with 
new information, such that novel therapeutic solutions can be brought to market in a timely 
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manner.  After all, the reality is that for diseases such as Alzheimer’s disease, the following 
mantra is more relevant today than ever before – “patients are waiting”. 
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Appendices 
 
Appendix A: Full Titan Graph Schema Script 
 
 
 
import com.thinkaurelius.titan.core.TitanFactory; 
import com.tinkerpop.blueprints.Vertex; 
import com.tinkerpop.blueprints.Edge; 
import com.thinkaurelius.titan.core.schema.Mapping; 
import com.thinkaurelius.titan.core.attribute.Text.CONTAINS; 
 
// Initialize graph and management system 
g = com.thinkaurelius.titan.core.TitanFactory.open('./config/titan-cassandra-
es.properties'); 
mgmt = g.getManagementSystem(); 
 
// WARNING: CLEARS KEYSTORE 
// Note: To fully drop keystore - 'DROP keyspace titan;' on Cassandra CLI 
// import com.thinkaurelius.titan.core.util.* 
// com.thinkaurelius.titan.core.util.TitanCleanup().clear(g); 
// config = g.getConfiguration(); 
// config.getBackend().clearStorage(); 
// g.shutdown(); 
 
// Unique identifiers 
mgmt.buildIndex('uri_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makePro
pertyKey('uri').dataType(String.class).make()).unique().buildCompositeIndex(); 
mgmt.buildIndex('nctid_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makeP
ropertyKey('nctid').dataType(String.class).make()).unique().buildCompositeIndex(); 
mgmt.buildIndex('pmid_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makePr
opertyKey('pmid').dataType(String.class).make()).unique().buildCompositeIndex(); 
mgmt.buildIndex('accession_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.m
akePropertyKey('accession').dataType(String.class).make()).unique().buildCompositeIn
dex(); 
 
// Schema-based metadata fields 
mgmt.buildIndex('schema_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.make
PropertyKey('schema').dataType(String.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('type_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makePr
opertyKey('type').dataType(String.class).make()).buildCompositeIndex(); 
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mgmt.buildIndex('source_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.make
PropertyKey('source').dataType(String.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('origin_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.make
PropertyKey('origin').dataType(String.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('date_created_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgm
t.makePropertyKey('date_created').dataType(Long.class).make()).buildCompositeIndex()
; 
mgmt.buildIndex('date_modified_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mg
mt.makePropertyKey('date_modified').dataType(Long.class).make()).buildCompositeIndex
(); 
 
// General node label fields (full-text search) 
mgmt.buildIndex('name_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makePr
opertyKey('name').dataType(String.class).make(),com.thinkaurelius.titan.core.schema.
Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('description_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt
.makePropertyKey('description').dataType(String.class).make(),com.thinkaurelius.tita
n.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('synonym_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.mak
ePropertyKey('synonym').dataType(String.class).make(),com.thinkaurelius.titan.core.s
chema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
 
// General edge weight fields 
mgmt.buildIndex('similarity_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.ma
kePropertyKey('similarity').dataType(Double.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('weight_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.makePr
opertyKey('weight').dataType(Double.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('strength_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.make
PropertyKey('strength').dataType(Double.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('certainty_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.mak
ePropertyKey('certainty').dataType(Double.class).make()).buildCompositeIndex(); 
 
// CT specific fields – Textual 
mgmt.buildIndex('brief_title_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt
.makePropertyKey('brief_title').dataType(String.class).make(),com.thinkaurelius.tita
n.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('brief_summary_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mg
mt.makePropertyKey('brief_summary').dataType(String.class).make(),com.thinkaurelius.
titan.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('criteria_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.ma
kePropertyKey('criteria').dataType(String.class).make(),com.thinkaurelius.titan.core
.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
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mgmt.buildIndex('study_design_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgm
t.makePropertyKey('study_design').dataType(String.class).make(),com.thinkaurelius.ti
tan.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('outcomes_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.ma
kePropertyKey('outcomes').dataType(String.class).make(),com.thinkaurelius.titan.core
.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('study_type_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.
makePropertyKey('study_type').dataType(String.class).make(),com.thinkaurelius.titan.
core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('gender_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.make
PropertyKey('gender').dataType(String.class).make(),com.thinkaurelius.titan.core.sch
ema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('interventions_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mg
mt.makePropertyKey('interventions').dataType(String.class).make(),com.thinkaurelius.
titan.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('phase_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makeP
ropertyKey('phase').dataType(String.class).make(),com.thinkaurelius.titan.core.schem
a.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('overall_status_idx',com.tinkerpop.blueprints.Vertex.class).addKey(m
gmt.makePropertyKey('overall_status').dataType(String.class).make(),com.thinkaureliu
s.titan.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('locations_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.m
akePropertyKey('locations').dataType(String.class).make(),com.thinkaurelius.titan.co
re.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('sponsors_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.ma
kePropertyKey('sponsors').dataType(String.class).make(),com.thinkaurelius.titan.core
.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('city_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makePr
opertyKey('city').dataType(String.class).make(),com.thinkaurelius.titan.core.schema.
Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('state_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makeP
ropertyKey('state').dataType(String.class).make(),com.thinkaurelius.titan.core.schem
a.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('country_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.mak
ePropertyKey('country').dataType(String.class).make(),com.thinkaurelius.titan.core.s
chema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex("geo_loc_idx",com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.mak
ePropertyKey("geo_loc").dataType(com.thinkaurelius.titan.core.attribute.Geoshape.cla
ss).make()).buildMixedIndex("search"); 
 
// CT specific fields - Numerical 
mgmt.buildIndex('enrollment_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.ma
kePropertyKey('enrollment').dataType(Integer.class).make()).buildCompositeIndex(); 
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mgmt.buildIndex('min_age_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.makeP
ropertyKey('min_age').dataType(Integer.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('max_age_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.makeP
ropertyKey('max_age').dataType(Integer.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('referencestart_date_idx',com.tinkerpop.blueprints.Edge.class).addKe
y(mgmt.makePropertyKey('referencestart_date').dataType(Long.class).make()).buildComp
ositeIndex(); 
mgmt.buildIndex('lastchanged_date_idx',com.tinkerpop.blueprints.Edge.class).addKey(m
gmt.makePropertyKey('lastchanged_date').dataType(Long.class).make()).buildCompositeI
ndex(); 
mgmt.buildIndex('start_date_idx',com.tinkerpop.blueprints.Edge.class).addKey(mgmt.ma
kePropertyKey('start_date').dataType(Long.class).make()).buildCompositeIndex(); 
mgmt.buildIndex('verification_date_idx',com.tinkerpop.blueprints.Edge.class).addKey(
mgmt.makePropertyKey('verification_date').dataType(Long.class).make()).buildComposit
eIndex(); 
mgmt.buildIndex('firstreceived_results_date_idx',com.tinkerpop.blueprints.Edge.class
).addKey(mgmt.makePropertyKey('firstreceived_results_date').dataType(Long.class).mak
e()).buildCompositeIndex(); 
mgmt.buildIndex('firstreceived_date_idx',com.tinkerpop.blueprints.Edge.class).addKey
(mgmt.makePropertyKey('firstreceived_date').dataType(Long.class).make()).buildCompos
iteIndex(); 
mgmt.buildIndex('primarycompletion_date_idx',com.tinkerpop.blueprints.Edge.class).ad
dKey(mgmt.makePropertyKey('primarycompletion_date').dataType(Long.class).make()).bui
ldCompositeIndex(); 
mgmt.buildIndex('completion_date_idx',com.tinkerpop.blueprints.Edge.class).addKey(mg
mt.makePropertyKey('completion_date').dataType(Long.class).make()).buildCompositeInd
ex(); 
 
// CT edge-based properties 
mgmt.buildIndex('value_restriction_idx',com.tinkerpop.blueprints.Edge.class).addKey(
mgmt.makePropertyKey('value_restriction').dataType(Double.class).make()).buildCompos
iteIndex(); 
mgmt.buildIndex('value_restriction_min_idx',com.tinkerpop.blueprints.Edge.class).add
Key(mgmt.makePropertyKey('value_restriction_min').dataType(Double.class).make()).bui
ldCompositeIndex(); 
mgmt.buildIndex('value_restriction_max_idx',com.tinkerpop.blueprints.Edge.class).add
Key(mgmt.makePropertyKey('value_restriction_max').dataType(Double.class).make()).bui
ldCompositeIndex(); 
mgmt.buildIndex('value_restriction_stype_idx',com.tinkerpop.blueprints.Edge.class).a
ddKey(mgmt.makePropertyKey('value_restriction_stype').dataType(String.class).make())
.buildCompositeIndex(); 
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mgmt.buildIndex('value_restriction_description_idx',com.tinkerpop.blueprints.Edge.cl
ass).addKey(mgmt.makePropertyKey('value_restriction_description').dataType(Double.cl
ass).make()).buildCompositeIndex(); 
 
// PubMed node-based properties 
mgmt.buildIndex('title_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.makeP
ropertyKey('title').dataType(String.class).make(),com.thinkaurelius.titan.core.schem
a.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('abstract_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.ma
kePropertyKey('abstract').dataType(String.class).make(),com.thinkaurelius.titan.core
.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('primary_authors_idx',com.tinkerpop.blueprints.Vertex.class).addKey(
mgmt.makePropertyKey('primary_authors').dataType(String.class).make(),com.thinkaurel
ius.titan.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('published_date_idx',com.tinkerpop.blueprints.Vertex.class).addKey(m
gmt.makePropertyKey('published_date').dataType(String.class).make(),com.thinkaureliu
s.titan.core.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('journal_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.mak
ePropertyKey('journal').dataType(String.class).make(),com.thinkaurelius.titan.core.s
chema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
mgmt.buildIndex('citation_idx',com.tinkerpop.blueprints.Vertex.class).addKey(mgmt.ma
kePropertyKey('citation').dataType(String.class).make(),com.thinkaurelius.titan.core
.schema.Mapping.TEXT.getParameter()).buildMixedIndex("search"); 
 
mgmt.commit(); 
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Appendix B: Full ARRASTRA Toolkit Example 
 
 
 
 
from arrastra import SERVER_CFG, URI_EDGE_LABELS, G_METRICS, G_CLUSTERS, NODE_WEIGHT 
from arrastra.config import ArrastraConfig as cfg  
from arrastra.data import asymspace2c as ar 
from arrastra.data.utils import DataUtils 
from arrastra.web import titangraph as tg 
from arrastra.graph import metro 
from arrastra.ui import treestyle as ts, graphstyle as gs, dashboard 
 
#- Link properties to include 
link_types = [URI_EDGE_LABELS['CT_DESCRIBES'], URI_EDGE_LABELS['CT_SUMMARIZES'], 
URI_EDGE_LABELS['CT_HASCONDITION'], URI_EDGE_LABELS['CT_HASARM'], 
URI_EDGE_LABELS['CT_MAIN_THERAPY']] 
follow_links = [URI_EDGE_LABELS['RDFS_SUBCLASS'], URI_EDGE_LABELS['RDF_TYPE'], 
URI_EDGE_LABELS['OWL_SAMEAS'], URI_EDGE_LABELS['CT_DRUG_TARGET']] 
 
#- Load client-side configuration file 
config = cfg.ArrastraConfig().get_configuration("./config/ct31_v1.json") 
 
#- Load configuration file, initialize Titan object 
titan = tg.TitanGraph(config=SERVER_CFG) 
 
#- Query Titan 
graph = titan.expand_by_property(search_field='uri', to_follow=link_types, 
return_property='uri', vfilter=('type','clinical_trial'))['results'] 
 
#- Collect all biomedical concepts of the graph, query, and expand 
to_expand = sorted(list(set([c[2] for c in graph]))) 
expanded = titan.expand_by_field(uris=to_expand, to_follow=follow_links)['results'] 
new_graph = DataUtils.merge(x=graph, y=expanded, 
mappings=(URI_EDGE_LABELS['CT_MAIN_THERAPY'],URI_EDGE_LABELS['CT_DESCRIBES'])) 
 
#- Retrieve node metadata 
all_metadata = titan.get_metadata(uris=list(set([s[0] for s in graph])), search_field= 
'uri')['results'] 
ct_metadata = DataUtils.filter_dict(d=all_metadata, 
to_keep=['uri','nctid','brief_title','firstreceived_date','enrollment','overall_status']) 
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#- Generate feature space and impute document term weights 
aspace = ar.AsymSpace2(statements=new_graph, metadata=ct_metadata, config=config) 
aspace._node_method = NODE_WEIGHT.ATF_IDF 
aspace.init() 
aspace.generate_vector_space() 
 
#- Generate feature space and impute document term weights 
aspace.factorize_bhtsne() 
 
#- Native scatterplot 
aspace.scatter_plot(aspace._ldata, labels=aspace.get_labels(), category_labels=None, 
color_map="Paired", level=1, label_categories=False, highlight=None, 
highlight_only=False, lbl_combine=False) 
 
#- Upload interactive scatterplot to Plotly 
aspace.plotly_scatter_plot(aspace._ldata, aspace.get_labels(), scatter_categories, 
level=1, color_map="Spectral", alpha=0.5, export_name='ct-plot') 
 
 
 
#- Native dendrogram with cluster information 
clusts = aspace.dendrogram(aspace._ldata, labels=aspace.get_labels(lbl_field='nctid'), 
csize=10, method='complete', metric='euclidean') 
 
#- Generate a graph of trials, filter graph based on GLoSS 
aspace._efilter, aspace._nneighbors, aspace._sig_level = 0.55, 10, 0.05 
graphs = aspace.to_directed_graphseries(labels=aspace.get_labels(lbl_field='uri'), 
groups=None, years=[d['firstreceived_date'] for d in ct_metadata], prune=True) 
#- Bind metadata to network nodes 
graphs[2015].bind_data_dict(dict=ct_metadata, dict_idx_name='uri', idx_name='label', 
pidx_names=['glabel','overall_status']) 
#- Remove detached nodes 
disconnected_idx = graphs[2015].remove_disconnected_nodes() 
#- Refresh graph after removing detached nodes 
aspace.update_labels_and_categories(disconnected_idx) 
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#- Extract cluster information from all cluster and generate MetroMap 
cluster_details = aspace.graph_summary(ntop=3, membership=G_CLUSTERS.INFOMAP) 
#- Calculate burst metrics and write Sparkline data to CSV 
bursts = aspace.calculate_bursts(metric=G_METRICS.BETWEENNESS_CENTRALITY, 
from_slice=2000, to_slice=2015, s=2, gamma=0.2) 
 
aspace.metric_to_sparklines(file="sparklines_between.csv", trials=[l[0] for l in bursts], 
id_field='uri', from_slice=2000, to_slice=2015, metric= G_METRICS.BETWEENNESS_CENTRALITY) 
 
#- Compile dataset for survival analysis 
aspace.to_cox_proportional_hazard_model(file=”cphm_walktrap_between.csv", 
from_slice=2000, to_slice=2015, cluster_type=G_CLUSTERS.INFOMAP) 
 
#- Generate the MetroMap 
mmap = metro.MetroMap(summaries=graphs, concepts= details, years=list(range(2000,2015)), 
cluster=G_CLUSTERS.INFOMAP) 
mmap.generate_map() 
mmap.write_json(f='metro.json') 
 
#- Launch the ARRASTRA embedded browser  
dashboard.UI(metromap=mmap).show() 
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Appendix C: Top 50 Clinical Trials – Out-degree Strength Burst Activity 
 
 
NCTID Year Burst Title 
NCT00001480 1999 2000-2008 The Evaluation and Follow-up of Individuals With Memory Disorder 
NCT00000178 1999 2000-2010 Multicenter Trial of Prednisone in Alzheimer's Disease 
NCT00001235 1999 2005-2007 Genetic Studies in Alzheimer's Disease 
NCT00024531 2001 2001-2009 Lipitor as a Treatment for Alzheimer's Disease 
NCT00244322 2005 2005-2008 Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease 
NCT00182897 2005 2008-2010 PACT: Providers and Alzheimer's Caregivers Together 
NCT00255086 2005 2009-2012 The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients 
NCT00369603 2006 2008-2011 Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease 
Patients NCT00403520 2006 2009-2012 Hippocampus Study: Comparative Effect of Donepezil 10 mg/d and Placebo on Clinical and 
..Radiological Markers NCT00304629 2006 2012-2015 Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease 
NCT00433121 2007 2007-2009 Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD 
NCT00500500 2007 2009-2011 Effect of EGb 761 on Patients With Mild to Moderate Alzheimer's Disease 
NCT00574132 2007 2012-2013 Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) 
NCT00575055 2007 2012-2013 Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) 
NCT00715858 2008 2008-2010 A Pilot Study of Inflammatory Markers in Alzheimer's Disease 
NCT00594269 2008 2009-2011 Dementia Antipsychotics And Antidepressants Discontinuation Study 
NCT00594568 2008 2009-2011 Effect of LY450139 on the Long Term Progression of Alzheimer's Disease 
NCT00637442 2008 2009-2011 Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy 
in Alzheimers Disease (AD) NCT00753662 2008 2012-2013 Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease 
NCT00684944 2008 2012-2015 Open Label Study of TRx0014 in Alzheimer's Disease 
NCT00890890 2009 2009-2010 A Multicenter Double Blind Placebo-Controlled Safety and Tolerability Study of BMS-708163 in 
Patients With Prodromal Alzheimer's Disease NCT00950430 2009 2009-2010 Imaging of Brain Amyloid Plaques in the Aging Population 
NCT00880347 2009 2009-2011 Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease 
Compared to Patients Suffering From Other Types of Dementia NCT00862940 2009 2010-2012 A Clinical Study Evaluating the Effects of Memantine on Bra n Atrophy in Patients With 
Alzheimer's Disease NCT00916617 2009 2012-2015 Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab 
NCT00934050 2009 2012-2015 ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease 
NCT00955409 2009 2012-2015 Long Term Extension Study Evaluating Safety Tolerability and Immunogenicity Of ACC-001 In 
Subjects With Mild To Moderate Alzheimer's Disease NCT00904683 2009 2014-2015 Effect of LY2062430 on the Progression of Alzheimer's Disease 
NCT01000038 2009 2014-2015 Wii-fit for Activity Balance and Gait in Assisted Living 
NCT01117181 2010 2010-2011 Apathy in Dementia Methylphenidate Trial (ADMET) 
NCT01227564 2010 2010-2011 Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease 
NCT01179373 2010 2012-2013 Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease 
NCT01148498 2010 2014-2015 A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's 
NCT01409694 2011 2011-2012 Alzheimer's Disease - Input of Vitamin D With mEmantine Assay 
NCT01345110 2011 2013-2014 A Longitudinal Multidimensional Population Study on Brain Aging 
NCT01565356 2012 2012-2013 Evaluation of PET Scan Timing Relative to AV-45 Injection Time 
NCT01574456 2012 2012-2013 Blood-brain Barrier Permeability in Alzheimer's Disease 
NCT01577004 2012 2012-2013 Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-
3 Fatty Acid Metabolism? NCT01723488 2012 2012-2013 A Phase 0 Open Label Multi-Center Exploratory and Safety Study of [F-18]T808 
NCT01624389 2012 2013-2014 Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study 
NCT01727622 2012 2013-2014 Arterial Spin Labeling (ASL) MRI for Cognitive Decline 
NCT01773915 2012 2013-2014 New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study 
NCT01582919 2012 2013-2015 Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study 
NCT01800214 2013 2013-2014 The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's Vascular and Other 
Dementias NCT01819545 2013 2013-2014 The Study of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 
1 (BACE1) NCT02058043 2013 2013-2014 Study of MRI 3 Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive 
Atypical and Comparison to the FDG-PET NCT02051244 2014 2014-2015 Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of 
Alzheimer's Disease? NCT02196545 2014 2014-2015 Physical Activity Training Program for Patients With Alzheimer's Dementia 
NCT02267499 2014 2014-2015 Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The LLM 
Project  
 
Table 8.  Top 50 clinical trials and their burst profiles capturing out-degree strength 
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Appendix D: Top 50 Clinical Trials – Betweenness Centrality Burst Activity 
 
 
NCTID Year Burst Title 
NCT00001480 1999 2000-2008 The Evaluation and Follow-up of Individuals With Memory Disorder 
NCT00083421 2004 2004-2007 Effects of ONO-2506 PO in Patients With Alzheimer's Disease 
NCT00087724 2004 2006-2009 A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease 
NCT00211159 2005 2005-2006 OmegAD (Omega-3 and Alzheimer's Disease) 
NCT00249080 2005 2005-2009 Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease 
NCT00182897 2005 2005-2010 PACT: Providers and Alzheimer's Caregivers Together 
NCT00106899 2005 2005-2011 ADNI: Alzheimer's Disease Neuroimaging Initiative 
NCT00259454 2005 2007-2009 Project COPE:Managing Dementia at Home 
NCT00371059 2006 2006-2007 Memantine for Agitation in Dementia 
NCT00384423 2006 2006-2008 Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept 
NCT00403520 2006 2006-2010 Hippocampus Study: Comparative Effect of Donepezil 10 mg/d and Placebo on Clinical and Radiological 
NCT00287742 2006 2006-2011 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With …. 
NCT00409279 2006 2007-2010 An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease 
NCT00366288 2006 2007-2011 Study Evaluating PAZ-417 in Healthy Young/Elderly  
NCT00412048 2006 2007-2011 Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease 
NCT00355498 2006 2013-2015 Amyloid Plaque and Tangle Imaging in Aging and Dementia 
NCT00483028 2007 2008-2011 A Randomized Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI 
NCT00753662 2008 2008-2009 Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease 
NCT00800709 2008 2008-2010 Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease 
NCT00762411 2008 2008-2011 Effects of LY450139  on the Progression of Alzheimer's Disease as Compared With Placebo 
NCT00594568 2008 2009-2010 Effect of LY450139 on the Long Term Progression of Alzheimer's Disease 
NCT00706186 2008 2009-2012 Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients 
NCT00715858 2008 2010-2015 A Pilot Study of Inflammatory Markers in Alzheimer's Disease 
NCT00606476 2008 2014-2015 AAB-001 (Bapineuzumab) Open-Label Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's  
NCT00842920 2009 2009-2010 Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients 
NCT01002586 2009 2009-2010 Wii-Fit For Improving Activity Gait And Balance In Alzheimer's Dementia 
NCT00862940 2009 2009-2011 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease 
NCT00869817 2009 2012-2014 Dominantly Inherited Alzheimer Network (DIAN) 
NCT00843518 2009 2013-2014 Treatment for Aggression and Agitation in Patients With Alzheimer's Disease 
NCT00991419 2009 2013-2014 To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden 
NCT00866060 2009 2014-2015 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease 
NCT00904683 2009 2014-2015 Effect of LY2062430 on the Progression of Alzheimer's Disease 
NCT01117181 2010 2010-2011 Apathy in Dementia Methylphenidate Trial (ADMET) 
NCT01217021 2010 2010-2011 Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 
NCT01198093 2010 2012-2015 Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD) 
NCT01066546 2010 2014-2015 An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With … 
NCT01320527 2011 2013-2015 A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease 
NCT01680588 2012 2012-2013 Efficacy and Safety of the PET Imaging Agent [18 F]NAV4694 in Subjects With Probable AD … 
NCT01565356 2012 2012-2014 Evaluation of PET Scan Timing Relative to AV-45 Injection Time 
NCT01894646 2013 2013-2014 PET Imaging of Extrathalamic 42-nicotinic Acetylcholine Receptors in Health and Disease With [18 F]XTRA 
NCT01812213 2013 2013-2014 Beta-Amyloid Imaging With [18 F]NAV4694 Positron Emission Tomography (PET) in Predicting … 
NCT01962753 2013 2013-2014 Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18 F] AV-45 … 
NCT01962779 2013 2013-2014 Sleep Disordered Breathing in Normal Elderly and Alzheimer's Disease Prevention Study 
NCT02008357 2013 2013-2014 Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss 
NCT01885806 2013 2013-2015 Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease 
NCT01976832 2013 2013-2015 Music-with-Movement Intervention for People With Early Dementia and Their Families 
NCT01965756 2013 2014-2015 Effect of Insulin Sensitizer Metformin on AD Biomarkers 
NCT02227966 2014 2014-2015 A Pilot Study of tDCS for Mild Cognitive Impairment 
NCT02289118 2014 2014-2015 Tau Imaging in Young Onset Dementia 
NCT02343757 2014 2014-2015 Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid 
 
  Table 9.  Top 50 clinical trials and their burst profiles capturing betweenness centrality 
308 
 
Appendix E: Citation Counts for Out-degree Strength Burst Trials 
 
 
NCTID PubMed ID Citation Count Reason Status 
NCT00001480 8268327 53  
NCT00000178 10680787 478  
NCT00001235 7596406 3811  
NCT00024531 15883262 429  
NCT00244322 18695053 306  
NCT00182897 8907091 491  
NCT00255086 N/A 0  
NCT00369603 N/A 0  
NCT00403520 N/A 0  
NCT00304629 17621382 19  
NCT00433121 N/A 0  
NCT00500500 N/A 0  
NCT00574132 24450891 518  
NCT00575055 24450891 518  
NCT00715858 14962152 115  
NCT00594269 22408266 52  
NCT00594568 23883379 280  
NCT00637442 N/A 0 Unknown 
NCT00753662 N/A 0 Unknown 
NCT00684944 N/A 0  
NCT00890890 26414022 14  
NCT00950430 N/A 0  
NCT00880347 N/A 0  
NCT00862940 22269160 22  
NCT00916617 N/A 0  
NCT00934050 N/A 0  
NCT00955409 N/A 0  
NCT00904683 24450890 460  
NCT01000038 N/A 0 Unknown 
NCT01117181 24021498 40  
NCT01227564 N/A 0  
NCT01179373 N/A 0 Unknown 
NCT01148498 N/A 0  
NCT01409694 22233455 34  
NCT01345110 24063518 8  
NCT01565356 N/A 0  
NCT01574456 N/A 0  
NCT01577004 24829492 13  
NCT01723488 N/A 0  
NCT01624389 N/A 0 Unknown 
NCT01727622 N/A 0 Ongoing 
NCT01773915 19056867 314  
NCT01582919 N/A 0 Ongoing 
NCT01800214 N/A 0 Ongoing 
NCT01819545 25742200 6  
NCT02058043 N/A 0 Unknown 
NCT02051244 17543991 180  
NCT02196545 25884637 10  
 
Table 10.  Citation counts for trial outputs exhibiting out-degree strength burst behavior  
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Appendix F: Citation Counts for Betweenness Centrality Burst Trials 
 
 
NCTID PubMed ID Citation Count Reason Status 
NCT00001480 8268327 52  
NCT00083421 N/A 0  
NCT00087724 N/A 0 Terminated 
NCT00211159 17030655 582  
NCT00249080 10931560 346  
NCT00182897 8907091 491  
NCT00106899 14732621 721  
NCT00259454 20810376 134  
NCT00371059 22567095 74  
NCT00384423 N/A 0  
NCT00403520 N/A 0  
NCT00287742 N/A 0  
NCT00409279 8940320 1014  
NCT00366288 N/A 0  
NCT00412048 N/A 0 Terminated 
NCT00355498 16407119 192  
NCT00483028 N/A 0  
NCT00753662 N/A 0 Unknown 
NCT00800709 N/A 0  
NCT00762411 26402769 3  
NCT00594568 23883379 280  
NCT00706186 N/A 0 Terminated 
NCT00715858 14962152 115  
NCT00606476 25669746 5  
NCT00842920 N/A 0 Ongoing 
NCT01002586 N/A 0 Unknown 
NCT00862940 22269160 22  
NCT00869817 17210801 650  
NCT00843518 23257314 16  
NCT00991419 N/A 0  
NCT00866060 N/A 0 Unknown 
NCT00904683 24450890 460  
NCT01117181 24021498 40  
NCT01217021 N/A 0  
NCT01198093 26845282 0  
NCT01066546 N/A 0 Terminated 
NCT01320527 25589719 18  
NCT01680588 N/A 0 Ongoing 
NCT01565356 N/A 0  
NCT01894646 N/A 0 Ongoing 
NCT01812213 N/A 0 Ongoing 
NCT01962753 N/A 0 Ongoing 
NCT01962779 N/A 0 Ongoing 
NCT02008357 N/A 0 Ongoing 
NCT01885806 N/A 0 Unknown 
NCT01976832 26354593 0  
NCT01965756 N/A 0 Ongoing 
NCT02227966 N/A 0 Unknown 
NCT02289118 N/A 0 Ongoing 
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